|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/26 ¤W¤È 12:25:12²Ä 2720 ½g¦^À³
|
Dr. Rugo Åܤ£Åܤ߻P«¥Ìªº·sÃĦó¤z¡H¦oY¦£©ó¦Û®aªº·sÃÄ¡A¨S®É¶¡Ãö·Ó«¥Ìªº·sÃÄ¡A¨º¤½¥q´N¨S¤H¥i¥Hpresent µ²ªG¤F¶Ü¡H ¬Q¤Ñ¦¤W§Ú¥Î¯S§O¥J²Ó¡u¤p¤ßªº¥Îµü¡v¡A¬G·N¥[¤W«D±`¸Ø±iªº»¡ªk¡A§â¨º½gºâ¬O·sªº³ø¾É¶K¤Wª©¨Ó¡A¬Ý¬Ý¤j®aªº¤ÏÀ³¦p¦ó¡CÃø¹D¬Ý¤£¥X¨Ó¬O¤@ºØ¤Ï¿Øªº»y®ð¡H ³o¼Ëªº¬ã¨s³ø¾É·íµM¤£¥u³o»ò¤@½g¡A·í¨ÅÀùªº¼Ðªº°÷¤j¡AÅý¦U®aÃļtı±o¬O§Q°ò©Ò¦b®É¡A¬ÛÄ~§ë¤J¬ãµo¥»¤D§L®a±`¨Æ¡A¥un¥¼¦ÜÁ{§É¤G´Á¸ÕÅ窺¶i«×¡A¥un°lÂܧY¥i¡A³o¼Ëªº»¡ªk¡A§Ú¤]¦P·N¡F¤£¹L¡A±N¤ß¤ñ¤ß¡A¨º833¤~è¶i¤J¤@´Á¦¬®×¡A¦b§O®aÃļt²´¤¤¬Ý°_¨Ó¤]¬O°lÂܧY¥i¡A½Ð«O«ù¥±`¤ß¡A¤£nµ¹¤©¹L«×¤£·íªº·P±¡§ë®g¡A»¡¨ì¦Û®aªº¥Ê´N¤@©w²¢¡C¤@´Áªº¥Î·N¤£¦bÀø®Ä¡A´N¬O¥Î¨Ó¬Ý¦w¥þ©Ê¡A«Ü³æ¯Â¡C §Úªº¥Øªº¤]«Ü³æ¯Â¡A´N¬O§Æ±æ¤j®a«O«ù§NÀR¡B²z©Ê¡A¦³¦h¤Ö¬ì¾ÇÃÒ¾Ú¡A¤~°µ¬Û¹ï¦X©yªºµûµ¥¡AÃÒ¾Ú¨ìþ¸Ü´N»¡¨ìþ¡A¹ï¤½¥q¡B²£«~¦³«H¤ß¬O°ò¥»«H¥õ¡A§_«h¤£»Ý¦b¦¹®ö¶Oºë¤O¡A¤@¨Çºë¯«³Û¸Ü¬Ý¦h³Û¦h¡A¦b¸Ñª¼«e¤w¦bª©¤W²Ö¿n°÷¦hªº½g´T¡A¦b¸Ñª¼«áÀ³¸Ón¨I¾ý¤U¨Ó¡AÄYµÂ¥H¹ï¡A¹ê¨Æ¨D¬O¡C¸Ñª¼«eªºª½±µ¸ê®Æ¦³¡A¹ï¤H¨Æªº«H¿à·|¦h©ó¹ï¨Æªºn¨D¡F¦ý¸Ñª¼«áÀ³¸Ó¦h°w¹ï¤w¥X¨Óªº¼Æ¾Ú¡A¥H¤Î¥¼¨Ópµeªº°õ¦æ¯à¤O»P¥i¦æ©Ê§@±´°Q¡A´î¤Ö¹ï¤H¨Æªº¨Ì¿à¡C ¹ï¤½¥qªº¹ªÀy·íµM«n¡A¦ý¤£¸Ó¬O¥Î³Ûªº¡C¸Ñª¼«eº¦¨ì700¨S½æ¡A¤£¬O¹ªÀy¬O¬Æ»ò¡H¸Ñª¼«á¶^¦Ü321¤´¨S½æªº¤H¤]¦hªº¬O¡A³o¤£¬O¹ªÀy¬O¬Æ»ò¡H³Û¦h¡AªÑ»ù¤S¤£·|º¦¡F¦h³Û´XÁn¡AFDA´N·|§ïÅܺA«×¡AÅý822ª½±µ¹LÃö¡H ¾ú¸g¸Ñª¼«eªº¤@¤ù¬Ý¦n¡APFS Ȥ]´¿³Q¹w´ú¨ì¤Ñ°ª¡Aµ²ªG³ºµM¡K¡K¡A³o¼Ëªºover exaggeration¡A³o¼Ëªº¿ù¦ôÃø¹DÁÙn¦A¿ù¤@¦¸¡H°È¹ê¤@ÂI§a¡C ¥ú¬Op¹ºùتºmaintain therapyªº¤å¦r±Ôz¡A©ñ¦bºô¯¸¦h¦~¡A¦³½Ö´¿´£¥X¥¦ªº®í²§¤§³B¡H§Ú¤]¬O«áª¾«áı¡A°£¤F¤Wz¤§¥~¡A´N¦b¬Q¤Ñâ±á¡]10/25¡^¡AµL·N¤¤¤Sµo²{¤@¥÷¦Ñ¸ê®Æ¡A20Ó¤ë¨Ó¥¼´¿¥hŪ¹L¡Aµ²ªGŪ¤F¤§«á¦³¤@ºØ¬Û¨£«ë±ßªº·Pı¡An©Ç½Ö©O¡H¥u¯à©Ç¦Û¤v¯à¤O¤£¨¬¡C¤]ºâ¬O³¡¤À¸Ñµª¤F§Ú¦b10/9¶K¤åªººÃ°Ý¡C³o®ÉÔY§e²{¥X¨Ó¡A¤£³Q»{¬°¬O¬ÝÃa¤~©Ç¡A¬°§Kª§Ä³¼È®É«ö¤U¡C §Ún¾G«Án©ú¡A§Ú¨S¦³¬ÝÃa¡A¤]¤£¬O¨Ó·o¶Ã¡A¥u¬OºCºC¨I¾ý«á¡Aµo²{¦Û¤v¡u¤Ó¡v¼ÖÆ[¡Aª©¤Wªº®ðª^¤]¬O¡A©Ò¥H«Øij¹ê¨Æ¨D¬O¡A¡u¥¿±`¼ÖÆ[¡v´N¦n¡AÄÝ©óÓ¤H²q´úªº³¡¤À¡A½Ð¥[¤W¡u§Ú»{¬°¡v¡B¡u§Ú±À´ú¡v¡F¤Þ¥ÎÄݩ󤽥qµo¥¬ªº¥¿¦¡°T®§¤å¦r¡A¤£§«¼Ð¥Ü²M·¡¡F´X¤ÀÃÒ¾Ú»¡´X¤À¸Ü¡A¤£n»~¾É¡Aª©¤WÅ@½L¨S¦³·N¸qªº¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/25 ¤U¤È 11:21:05²Ä 2719 ½g¦^À³
|
²³¤j¤j µn®p¤j 1 µn®p¤j«Ü¯à´x´¤«ÂI ¤º¦æ¬Ýªù¹D 2 105/09/08 ¯E¹©¨üÁÜ°Ñ¥[·ç¤h«H¶UÁ|¿ì¤§17th Annual Asian Technology Conference ²³ø¸ê®Æ«Ü·sȱo¬Ý¬Ý www.tpex.org.tw/web/regular_emerging/investor_conference/latest/latest.php?l=zh-tw ©¹¤U§ä4174 »P 4147 ²³ø«e«á¨Ã±Æ ¨â®a³£¬O¬ãµo³Ð·s«¬·sÃÄ ¤]¬O³¯°|¤h¯S§O±À±Rªº¨â®a¥Í§Þ¤½¥q 3 ¥H«eASCO ²³ø¦³¨Ç½×z¤í¨Î,©ö¤Þ°_»~¸Ñ: ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤Î Globo H ªí²{¶qµLÃö 9¤ë²³ø±Ä¨ú¥¿±ªí¦C: ¤À¤l¼Ð°O¨È«¬ ªvÀø¤ÏÀ³Åã¥Ü©ó¦UÓ¸~½F¥Íª«¼Ð°O¨È«¬¡]¥]§tHER2 +/-,HR+/-, ¤T³±©Ê¡^¤Î¦UºØ¤£ ¦PGlobo H ªí²{¶qªº¨ü¸ÕªÌ¡C P 27 ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬µLÃö (¥H¤U¬OÓ¤H¸ÑŪ »P¤À¨É ¶È¨Ñ°Ñ¦Ò ) (¦pªG¦³Ãöªí¥Ü¥u¦³¬Y¨Ç¨È«¬¨ÅÀù¦³®Ä¨ä¥L¨È«¬µL®Ä,·íµM¬O»P¨È«¬µLÃö¤ñ¸û¦n,¥ô¦ó¥Íª«¼Ð°O¨È«¬³£¦³®Ä,¥¼¨Ó¥«³õ¤~·|¤j) ªvÀø¤ÏÀ³Åã¥Ü»PGlobo H ªí²{¶qµLÃö ( °²³]ªvÀø¤ÏÀ³Åã¥Ü»PGloboH ªí²{¶q¦³Ãöªí¥Ü±a¦³GloboHªº¦¸²Õ¸s¦³®Ä ,¨S¦³±a¦³GloboHªº¦¸²Õ¸sµL®Ä,¨S¦³±a¦³GloboHªº¦¸²Õ¸s¦pªG¤]¦³®Ä,³o¤£¬O¶¡±µÃÒ¹êSSEA-3 SSEA-4 ªº¦s¦b¶Ü ? ¥t¥~¦³Globo H ªí²{ªº¦¸²Õ¸s¥H·ÀI¤ñ¨Ó¬Ý ASCO P18 ¥ªÃä +3 > +2 > +1 , Globo H negative ªº¦¸²Õ¸s ·ÀI¤ñ ¬ù¦b0.5 ªí²{·¥¬°Àu²§ ³o·|¤£·|¬O SSEA-3 SSEA-4 ¥ß¤U¤j¥\? ) 4 ¦¸±Ú¸s¤ÀªRÃöÁ䦳´£¨ì: P35 a IgG , IgM ¤ÏÀ³§e§K¬Ì¤ÏÀ³ªÌ©MµL§K¬Ì¤ÏÀ³ªÌ ¤Î¨Ï¥Î¦w¼¢¾¯¤§¹ï·Ó²Õ¤ñ¸û(§E³Õªk»¡´£¨ìIgM §ÜÅé®Ä»ù¤]·|¤ÀªR) b Globo ¨t¦C§Ü줧ªí²{ ( ±q²³ø¨Ó¬Ý¥¼¨Ó·|¤ÀªRSSEA-3 SSEA-4 Globo ¨t¦C§Ü줧ªí²{) c ¦U±Ú¸s¤H¤f¤ÀªR d ¦a°Ï¤ÀªR e ¸~½F§ÎºA 5 Àù¯gªvÀø«¤jÅܲ P40 §C¾¯¶qMicro doses ¥Ö¤Uª`®gSubcutaneous @¨ü©Ê°ªWell-tolerated ¥ÎÃĦ¸¼Æ¤ÖLess frequent dosing ©µªøªø´Á¦s¬¡ÁͶÕTrending towards long-term survival 6 OBI-822Àu¶V¡B³Ð·sªºÀù¯g§K¬ÌÀøªk P47 aº³Ð©ÊÃĪ« °w¹ï¦hºØÀù¯g²ÓM§¡¦³ªí²{ªºGlobo¨t¦CÁÞ§Üì º¡¨¬©|¥F¦³®ÄªvÀøªºÃe¤jÂåÀø¥«³õ»Ý¨D b¨ã»¡ªA¤Oªº¼Æ¾Ú @¨ü©Ê¦n¡Aªø´Á¦s¬¡²v°ª ·§©À¤wÀò±o¦³¤Oªº¼Æ¾Ú¦LÃÒ c±M¤@©Ê±j ¥H Globo¨t¦CÁÞ§Ü쬰¼Ðªº¹ï¥¿±`²ÓM¨S¦³¼vÅT©Î¼vÅT·¥¤p d¨}¦n¥Í¬¡«~½è ·¥¤Ö¤£¨}¤ÏÀ³ (Few adverse events )¥ÎÃĦ¸¼Æ¤Ö(Less frequent dosing) e´¼°]«OÅ@©P±K ¤@Áçªk (One-Pot Synthesis) »Ã¯À¦X¦¨ªk (Enzymatic Synthesis ) ²q·Q¤j:ÁÂÁ´£¨Ñ¸ê°T: ¬ü¥Í§ÞªÑ¿ï«á±j¼u¡H¥~¸ê¡G¥Á¥DÄÒ¤£¤Ó¥i¯à¾î±½²³Ä³°| Ó¤H»{¬°¬ü°ê¤j¿ï¦³ÃöÃÄ»ù¨ì³Ì«á³£·|§´¨ó, °ªÃÄ»ùªº§K¬ÌÀøªkÃĪ«¥[´î¥´Ó§é¦©, §Æ©Ô¿¶¤]¤£·|§â¦Û¤v°ê®aªº¥Í§Þ·~·d«± ,¤£¹LµL½×¦p¦ó´î,ÃÄ»ù³£·|¤ñOBI822°ª¥X«Ü¦h, ³o¬OOBI822 »ù®æªºÄvª§¤O |
|
|
·|û¡Gµn®p³y·¥10143094 µoªí®É¶¡:2016/10/25 ¤U¤È 08:47:24²Ä 2718 ½g¦^À³
|
¤£n·W¡A¤£n«æ¡A¤@¤Á³£»Ýn®É¶¡¡A²{¦b¥unª`·N¤U¦C®Éµ{: 1 .EOP2 2.BTD 3.¥þ²y¤T´ÁÁ{§É 4.OS¦ó®É¹F¼Ð 5.©Ò¦³Á{§Éªº¼Æ¾Ú¦ó®É¤½§G 6.822ªº¨ä¥LÀ³¥Î 7.833®Éµ{ 8.888®Éµ{ ²³æ§ãn¡A¬Û«H¤½¥q¡A¬Û«H±i¸³¡A¯E¹©¬O¦Ñ¤Ñµ¹ªÑªFªºÂ§ª«¡A ¬Û«H³o¨Ç¼Æ¾Ú³£·|¦b©ú¦~¤W¥b¦~«e§¹¦¨¡A¤]¤£·|«Ü¤[o ¥H¤W¬O¦Û¤vªº·Qªk¡AÂԨѰѦҡC§ë¸ê¦³ÁȦ³½ß¡A¬ÕÁ«¦Ût¡C |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/10/25 ¤U¤È 12:00:16²Ä 2717 ½g¦^À³
|
¥L¤£¬Ocoresponding author www.nature.com/nm/journal/vaop/ncurrent/full/nm.4213.html#author-information Corresponding authors Correspondence to: Dai Horiuchi or Andrei Goga ¤£¹L§Úı±o¨S®t ²z¥Ñ¸ò§Ú¤§«e»¡ªº¤@¼Ë ÃĦ³¦Ê¦ÊºØ |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/10/25 ¤W¤È 10:37:59²Ä 2716 ½g¦^À³
|
·PÁ Cliff ¤jªº¸ê°T... ¦ý¤p§Ì¹ï4174ÁÙ¬O«Ü¦³«H¤ß.. Rugo ³o½g¦b¤µ¦~3/24§ë½Z...»¡¥LÅÜ¤ß À³¸Ó¬OÅܨì4174§a.. XD Nature Medicine (2016) doi:10.1038/nm.4213 Received 24 March 2016 Accepted 21 September 2016 Published online 24 October 2016 Rugo ªº±¾¦W¦ì¸m ´N¬Ý±o¥XºÝÙ.. ¦pªG¦P¼Ë¬O4174ªºpaper ¨ºRugo À³¸Ó¬OCorresponding authors ©Ò¥HÀ³¸Ó¬O¦b3/24«e ´NÅܤߤF.. XD |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/10/25 ¤W¤È 10:30:08²Ä 2715 ½g¦^À³
|
ı±oÁÙ¦nC ¦pªG¬ã¨sªºªF¦è´N¥u¦³¤@ºØ ¨º»ò«æ¯f«ç»ò³Q¥´±Ñ©O? ¦ý¬O¥u¯à¦³¤@ºØÃÄ¶Ü ¤£ºÉµM§a ¤£À´¬°¤°»òÁ¿ªº¦n¹³«Ü¥¢±æ ´Nºâ¬ORugoªº¬ã¨s³æ¦ì¤S¦p¦ó©O? ¹ï©ó¤@Ó¬ì¾Ç®a¨Ó»¡¡A¾Ô³Ó¯e¯f¤~¬O«ÂI¤£¬O¶Ü? ¦pªG®`©Èªº¸Ü¡A¤£µM¤]¥h§ë¸ê¤@¤U¨ä¥L¬ÛÃöÃļt§r |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/10/25 ¤W¤È 09:57:23²Ä 2714 ½g¦^À³
|
Cliff¤j ¦b³o·«BÄÆ·nªº®É¨è¡A±z¤µ¦³o½g¤å³¹½T¹ê«À»¤p§Ì«H¤ß¡A ¦]¬°¤¤¶¡¯A¤Î¬Ý¨ì¸ê®Æµoªí¸ê®Æªº±M®a¡ADr. Rugo ¬Ý¨Ó¤p§Ì»Ýn«·s¦n¦n¬Ù«ä¡A¤£µM£¸ª½²`«H±i¸³ªº¨º¨Ç¸Ü ....³o¬O¤W¤Ñµ¹¯E¹©¹Î¶¤ªºÂ§ª«¡A¤]¬Oµ¹§ë¸ê¤HªºÂ§ª«¡A¤]¬Oµ¹¥xÆWªºÂ§ª«¡A.... §ÚÌ·|¤£Â_§â¦nªº®ø®§§i¶D¤j®a¡A.... ¤p§Ì£¸ª½²`«H±i¸³·|¤U³oºØµ²½×¡A£¸©w¬O¦³©Ò¥»¡A ¤ô¯uªº«Ü²` |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/10/25 ¤W¤È 09:52:39²Ä 2713 ½g¦^À³
|
¤p§Ì¤£¤~¡A¦³¤@Ó°ÝÃDºô¤W¨S§ä¨ìµª®×¡A½Ð±ÐªO¤W«e½ú¤j¤j¡C2016¦~2¤ë¥HLR¸Ñª¼«á¡A¯E¹©ÁÙ¥i¥H±Ä¨úCR¡A¦A°µ¤@¦¸¸Ñª¼¶Ü¡H |
|
|
·|û¡G¶Â³Ç§J10142064 µoªí®É¶¡:2016/10/25 ¤W¤È 09:48:23²Ä 2712 ½g¦^À³
|
«ÂI¦b©ó : ¦k¥[´¢´ú§O¤H , ¨Ã±N¦Û¤vªº·Qªk¬Ýªk¥[½Ñ¨ä¤W ...... ®¤¤p§Ì¤£¦A¦^À³¤F , ½Ð¦Û« ~~ |
|
|
·|û¡Gºô¸ô¥@¬É10141607 µoªí®É¶¡:2016/10/25 ¤W¤È 09:42:40²Ä 2711 ½g¦^À³
|
©êºp, ¶Â³Ç§J¤j ¶}Ó¤pª±¯º ¦p¦³«_¥Ç½Ð¨£½Ì ¬Ý¨ì³oÓ¦W¦r+·sÃÄ©Ò¥HÅý§ÚÁp·Q°_¤F©ÇÂå³oÓº©µe¤Hª« |
|
|
·|û¡G¶Â³Ç§J10142064 µoªí®É¶¡:2016/10/25 ¤W¤È 09:35:03²Ä 2710 ½g¦^À³
|
ºô¸ô¤j ½ÐÂÔ·Vµo¨¥ !!! |
|
|
·|û¡Gºô¸ô¥@¬É10141607 µoªí®É¶¡:2016/10/25 ¤W¤È 09:31:03²Ä 2709 ½g¦^À³
|
²q·Q¤j ¦ý¬OªÑ»ù¯uªº¬O±q¤K¤ë¤@¸ô¶^¨ì²{¦b ¬O¤£¬O¯u¦pcliff©Î¬O©ÇÂå¶Â³Ç§J ¤j©Ò²q´ú ·sÃįu¬O²`¦p¤j®ü ¤@¯ë¤H¯u¬OÃø¿s¨s³º |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/25 ¤W¤È 09:15:43²Ä 2708 ½g¦^À³
|
ºô¸ô¤j¤j »¡²¾±¡¤ÓÄY« »¡¦h±¡©Î³\¸û¦X¾A ¤jµPÂå®v¦P®ÉݫܦhÃļt©e°U¬ã¨s «Ü¥¿±` ªp¥B³o½g½×¤åÁö¬O¤µ¤é¥Z¥X ¦ý¹êÅç¬ã¨sªº¾úµ{ ¥i¯à¤]¤£¬Oªñ´Á ¤]´N¬O¤£¬O¤µ¤é¤~¶}©l¥[¤J ³o¬O¤p§Ìªº²q´ú Cliff¤j®¦¼wªº´£¿ô ¤p§ÌÂÔ°O¦b¤ß ¨CÀÉ·sÃĤ]³£»Ýn¦p¦¹ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/25 ¤W¤È 09:08:39²Ä 2707 ½g¦^À³
|
²³¤j¤j Cliff¤j Àù¯g¬ãµo¦¨¥\²v¬Û·í§C¡A¯E¹©¯à¨«¨ì¤µ¤Ñ³oÓ¦a¨BÀ³µ¹¤©§ó¦h¹ªÀy¡A¤j®a¤]À³·P¨ì¼y©¯¡A·íµM¾é¸Ñ¹ï¤âªºÃĪ«¬Û·í«n¡A¯S§O¬OÄvª§ÃĪ«ÁÙ¦b¦´Á¬ãµo¶¥¬q¡A°£«D¤wµoªí¤G´ÁÁ{§ÉÀø®Ä¡A§_«h°lÂܧY¥i¡ARugoªº¬ãµo³æ¦ìµoªí·sªºÃĪ«¸ê°T³o¬O±`ºA¡A¤¤¬ã°|¤]±`µoªíÀù¯g¬ãµo¸ê°T¡A§Ṳ́]¤£·|»¡¤¤¬ã°|ÅܤߤF¡A¨Ï¥Î³oºØ¥Îµün¯S§O¤p¤ß¡A¤£¹Lª©¤W¤j¤j¤]³£¦³¿W¥ß«ä¦Ò»P§PÂ_¯à¤O |
|
|
·|û¡Gºô¸ô¥@¬É10141607 µoªí®É¶¡:2016/10/25 ¤W¤È 08:48:15²Ä 2706 ½g¦^À³
|
ü ªÑ²¼¥Ã»·³£¦³¥ýª¾ªº¤H ¦hÁÂciffªº«üÂI°g¬z ¦Ü¤ÖÅý¤pªºª¾¹D¥i¯à¿é¦bþ¸Ì è¬Ý½u«¬ ªÑ»ùÁÙ¯uªº±q¤K¤ëªì¤@¸ô¶^¨ì²{¦b©O rugo¤»¤ëµn¥xasco«ç·|¤K¤ë´N²¾±¡ ¤£¸Ñ |
|
|
·|û¡G¶Â³Ç§J10142064 µoªí®É¶¡:2016/10/25 ¤W¤È 08:23:09²Ä 2705 ½g¦^À³
|
Cliff¤jªº³Ì«á¤@¥y´N¬O¤p§Ì·íªì»¡ªº§Æ±æ[¤K¤ëÄƨӮ۪á»] ...... ¥i±¤ªº¬O ©~µM³s¤@¤BÂI®ø®§³£¨S¶Ç¥X ~~ ¦Ó§¡½uªÈµ²ªº§Þ³N±(¤]³\¥NªíµÛ²³¤H¸êª÷ªºµ¥«Ý)¤£¦ýµLªkÂǦ¹®ø®§±¶X¶Õ©Ô°_¤W§ð , ¤Ï¦Ó ....... ªÑ»ù·|»¡¸Ü , ¸Ó§ð¤£§ð ¸Ó¶^¤£¶^®É ... I«á³q±`¦³§A§Ú¤@¯ë¤H©Ò¤£ª¾ªº²[¸q¦b ~~ ¤p§Ì¤£¤~ , ¥»»â³q¤ÑªÌ ½Ð¤£n¯º¤Ó¤jÁn ~~ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/25 ¤W¤È 07:12:22²Ä 2704 ½g¦^À³
|
¤T³±Àù·s¼ÐªºPIM1 inhibitor for MYC¥X¦¿´ò¡C RugoÅܤߤF?! ±ó822·R¦Ó´N·sÅw? Rugo©Ò¦bªº¬ã¨s³æ¦ìUSCF Helen Diller Family Comprehensive Cancer Centerµo¥¬ªº·s»D³ø¾É ¡uDrug Target for Triple-Negative Breast Cancer Found in New Study¡v¡]www.newswise.com/articles/drug-target-for-triple-negative-breast-cancer-found-in-new-study¡^ MYC»P¤T³±¨ÅÀùªºÃö«Y¡G ¡uMYC expression is disproportionately higher in triple-negative tumors than in tumors expressing hormone receptors and/or HER2.¡v ¬°¦ó¹Ð«Ê30¦h¦~¡H MYC¡A°á¦¨»P mick¦Pµ¡A¬O30¦~«e´N³Qµo²{ªºªF¦è¡C ¦]¬°¦b¦b¥¿±`²ÓM¤¤¦³¤§¡A©Ò¥H¤@«×³Q»{¬°¬O¤£¨ãÃĪ«¶}µo»ùÈ¡A¦ý³Ìªñªº¬ã¨s¦³¤F·s¶i®i¡C ¡ubecause of its physical characteristics and its fundamental role in normal cellular function, MYC has long been considered an ¡§undruggable¡¨ protein.¡v ¦p¦ó½Õ±±MYC¡G MYC¨ü¤@°ïªº¿E酶(kinase )©ÒÁÍ°Ê¡A¥Dn¬OPIM1¡C ¡udrugs that act on the newly discovered target, a protein known as PIM1, are already in clinical trials for leukemia and multiple myeloma. ¡v ¡uThe experiments revealed that MYC depends on a number of kinases to drive cell growth, but especially on one called PIM1.¡v ±±¨îPIM1´N¥i¥H½Õ±±MYC¡H ¡uThe experiments revealed that MYC depends on a number of kinases to drive cell growth, but especially on one called PIM1. When shRNAs deactivating PIM1 were introduced to cells expressing MYC, those cells died, demonstrating a synthetic lethal relationship between MYC and PIM1.¡v New target for TNBC¡GPIM1§í¨î¾¯¡G ¡uWe found that PIM1 is indeed highly upregulated in these more aggressive breast cancers that have high MYC expression¡K..and that patients with high PIM1 tend to do more poorly.¡v PIM1§í¨î¾¯ªº°Êª«¸ÕÅç¡A¦æ¶Ü¡H ¤p¹«¸ÕÅç¡uthe administration of PIM1 inhibitors resulted in significant tumor regression.¡v¾ÉP¸~½F©úÅãµäÁY¡C ¦³¨S¦³§Oªº¾ÇªÌ¤]»{¦P¡H¦³¡AProfessor Andrew Tutt ¡FinÛ´° ¡uFurther bolstering these results, a complementary paper in the same issue of Nature Medicine by researchers at the Institute of Cancer Research (ICR) in London, led by Professor Andrew Tutt, also fingered PIM1 as a target in triple-negative breast cancer, and the ICR team arrived at this conclusion using completely different methods than those used by Goga and colleagues.¡v ±µ¤U¨Ó©O¡H ¥´ºâ¶i¤J¤HÅé¸ÕÅç¡A¤]¦Ò¼{»P¨ä¥L¼Ð¹vÃĪ«¦p§K¬ÌÀøªk°µ¦X¨ÖªvÀø¡C ì¤åºKn¡G ¡uPIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression¡v¡]www.nature.com/nm/journal/vaop/ncurrent/full/nm.4213.html#t ¡^ ¦AºCºC¿i§a¡A³sRugo ³£nÅܤߤF¡A¤K¤ë¨Ó¥x®É¡A¬O§_§Aªº¤ß¸Ì¦¤w¦³¤F¡u£y£«¡v¡H...... ±¡·Pªº¤ä«ù©TµM¨S¿ù¡A§A§Ú³£¦³¿@¿@ªº¤ä«ù±¡·P¡A¦ý¬ì¾ÇÂk¬ì¾Ç¡A¤£n§â±¡·Pªº§ë®g»P¬ì¾ÇªºÃÒ¾Ú²VÂø¡A¤£n§â¦Û¤vªº·P±¡»P±À´ú²V¶i§ë¸ê«äºû¤¤¡A¤×¨ä¤£¯à©tªÚ¦Û½à¡A·U¬Ý¦Û¤v·Uº}«G¡K¡KÅý¤£©ú´N¸Ìªº¤H¸òµÛ¸õ¶i¨Ó¡A¨ìÀY¨Ó½ß¤F¿ú¦A¤Wª©¨Ó³ÛªÅ¡C Rugo¤K¤ë¨Ó¥x«áµ¹¤F¤½¥q¬Æ»ò«Øij¡A·s¤T´Áªºpµe¼g±o¶¶¶Ü¡AFDAªºÆ[ÂI¦p¦ó¡A¦ó®É¸òFDA¬ù·|¡A¥Ø«e¹J¨ìªº²~ÀV¬O¬Æ»ò¡K¡K¦b¦b³£¬O§Ú²{¦b·Qª¾¹Dªº¡A¬Û«H¤]¬O¤j®a·Qª¾¹Dªº¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/25 ¤W¤È 12:09:32²Ä 2703 ½g¦^À³
|
2014/7/21§¹¦¨³Ì«á¤@¦ì¦¬®×¡A¥[¤W5¦~ªºOS°lÂÜ´Á¡A2019/6¬O¯u¥¿ªº¥þ³¡Ó®×°lÂܧ¹¦¨ªº®ÉÔ¡A©Ò¥Hºô¯¸¤Wªº¡uLast follow-up date¡v©Ò«ü¦ó¨Æ¡H´N¦U¤H¦Û¦æ¸ÑŪ¤F¡A©Î³\´N¦p²q·Q¤j¤j©Ò¨¥¡C¡]www.obipharma.com/index.aspx?lang=chi&fn=news_content&no=28 ¡^ ¡uActive, not recruiting¡v¡G ¡uclinicaltrials.gov/ct2/about-studies/glossary#recruitment-status ¡v¤U©Ô§ä¥X¡uRECRUITMENT STATUS¡v´N¥i²M·¡¬Ý¨ì¡uActive, not recruiting¡v¬OÄÝ©ó¡uClosed Studies¡v¡C¤wÃö³¬¤£¦A¦¬®×¡C |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2016/10/24 ¤U¤È 09:12:26²Ä 2702 ½g¦^À³
|
¦]¬°¤µ¤Ñ¤@ª½¦£¨ìèè¤~¦³ªÅ¡A¨S¥ß§Y¦^À³¡A©êºp¡I «D±`·PÁ²³¤j¤jªº¶O¤ß»¡©ú¡A¤×¨ä¥xÁÞ¤j¡A¦b®È¹C¤¤ÁÙ¦p¦¹Ãö¤ß¯E¹©ªº³oÓª©±¡C Á`¤§·PÁ¦A·PÁ¡A±ß¤@ÂI¦A¸Ô²Ó¬Ý¡BºCºC¬Ý¡A²ön¶dt¦U¦ì¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/24 ¤W¤È 10:15:24²Ä 2701 ½g¦^À³
|
5619¤j ÁÂÁ±zªº¸ê®Æ ¤p§Ì¥¿¦b½§ä³oÓ¸ê®Æ ·PÁ±zªº´£¨Ñ ©µ«áªºì¦] ¤p§Ì·Q ¥i¯à¬O¤½¥q§PÂ_OS¼Æ¾Ú©|¥¼¦¨¼ô ¬G©µ¤§ ¥H«á»¡¤£©wÁÙ·|¦A©µ ¬ÝOS¨Æ¥ó¼Æ¦Ó©w Ó¤H¬Oı±o¶V«á¶}¼ú ´N¸ÕÅç²Õ¨Ó»¡¶V¦n ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/10/24 ¤W¤È 10:02:02²Ä 2700 ½g¦^À³
|
ClinicalTrials.gov A service of the U.S. National Institutes of Health Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects 2016-09-12 updated Status Active, not recruiting Start date 2011-12 Last follow-up date 2017-02 (Anticipated) Primary completion date 2016-12 (Anticipated) ------------------ 2016-01-05 updated Last follow-up date 2016-12 (Anticipated) Primary completion date 2016-03 (Anticipated) ------------ 2014-08-12 updated Last follow-up date 2016-12 (Anticipated) Primary completion date 2016-08 (Anticipated) ---------------------- 2016-09-12 ¯E¹©±NLast follow-up date©µ«á3Ó¤ë¡A±NPrimary completion date©µ«á9Ó¤ë¡C ½Ð±Ðª©¤W±M®a¤j¤j¡A³o·N¨ý¤°»ò¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/24 ¤W¤È 09:15:14²Ä 2699 ½g¦^À³
|
²q·Q¤j 1OBI822¤w¸g¦¬®×§¹¦¨¡AµLªk¦A°Ñ¥[¹êÅç¡A¤£·|¦C¤J¡A°²³]¦³¥þ²y¤T´Áªº¸Ü¡An°Ñ¥[822Á{§É¸ÕÅ窺¼Ú¬ü¯f±w½Ð¦¡A¤@§K¦V¶¨¡C ÁÂÁºôb¤j´£¨Ñªº¸ê°T¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/24 ¤W¤È 09:01:50²Ä 2698 ½g¦^À³
|
ÁÙ¬O¥xÁÞ¤j¤j²Ó¤ß ÁÂÁ±zªº«ü¥¿ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/24 ¤W¤È 08:48:13²Ä 2697 ½g¦^À³
|
²q·Q¤j¡A¾å¦à¤j ì¤å»¡©ú¤w¥]¬A¨ä¥L¤TºØÀù¯g¡Aì¤å½Ķ¦p¤U OBI-833¬Ì]¡A¹v¦VGlobo H³oӼйv¡A³oÓ¹v´¶¹M³Qµo²{¦b¦UºØ¸~½F²ÓM¤W¡A¿ï¾ÜÂಾ©ÊÀù¯g´£¨Ñ¯f±w¨Ó¿ï¾Ü¡A¨ÅÀù¤]¥]¬A¦b¤º¡C Cancers,¦³¥[s. |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/10/24 ¤W¤È 08:33:38²Ä 2696 ½g¦^À³
|
¾å¦à¤j ±z´£¨ì¤w¸g¶i¦æ¨ì¤T´ÁªºÃÄÀ³¸Ó¬O«ü¥H¤U³oÁû Pembrolizumab (KeytrudaR, MK-3475): A PD-1 Antibody A phase III trial for patients with metastatic triple-negative breast cancer, versus chemotherapy (NCT02555657). ½Ðª`·N¬Ýtriple-negative breast cancer³o´XÓ¦r ³o»¡©ú³oÁûÃÄ¥u¾A¥Î©ó¡§¤T³±©Ê¨ÅÀù¡¨±wªÌ ¦Ó¥B³oÁûÃĬOÄÝ©ó¡¨Checkpoint Inhibitors/Immune ModulatorsÀˬdÂI§í¨î¾¯¡§ªºÃÄ ¤£¬OªvÀø©Ê¬Ì]ªºÃÄ ¤º®e¤¤©Ò¦³¸Ô¦C¥i¥H°Ñ»PÁ{§É¸ÕÅ窺ªvÀø©Ê¬Ì]³£ÁÙ¦b²Ä¤@´Á¹êÅ綥¬q ¥H¤U¬O§Ú±q¤º¤å½Æ»s¨Óªº¤º®e Therapeutic Vaccines Cancer vaccines are designed to elicit an immune response against tumor-specific or tumor-associated antigens, encouraging the immune system to attack cancer cells bearing these antigens. Several trials of vaccines, given alone or with other therapies, are currently enrolling breast cancer patients: NeuVax (nelipepimut-S or E75) is under investigation to prevent breast cancer recurrence among patients with low-to-intermediate levels of HER2 expression (HER2 1+ and 2+) following surgery. A phase III trial (PRESENT) is now fully enrolled (NCT01479244). The trial has been granted a Special Protocol Assessment (SPA) by the FDA, meaning that, if the trial meets its pre-specified endpoint, it will fulfill the necessary criteria to file for regulatory approval. There is also a phase IIb trial of NeuVax for node-positive or triple-negative following standard-of-care treatment (NCT01570036), and a phase I/II among neoadjuvantly treated node-positive and -negative HER2 3+ patients not achieving a pathological complete response, or adjuvantly treated node-positive HER2 3+ patients (NCT02297698). A phase I study of two vaccines¡XINO-1400, targeting TERT, which has been detected in more than 85% of all human cancers, and INO-9012, targeting interleukin 12 (IL-12), which enhances immune cell activity¡Xfor patients with select tumors, including breast cancer (NCT02327468). A phase I trial of OBI-833 vaccine, which targets the Globo H marker that is commonly found on a variety of tumors cells, for patients with select metastatic cancers, including breast cancer (NCT02310464). A phase I study of the MAG-Tn3 vaccine, which targets Tn carbohydrate antigen that is overexpressed in a number of tumor types, for patients with localized breast cancer at high-risk of relapse (NCT02364492). A phase I trial of a HER2 peptide vaccine in patients with breast cancer (NCT02276300). A phase I trial of a dendritic cell vaccine in patients with metastatic breast cancer (NCT02479230). A phase I trial of a personalized vaccine in patients with persistent triple-negative breast cancer following neoadjuvant chemotherapy (NCT02348320). A phase I trial of a personalized vaccine plus Poly-ICLC, a Toll-like receptor 3 agonist, in patients with persistent triple-negative breast cancer following neoadjuvant chemotherapy (NCT02427581). ÁÂÁ¾å¦à¤jªººÃ°Ý ¤j®a¤@°_¦¨ªø ·PÁ¦A·PÁ |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/10/24 ¤W¤È 08:19:23²Ä 2695 ½g¦^À³
|
©êºp,¤W¤@½g¤º®e½s¿è¤£¶¶ ¥H¤U¨Ñ¾å¦à¤j°Ñ¦Ò Study Status: This study is ongoing, but not recruiting participants. Estimated Study Completion Date: February 2017 Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure) Sponsor: OBI Pharma, Inc Information provided by (Responsible Party): OBI Pharma, Inc ¥H¤W¤º®e¨Ó¦Û¯E¹©©xºô©Ò³sµ²ClinicalTrials.gov·j´MNCT015163079(¸Ô¦C©Ò¦³³q¹L¬ü°êFDA¤¹³\¶i¦æÁ{§É¸ÕÅ窺ÃĪº©Ò¦³¸Ô²Ó¸ê°T) ¤º®e¥Dn»¡©úobi-822ªº¹êÅçÁÙ¦b¶i¦æ¤¤ ¦ý¤w°±¤î¦¬®× ¹w¦ô2017¦~¤G¤ë§¹¦¨¹êÅç ¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã¡ã ¾å¦à¤j,½Ð¬Ý¡B²Ä¤@Ó¥y¤l This study is ongoing³o¥y¸Üªº¤¤¤å·N«ä¬O¡§³oÓ¬ã¨sÁÙ¦b¶i¦æ¤¤¡¨ but not recruiting participants³o¥yªº·N«ä«h¬O¡§¦ý¤£¦¬°Ñ»P¹êÅçªÌ¡¨ §Ú¬O¥Ñ¦¹§PÂ_¨ÅÀù¥½´Á¯f¤HµLªk°Ñ¥[obi-822¹êÅ窺ì¦] |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/10/24 ¤W¤È 08:11:16²Ä 2694 ½g¦^À³
|
¾å¦à¤j,±z¦n,±z¥H¤UªººÃ°Ý¡G §Ú¦bì¤å¤¤¬Ý¤£¥XºÃ´bªÌ¤j©Ò»¡ -------------------------------------------------------- ¦Ü©ó¬°¤°»ò¨S¦³´£¨ìobi-822 ¦]¬°³o½g¤å³¹¥Dn¦b¤¶²Ð¥Ø«eÁÙ¦bÁ{§É¸ÕÅ礤¥BÁÙ¦³¦b¦¬®×¯f¤HªºÃÄ ¹ªÀy¨ÅÀù¥½´Á¯f¤H¿n·¥°Ñ»P¸ÕÅç ---------------------------------------------------------- Study Status: This study is ongoing, but not recruiting participants. Estimated Study Completion Date: February 2017 Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure) Sponsor: OBI Pharma, Inc Information provided by (Responsible Party): OBI Pharma, Inc ¥H¤W¤º®e¨Ó¦Û¯E¹©©xºô©Ò³sµ²ClinicalTrials.gov·j´MNCT015163079(¸Ô¦C©Ò¦³³q¹L¬ü°êFDA¤¹³\¶i¦æÁ{§É¸ÕÅ窺ÃĪº©Ò¦³¸Ô²Ó¸ê°T) ¤º®e¥Dn»¡©úobi-822ªº¹êÅçÁÙ¦b¶i¦æ¤¤ ¦ý¤w°±¤î¦¬®× ¹w¦ô2017¦~¤G¤ë§¹¦¨¹êÅç ¯à§i¶D§Ú¬Oþ¬q/¥y¤l´£¨ì³oÂI¡H ¥L̼g±o¨º»ò¸Ô²Ó¡Aobi-822 µ´¹ï¬O¸Ó³Q´£¤Îªº¡C ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Study Status: This study is ongoing, but not recruiting participants. Estimated Study Completion Date: February 2017 Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure) Sponsor: OBI Pharma, Inc Information provided by (Responsible Party): OBI Pharma, Inc ¥H¤W¤º®e¨Ó¦Û¯E¹©©xºô©Ò³sµ²ClinicalTrials.gov·j´MNCT015163079(¸Ô¦C©Ò¦³³q¹L¬ü°êFDA¤¹³\¶i¦æÁ{§É¸ÕÅ窺ÃĪº©Ò¦³¸Ô²Ó¸ê°T) ¤º®e¥Dn»¡©úobi-822ªº¹êÅçÁÙ¦b¶i¦æ¤¤ ¦ý¤w°±¤î¦¬®× ¹w¦ô2017¦~¤G¤ë§¹¦¨¹êÅç ¾å¦à¤j,½Ð¬Ý¡B²Ä¤@Ó¥y¤l This study is ongoing³o¥y¸Üªº¤¤¤å·N«ä¬O¡§³oÓ¬ã¨sÁÙ¦b¶i¦æ¤¤¡¨ but not recruiting participants³o¥yªº·N«ä«h¬O¡§¦ý¤£¦¬°Ñ»P¹êÅçªÌ¡¨ §Ú¬O¥Ñ¦¹§PÂ_¨ÅÀù¥½´Á¯f¤HµLªk°Ñ¥[obi-822ªº¹êÅ窺 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/24 ¤W¤È 06:45:03²Ä 2693 ½g¦^À³
|
¾å¦à¤j 833 ¥u¦b¨ÅÀù¶µ¥Ø³Q¦C¥X ¨ä¥L¤@´Áªº¾AÀ³¯g¡A¦pªÍ¡B¤j¸zª½¸z¡BGµ¥¨Ã¥¼³Q¿ï¤W ³o¥i¯à»¡©ú¬O822ªºÀø®ÄÃö«Y¡A¦b¦³¼Æ¾Ú¥i½]ªº±¡ªp¤U¡A©Ò¥H´À¥N822³Q¿ï¤J §Ú·Q¡A´N¦pºÃ´bªÌ¤j©Ò¨¥¡A³o¬O¦]爲822¤w°±¤î¦¬®×ªº´À¥N§@ªk ¦Ü©ó¨ä¥LªºÀøªk¡A¤p§Ì©|«Ý¬ã¨s ¤£¹L¦b§Úªº·Qªk¸Ì¡A°£«D¨ä¥LÃĶW±j¡AÅó¶i¤j³¡¤À±wªÌ §_«h¥H¯E¹©ÃĪº¾÷¨î©M¥L¤H¤£¦P¡A¿W¥ß©ÎÁp¦X¥ÎÃÄÀ³³£¦³ªÅ¶¡ ³o¬O¤p§Ìªì¨Bªº·Qªk ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2016/10/23 ¤U¤È 10:50:37²Ä 2692 ½g¦^À³
|
²q·Q¤j¡BºÃ´bªÌ¤j¡A §Ú¦bì¤å¤¤¬Ý¤£¥XºÃ´bªÌ¤j©Ò»¡ -------------------------------------------------------- ¦Ü©ó¬°¤°»ò¨S¦³´£¨ìobi-822 ¦]¬°³o½g¤å³¹¥Dn¦b¤¶²Ð¥Ø«eÁÙ¦bÁ{§É¸ÕÅ礤¥BÁÙ¦³¦b¦¬®×¯f¤HªºÃÄ ¹ªÀy¨ÅÀù¥½´Á¯f¤H¿n·¥°Ñ»P¸ÕÅç ---------------------------------------------------------- ¯à§i¶D§Ú¬Oþ¬q/¥y¤l´£¨ì³oÂI¡H ¥L̼g±o¨º»ò¸Ô²Ó¡Aobi-822 µ´¹ï¬O¸Ó³Q´£¤Îªº¡C ¥t¥~¡A¤å¤¤´¦ÅS¦³¨º»ò¦hÃĪ«¦b¬ãµo¤¤¡A¦³ªº¤]¨ì¤T´Á¡A¦pªG§O¤H·m¥ý±À¥X¡A¥H«án¥sÂå®v§ïÃÄ·|«Ü³Â·Ð¡A¦]¬°§Ú̬Omade in Taiwan. ©Ò¥H¤@©wn©é²Ä¤@¡A¤H®a¦³¿ú¡A¯{¤j¿ú¦hÓ¯gª¬¤@°_°µ¡A·mªº¤]¬O®É¶¡¡A³o¬O§Ú¯u¹êªº¾á¤ß¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/23 ¤U¤È 10:24:55²Ä 2691 ½g¦^À³
|
7 ¤µ¦~¤E¤ë¤G¤Q¤G¦³³ø¾É¯E¹©¨ÅÀùÃÄ10¤ë±N§¹¦¨Á{§É¤T´Á³]p¡A¯E¹©¤]¦³µoªí½×zªí¥Ü§¹¦¨³]p«áÁÙ»Ýn»P¬ü°êFDA°Q½×¥i¦æ©Ê¡A³oÀ³¸Ó¬O¤j®a¼ô±xªº¤G´ÁÁ{§É§¹¦¨ªº¿Ô¸ß·|ij¡A¨Ì¾Ú§Ú¬d¨ìªº¸ê°T¬O·|ij¤£·|©ìªd±a¤ô¡A¥H¤@¦¸¬°¡A¯E¹©À³¸Ó¤w±H¥X¤T´ÁÁ{§É¬ÛÃö¼Æ¾Ú¡A¨ó°Ó±Æ©w¤é´Á«á®i¶}¿Ô¸ß·|ij¡A¯E¹©¤]ªí¥Ü¥¼¨Ó¤@©w·|¦V¬ü°êFDA¥Ó½Ð¬ð¯}©ÊªvÀø¡A¬O§_·|®Öã±N¥Ñ¥DºÞ¾÷Ãö»{©w¡C¤Q¤@¡A¤Q¤G¤ënª`·N¬ü°êFDA°Ê¦V»Pª¾¦W´Á¥Z¼Æ¾Úªº¤½§i¡A©ú¦~¤@¡A¤G¤ënª`·NP13 MOS¼Æ¾Ú¬O§_¦¨¼ô? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/23 ¤U¤È 09:04:18²Ä 2690 ½g¦^À³
|
5 p17Á`¦s¬¡´Á112¤H¸g¹L32Ó¤ëµo¥Í¨Æ¥ó21¤H 18.75%(¦³¨Ç¤H¥i¯à¨S¦³¥´§¹¤E°w) ¡A¨S²£¥Í¨¬°÷§ÜÅ骺112¤Hµo¥Í¨Æ¥ó29¤H 25.89% ¡A¹ï·Ó²Õªí²{³Ì®t124¤H ¨Æ¥ó¼Æ35¤H28.23% ¡A¹êÅç²Õ»P¨ä¥L¨â²Õ¶}¤f©Ôªº«Ü¤j¡A³o±i¹Ï«Üȱo´Á«Ý¡A¥xÆW¤T´Á¡A¥þ²y¤T´Á³£·|¬Ýp12--P17¡A ¥t¥~©|¥¼µoªíªº«n´Á¥ZData ¤]·|¤@¨Ö°eªk³W³æ¦ì¼f¬d¡A¯E¹©¦³»¡·|§e³ø³Ì¦nªº¼Æ¾Úµ¹¬ÛÃö³æ¦ì¡C 6³o¥u¬O¨S¦³Áp¦X¥ÎÃĪºµ²ªG¡A¥H¤W¤»ÂI¬O®Ú¾Ú¨Æ¹ê½×z¡A¨S¦³¹L«×¼ÖÆ[¡A¬Û«H¯E¹©ªº½×z³Ì±µªñ¯u¹ê¡A¤£¬O¶Ü? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/23 ¤U¤È 08:33:48²Ä 2689 ½g¦^À³
|
¦V«e¤j 1§A«Ü·|°Ý°ÝÃD¡Aªí¥Ü¬O¤@¦ì·|¿W¥ß«ä¦Òªº¤H¡C 2±q¯E¹©¤G¤ëªk»¡¡A¤»¤ë¦~³ø»P¹Ãĸp¬ÛÃö´CÅé ¸ê°T¨Ó¬Ý¯E¹©·|§e²{³Ì¦nªº¼Æ¾Ú¥Ó½Ð¥xÆWÃÄÃÒ¡C ·j´M:¯E¹©¤U¤@¨B ¥Ó½ÐÃÄÃÒ³\¥i 3¥xÆW¤T´Á¦´Á¦¬®×¬Û·í§xÃø¡A¦]¬°¬O·sªº§K¬ÌÀøªk¡A¤S¦³¥i¯à¥´¨ì¦w¼¢¾¯¡AÁ`¦@¤]¤~¬ùªá¤T¦~®É¶¡§¹¦¨¡A¥þ²y¤T´Á¨C¤H¥´°w¯uÃĨÿz¿ï¯f¤H¡A¥[¤Wª¾¦W«×¤j¶}¡A¦w¥þ¦³®Ä¡AÂå®v¤ñ¸û¦³«H¤ß¹ªÀy¯f±w°Ñ¥[¡A¥l¶Ò¯f±w·|§Ö«Ü¦h¡A¥Ø«e¬ü°êFDAÁÙ¥¼ªíºA¡A»Ýn¤¦~¬O¦p¦ó±À´ú? 3 P17 ¦b32Ó¤ë®É pȤw¹F¼Ð ·ÀI¤ñ¤]«Üº}«G¡A¥¼¨Ó¥þ²y¤T´Á¬O¨C¤H¥´¯uÃÄ¡A¯f¿z¿ï¯f±w¡A¥¼¨Ó¥X¨ÓªºÁ`¦s¬¡´Á±À´ú·|¤ñP17§ó¥O¤H´Á«Ý¡A¤£¬O¶Ü? |
|
|
·|û¡G¹Ú·Q°_¸10138967 µoªí®É¶¡:2016/10/22 ¤U¤È 09:13:48²Ä 2688 ½g¦^À³
|
«HªÌ«í«H¡F¤£«HªÌ«í¤£«H °ò¥»±(ªø§ë) vs ªÑ»ù¡]µu½u¡^ §Æ±æÃįতéÀÙ¥@ vs ±qªÑ»ùÁȨú»ù®t¨«¤H... ¥XµoÂI¥»¤£¦P...¡A´L«¥«³õ¾÷¨î... ¥é ¯E§J¡BµL¤j¡BÂyªÌ... ²L¤ô¥h¤F |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/10/22 ¤U¤È 08:45:06²Ä 2687 ½g¦^À³
|
¾Ú§Ú©Òª¾ ¦³¤£¤Ö¯E¤Í±N¤£¤Ö°h¥ðª÷§ë¸ê¦b¯E¹© µ²ªG³Q¨rÆN¤W¨R¤U¬~¨ìÃø¥H¦¨¯v ¨ä¹ê·P¨ì«Ü¤ß¯k |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/10/22 ¤U¤È 08:27:04²Ä 2686 ½g¦^À³
|
Study Status: This study is ongoing, but not recruiting participants. Estimated Study Completion Date: February 2017 Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure) Sponsor: OBI Pharma, Inc Information provided by (Responsible Party): OBI Pharma, Inc ¥H¤W¤º®e¨Ó¦Û¯E¹©©xºô©Ò³sµ²ClinicalTrials.gov·j´MNCT015163079(¸Ô¦C©Ò¦³³q¹L¬ü°êFDA¤¹³\¶i¦æÁ{§É¸ÕÅ窺ÃĪº©Ò¦³¸Ô²Ó¸ê°T) ¤º®e¥Dn»¡©úobi-822ªº¹êÅçÁÙ¦b¶i¦æ¤¤ ¦ý¤w°±¤î¦¬®× ¹w¦ô2017¦~¤G¤ë§¹¦¨¹êÅç |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/10/22 ¤U¤È 08:10:51²Ä 2685 ½g¦^À³
|
Therapeutic VaccinesSome immunotherapies that have shown promise in recent clinical trials include: Cancer vaccines are designed to elicit an immune response against tumor-specific or tumor-associated antigens, encouraging the immune system to attack cancer cells bearing these antigens. Several trials of vaccines, given alone or with other therapies, are currently enrolling breast cancer patients: NeuVax (nelipepimut-S or E75) is under investigation to prevent breast cancer recurrence among patients with low-to-intermediate levels of HER2 expression (HER2 1+ and 2+) following surgery. A phase III trial (PRESENT) is now fully enrolled (NCT01479244). The trial has been granted a Special Protocol Assessment (SPA) by the FDA, meaning that, if the trial meets its pre-specified endpoint, it will fulfill the necessary criteria to file for regulatory approval. There is also a phase IIb trial of NeuVax for node-positive or triple-negative following standard-of-care treatment (NCT01570036), and a phase I/II among neoadjuvantly treated node-positive and -negative HER2 3+ patients not achieving a pathological complete response, or adjuvantly treated node-positive HER2 3+ patients (NCT02297698). A phase I study of two vaccines¡XINO-1400, targeting TERT, which has been detected in more than 85% of all human cancers, and INO-9012, targeting interleukin 12 (IL-12), which enhances immune cell activity¡Xfor patients with select tumors, including breast cancer (NCT02327468). A phase I trial of OBI-833 vaccine, which targets the Globo H marker that is commonly found on a variety of tumors cells, for patients with select metastatic cancers, including breast cancer (NCT02310464). ¥H¤W¬°²q·Q¤j¤j©Ò´£¨Ñªººô§}½Æ»s¨Óªº¤º®e ¦¹¤º®e¨Ó¦Û¡¨¬ü°êÀù¯g¬ã¨s¾÷ºc¡§ªººô¯¸ ¨ä¤¤´£¨ì´XºØ¨ÅÀù§K¬ÌÀøªk¤¤¦³§Æ±æ¦³«e³~ªºÃÄ ¯E¹©ªºobi-833¤]¦W¦C¨ä¤¤ ¯u¬O¤Ó¥O¤H®¶¾Ä¤F ³oªí¥Ü¬ü°êªºÂåÃĬɤ]»{¥i¯E¹©ªºÃÄ ¦Ü©ó¬°¤°»ò¨S¦³´£¨ìobi-822 ¦]¬°³o½g¤å³¹¥Dn¦b¤¶²Ð¥Ø«eÁÙ¦bÁ{§É¸ÕÅ礤¥BÁÙ¦³¦b¦¬®×¯f¤HªºÃÄ ¹ªÀy¨ÅÀù¥½´Á¯f¤H¿n·¥°Ñ»P¸ÕÅç ¦Óobi-822¦¤w°±¤î¦¬®× ¨Ã¹w¦ô©ú¦~ªì§¹¦¨©Ò¦³¹êÅç¼Æ¾Ú |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/22 ¤U¤È 06:57:14²Ä 2684 ½g¦^À³
|
cancer immunotherapy http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/breast-cancer |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/22 ¤U¤È 03:37:57²Ä 2683 ½g¦^À³
|
11 ¨Ì¾Ú¯E¹©2016¦~6¤ë27¤éªÑªF·|¦~³ø 80¶ OBI-822 ¥Ø«e¤w¶i¦æ¨ÅÀù¤Î§Z±_Àù¤§Á{§É¸ÕÅç¡A¥¼¨Ó§ó±N¬ãµo¨ä¦b¯ØŦÀùµ¥¾AÀ³¯g¡C OBI-822 ·|¬ãµo ¯ØŦÀù ( §Z±_¬ãÀù¥Ø«e¬O¤G´Á) ³o¨âºØÀù¯gÄÝ©óaggressive type ¯E¹©´±§â aggressive type ªºÀù¯g¦C¤JOBI-822 ¬ãµo ³o¤]¬O§Ú¹ïOBI-822¨t¦C²£¥Í§ó¤j«H¤ßªºì¦]¤§¤@ 12 OBI- 888¦]¬°³£·|²£¥Í§ÜÅé , OBI- 822 OBI-833 ¤£¯à²£¥Í§ÜÅ骺¯f±w±N¥Ñ OBI- 888 ¨Ó±µ¤âªvÀø ¬Û¤¬¤ä´© ¦³§ÜÅé¨S§ÜÅé¯E¹©¥þ®³ 2017¦~OBI- 822 ¦Xp±N¦³7 ºØÀù¯g( °²¦p +¯ØŦÀù ),OBI-833¦³4ºØÀù¯g, OBI- 888°²¦p¤]¦³4ºØÀù¯g¶i¤JÁ{§É, pipeline ¦Xp±N¦³15¶µÀù¯g¶i¤JÁ{§É¬ãµo,¥¼¨Ó¦A³v¨BÂX¤j¨ì ¤fµÄÀù ¹¹DÀù ÄáÅ@¸¢Àù ¤l®cÀVÀù ¸£Àù ÁxºÞÀù µÇŦÀù ¦åÀù ³oºØ³Ð·s«¬ÁÞ¤À¤l·sÃÄ ¦³¼ç¤Oªº¥Í§Þ¤½¥q Globo Series widely expressed in 15 different cancers ¤£¨ì11¬ü¤¸ ¦X²z¶Ü ? |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2016/10/22 ¤U¤È 03:12:51²Ä 2682 ½g¦^À³
|
T¤j: «D±`ÁÂÁ§Aªº¦^ÂлP«ü¾É §Ú¤j·§¤ß¸Ì¦³©³ ¤£¹LÁ`¬O¤@Ó¾÷·|. §A´£¨ìªºKeytruda ¸g§Ú¸ß°Ý¨ä¥L¬ÛÃö¤Hû ¯uªº¦p§A»¡ªº§@¥Î©úÅ㪺·|Åý¤H±¼²´²\ ¥LÌ»¡ÁöµM¬ÛÃöÁ{§ÉÁÙ¨S°µ§¹ ¦ý¥i¥H¦³®Ä´£¤É±wªÌ¥þ±ªº§K¬Ì¨t²Î3~4¿ ©Ò¥H¬O¤@Ó«Üȱo¦Ò¼{ªº¿ï¾Ü §ÚÌ·|¶}©l¿Ô¸ß¬ÛÃöÃĪ«ªº¨Ï¥Î. Keytruda·|¤£·|¬O¯E¹©³Ì¤jªº¹ï¤âÁÙ¬O²Ì¸}¥Û nÂÔ·V¤p¤ßªº¥hµû¦ô §K¬ÌÀøªkÁöµM¤~è¶}©l ¦ý«o¤w¸g¦³¤H¦¨¥\©¹«eÁÚ¦V¤@¤j¨B §Æ±æ¯E¹©ªº²£«~¯à¦¤éÃÒ©úÀø®Ä ¦]¬°¯uªº«Ü¦h¤Hµ¥µÛÃĨӱϩR. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/22 ¤W¤È 10:44:21²Ä 2681 ½g¦^À³
|
9 °£¤F¨ÅÀù¥~§Ú¤]¬Û·í¬Ý¦nOBI822 ªÍÀù¡A¤j¸zÀù¡AGÀù¡A¨xÀù¤G´ÁÁ{§Éªº¼ç¤O¡A³o¨Ç¾AÀ³¯g¥Ñ©ó¨ÅÀù¬ã¨sªºµo²{¦bÁ{§É³]p¤W¤@©w·|¿z¿ï¯à²£¥Í§K¬Ì¤ÏÀ³¦³§ÜÅ骺¨ü¸Õ¡C°²³]Àø®Ä·¥¬°ÅãµÛÀò±o¬ð¯}©ÊªvÀø®Ö㪺¾÷²v«Ü¤j¡C OBI833 ¥¼¨Óªº¤G´ÁÁ{§É¤]¦³³oºØ¼ç¤O¡A©Ò¿×¤@¯ß±a¦Ê¯ß¡A¥´³q¥ô·þ¤G¯ß¡C 10 ²³¤j¤@©w¬Ý¹LAbbvie ¥H210»õ¬ü¤¸¨ÖÁÊPharmcycyclics¡A³o®a¤p«¬¥Í§Þ¤½¥q¡A¨ä¤¤Imbruvica ¨t¦CÁ`¦@®³¨ì¬ü°êFDA 4Ó¬ð¯}©ÊªvÀø®Öã¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/21 ¤U¤È 02:42:12²Ä 2680 ½g¦^À³
|
¤W½g¶K¤å¸É¥R 6¹ï¥xÆW¤T´Á¨Ó»¡Ó¤H»{¬°2016 ASCO §ë¼v¤ù p13 ¬OÃÒ©ú¦s¬¡´Áªº¦³¤OÃÒ¾Ú¡A¦ý¹ï¥þ²y¤T´ÁÁ{§É¨Ó»¡2016 ASCO p17 ¤Ï¦Ó§óÅã«n¡A³o±iªíÁöµMp value¤w¹F¼Ð¡AHR ¤]¬Ý¨ì¦³«Ü¦nªº¼Æ¾Ú¡A¦ý¬OPower ÁÙ¨S¦³¹F¼Ð¡C 7 ³¯°|¤hªº½×zn»P¤G¤ë±i¸³½×zµ²¦X°_¨Ó¬Ý ¡A±i¸³¦³´£¨ìÁ{§É°µ¨ì¤@¥b ¦A®ÖãÃÄÃÒ¡A³o·|¤£·|¬O¥uÆ[¹î¨ì¤@¥b¡A¤]´N¬O´Á¤¤¤ÀªR ? 8Ó¤H¬ã§P»P¬ü°êFDA ¨ó°Ó°Q½×ªº²Õ¦X·|¬O¤Q¤À¦h¤¸ªº |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/21 ¤U¤È 12:42:26²Ä 2679 ½g¦^À³
|
¦³¹Ú¤j ¹Ú·Q»Ý¬ã¨sµ²ªG¨ÓÅçÃÒ¡A¬ã¨sµ²ªG«h»Ý®É¶¡¨Óµ¥«Ý¡Aµ¥«Ý¬O±ø©t¿Wªº¸ô (§¹¥þ»{¦P) A ³¯°|¤h³X½Í´£¨ì:®É¶¡¤£·|ªá«Ü¤[?¨ì©³·tÂæóºØ¥È¾÷?¥H¤U¬OÓ¤H²q·Q ¶È¨Ñ°Ñ¦Ò ,¤£ª¾²³¤j¤j¬O§_¦³§ó¦nªº²q·Q? 1 ¿z¿ï¯f±w¨C¤H¥´¯uÃÄ ,Æ[¹î¤@Ӥ릳§ÜÅé´N¦¬,¦¬®×³t«×·|«Ü§Ö, ¬ü°êÀù¯gµn¤ëp¹º¦³´£¨ì:¬ü°êªº§ÜÀù¬ã¨sÁö¤Q¤À¥ý¶i¡A¦ý³o¨Ç¦yºÝªº¬ã¨s¦¨ªG¡A«o¥u¦³5% ªº±wªÌ¯à¶i¦æÁ{§ÉªvÀø¡A©Ò¥H¤]n¼W¥[¾A¦X°Ñ»PÁ{§É¸ÕÅ窺Àù¯g±wªÌªº¼Æ¶q 2 ¦p¦³¹Ú¤j©Ò´£:ÀR«ÝOS¼Æ¾Ú (¼Æ¾Ú¹F¼Ð´N¥i¥Ó½ÐÃÄÃÒ) 3 FDA ¬ð¯}©ÊªvÀø®Öã ¥[°µ¤p«¬¤T´Á 4 ¥þ²y¤T´Á¥u´ú¶q§ÜÅé®Ä»ù,¨C¤H»Ý¥´§¹9°w,¨Ã¨Ì¾Ú¥xÆW¤T´Á§ÜÅé®Ä»ù»P¦s¬¡¹ïÀ³Ãö«Y¬Û¤ñ¹ï¬O§_¼Æ¾Ú±µªñ,,¨Ãµ¥«ÝP17 ¼Æ¾Ú¦¨¼ô®É«Å§G°±¤îÁ{§É 5 ³¯°|¤h³X½Í´£¨ì:FDA«Ü·Q¨ÓÀ°¦£¯E¹© ³zÅS OBI822 ²Å¦X¬ü°ê²{¦æªº«P¶iÄY«¯e¯fÃĪ«¼f¬dpµe¾÷²v«Ü°ª B 833 »P 822 ¥¼¨Ón°µªº¾AÀ³¯g¦³«Å|, ì«h¤W¥ý¬ãµo¤jÃıϤH, ¨ÃÆ[¹î¦óºØ¸ÕÀ³¯g¾A¦X¨Ï¥Î¦óºØOBI ¨t¦C ¬Û¤¬¤ä´© ¥H¤W¬OÓ¤H²L¨£ ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/10/21 ¤W¤È 08:06:49²Ä 2678 ½g¦^À³
|
Cliff¤j¤j§A¦n, §Ú°O±o2¤ëªk»¡«á¦³Óª§Ä³¡¨±wªÌ¯àµ¥¨º»ò¤[¶Ü?¡¨,³oª§Ä³¨Ó¦Û©ó±i¸³»¡¡¨8¡B9¡B10¬P´Á¥H«á¤~·|²£¥Í§ÜÅé,¡¨®É¶¡¤W®t¤£¦h¨âÓ¤ë,¥H¥´°wºâ,9°w®Éµ{¤]¥´¨ì¤F²Ä5°w ³Ìªñ¬O¤Q¤ë,³X½Í¬O¡u¡K¤@Ó¤ë¬Ý¬Ý¦³µL§ÜÅé ¦³§ÜÅ骺¶i¨Ó¡K¡v ¹ï¤ñ¤U ±oª¾ªº§ÜÅ骺®Éµ{2Ó¤ëÁYµu¨ì1Ó¤ë ¼ÖÆ[¬Ý C ¦n°ª¿³ ¦ý¬O¹ê»Ú¦p¦ó ¼K¼K ??? µ²½×¤]¬O¦p§A»¡ªº¡¨ §Ú§â³¯³Õ¤h¹ï822ªº¬Ýªk¥H¤j¤è¦V¨Ó¬Ý«Ý¡A¨S¦³¥h¦r¦r±ÀºV¡A²¦³ºÁÙ¬O¥H¸gÀçªÌ³oÃäµo¥¬ªº°T®§¬°«¡C¡¨ ¦n¹³¤]¬O ¥u¯à¦Aµ¥¤F ¯E¹©2/22ªk»¡ ²Ä¤@Ó´N¬O§Ú̬°¤°»ò·íªì2009¦~³]pªºPFS¨S¦³¹F¼Ð¡A³o¸Ì¦³¤TÓ«n¦]¯À¡G (1). 2009¦~³]p®É¨S¦³¦Ò¼{¨ì¤]¤£ª¾¹D IMMUNOTHERAPY ¦³DALAY RESPOND¡A¤£·|¨º»ò§Ö²£¥Í§ÜÅé¤j·§¦³¥´¨ì3¡B4°w¥H«á¤j·§n8¡B9¡B10¬P´Á¥H«á¤~·|²£¥Í§ÜÅé¡A¹ï¨Å骺PFS ,OVERALL SURVINALn¦³À°§Uªº¸Ün¦³¤@¬q®É¶¡¡A¿ï¯f¤Hªº®ÉÔ¨S¦³¦Ò¼{³o¤@ÂI¡A«Ü¦h¯f¤H¶i¨ÓÁÙ¨S²£¥Í§ÜÅé´N¤T®¶¥X§½¡C 20161014Ä_®q¥þ¥@¬É ±M³X¤¤¬ã°|¤h ³¯¨}³Õ ¡u¡K¤@Ó¤ë¬Ý¬Ý¦³µL§ÜÅé ¦³§ÜÅ骺¶i¨Ó¡K¡v |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/21 ¤W¤È 07:36:59²Ä 2677 ½g¦^À³
|
Cliff ¤j®¦¼w ÁÂÁ±zªá¤F¤j¶q®É¶¡¤Î«Ü¤jªº½g´T¡AÀ°¤pªº¸Ñµª°g¬z ¤å³¹²`«×¤Ï¬MµÛ¼¶¼gªÌªº¤º²[¡A©P©µ¥NªíµÛ«ä¸ôªº¼sÁï¡AÁ¾¨R§ó¬O¨IäºÀĪº¦ÛµM´²µo ¤pªºªY½à¤j¤å¡AÁ`¤ÏÂЫ~¨ý¦A¤T«ä¦Ò¡A²`©È¤£¸Ñ±zÁô³ë¤¤©ÒÁßÂò`«×ªº©¶¥~¤§µ ¤pªº¨C¦¸¾\Ū¤j¤å¡AÁ`¦¬Ã¬º¡º¡¡AµM©Î¥¼¯à¤F¸Ñ±z±ý¶Ç¹Fªº¤d¤À¤§¤@¡B¸U¤À¤§¤@ ÁöµM¦p¦¹¡A¤pªº¤]©|¯à·P¨ü±zªº·t¥Ü¡A³oÀ³¤£¬O¤pªº¹L«×²q·Q ¦A¦¸·PÁ±z |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/21 ¤W¤È 12:27:46²Ä 2676 ½g¦^À³
|
²q·Q¤j¤j¡A ³¯¨}³Õ°|¤hªºªÍµÆ¤§¨¥¡Aµ´¹ïȱo¤@Å¥¦AÅ¥¡A¥L¦³¾Ç¬Éªº¸ê¾ú¡A¤S¦³³Ð§ëªº¸gÅç¡A¥[¤W¹ï¥xÆW´µ¤gªº¼ö¸Û¡A¥Lªºµo¨¥¦³¤@©wªº»ùÈ¡AÓ¤H»{¬°³o¬OµL±e¸mºÃªº¡C¤£¹L¥D«ù¤H¦n¹³¨S¦³´£¨ì³¯³Õ¤h¦b¤µ¦~¥|¤ë¶¡±µ¥ôÁÞ°ò¸³¨Æªø¤§«e¬O¾á¥ô¤¤¸Î¬ü°ê¤l¤½¥qªº¸³¨Æªø¡A¦Ó¥B¤S¬O·í¦~¦t©÷¥Í§Þªº¶Ê¥ÍªÌ¡A©Ò¥H¥L¹ï¤¤¸Î·sÃĤº²[ªº´x´¤µ´¹ï¤£°µ²Ä¤G¤H·Q¡C³o¦¸³X½Í¤¤¥L¤]¦P®É³zÅS¤F¤@¨Ç¥L¹ï822ªº¬Ýªk¡A¦]¬°¥L»P°|ªø¦h¦~ªº±¡½Ë¡A§Ú¬Û«H¥L¹ï822ªº¤F¸Ñ¥ç¦h©ó±`¤H¡A©Ò¥HÓ¤H¤]ı±o³Õ¤h©Ò¨¥È±o«µø¡A¤£¹LÓ¤HÁÙ¬O§â¥¦·í§@¬O¤j¤è¦Vªº°Ñ¦Ò¡A¦Ó¤£»{¬°»Ýn¦r¦r°l³v¡A¥|¤ë«á¥L±µ¥ôÁÞ°ò¸³®y«á»P¯E¹©ªº¤¬°Ê¦p¦ó¨Ã¤£²M·¡¡A¡u¡K¤@Ó¤ë¬Ý¬Ý¦³µL§ÜÅé ¦³§ÜÅ骺¶i¨Ó¡K¡v¡A³oÓ±Ôz¨ä¹ê«¥Ì¦b¤µ¦~¤W¥b¦~¶¡¤w¤£¥u¤@¦¸±q±i¸³¤f¤¤Å¥¨ì¡A¬Æ¦Ü«á¨ÓÁÙÅ¥»¡·|¥HIgM®Ä»ù°µ¬°ªì¨B¦¬®×»P§_ªº¿z¿ï±ø¥ó¤ª¤ª¡K¦ý®É¦Ü¤Q¤ë¡A¾ú¸g¤K¤ëDr. Rugo¨Ó¥x«á¡A³o¼Ëªº½×½Õ¬O§_¤w³Qק藍±o¦Óª¾¡F·s¤T´Áªº³W¹º¶i«×¦p¦ó¡H¡K¡A§Ú§â³¯³Õ¤h¹ï822ªº¬Ýªk¥H¤j¤è¦V¨Ó¬Ý«Ý¡A¨S¦³¥h¦r¦r±ÀºV¡A²¦³ºÁÙ¬O¥H¸gÀçªÌ³oÃäµo¥¬ªº°T®§¬°«¡C ÁÙ¦³§Úı±o§ÚÌ¥u¬Ý¨ì¸Ñª¼«áªº§½³¡¸ê®Æ¡A°|ªø¬Ý¨ìªº¤º®eµ´¹ï¤ñ§Ú̬ݨ쪺n¦h±o¦h¡A¥ôÁ|¤@¨Ò¡A¹³¡u¡K¦b±µ¨üOBI-822·sÃĪvÀøªº¯f¤H¤¤¡A¦³¦Ê¤À¤§¤K¤Q¤·|²£¥ÍIgG¡BIgM§K¬Ì§ÜÅé¤ÏÀ³¡K¡v¡A³o¼Ëªº¤º®e¨Ã¥¼¦bASCO¤W§e²{¡A¥¼¨Ó·|¤£·|¦A´¦ÅSȱoÆ[¹î¡C ²q·Q¤j¤j¡A¤p§Ì»X±z¤£±ó¤w·P¨I«¡A¦ó¨Ó¨ã¦³¤W¹F¤ÑÅ¥¤§¯à¡H¥u¬O¸I¸I¹B®ð°¸º¸¼´¨ì¤@¨Ç¸ê®ÆŪ¨Ó¸ò¤j®a¤À¨É¦Ó¤w¡A¯un·PÁªº¸Ü¡AG¤j¬O³Ì¤j¥\¦Ú¡A¨S¦³¥L¤@¤ÁÁÙ¥ð¡C®ø®§¤è±³£¬O¥õ¿àª©¤W¦h¦ì¤j®a¼ôª¾ªº¯E¤Í¡A¤Î¨p¤U¦h¦ì¨S¦³Ãn¥úªº¤j©@¯E¤Í©Ò´£¨Ñ¡A¤p§Ì¥u¬O¬B¤H¤ú¼z¡A²q·Q¤j¤j¤Å°µ¹L«×¡u²q·Q¡v¡C G¤j¬O½Ö¡H´N¬OGoogle¡C§Ú§ä±o¨ìªº¸ê®Æ¡A¤j®a¤]¤@©w§ä±o¨ì¡A³o¤@ÂI¤]¤£µ}©_¡C |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/10/20 ¤U¤È 05:33:09²Ä 2675 ½g¦^À³
|
·PÁ Cliff¤j¸Ô²Ó¸Ñ»¡ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/20 ¤U¤È 04:38:35²Ä 2674 ½g¦^À³
|
chen6053¤j¤j ÁÂÁ±zªº¸Ñ»¡©MÃö¤ß ·PÁ±z |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/10/20 ¤U¤È 04:04:31²Ä 2673 ½g¦^À³
|
²q·Q¤j¤j§A¦n, ³¯³Õ¨º³X½Í Å¥§¹«á §Ú¦^ÀY¥h¬Ý 2¤ëªk»¡¥H¨Óªº¤@¨Ç¯d¦s¸ê®Æ ²³æ¤Æ«á ´N³o¬q , ....¦]¦¹¡A¥L»{¬°±N¨Ó¦b¥þ²y¶i¦æ²Ä¤T´ÁÁ{§É¸ÕÅ窺³]p¡A¥un°w¹ï¯à²£¥Í§ÜÅé¤ÏÀ³ªÌ¦C¤J²Îp¡A´N¯à¦¨¥\¡C..... ¦r¥y©Î¤£¦P ¦ý·N«ä¦P ±i¸³¤]»¡¨£ªk»¡»¡ªk ³¯³Õ¤]»¡¤@Ó¤ë¬Ý¬Ý¦³µL§ÜÅé ¦³§ÜÅ骺¶i¨Ó ÁÙ¦³¬ðµM ¥¼¨£§AµoÁn ¦³ÂI¾á¤ß §A¥XÁnªº ¨º¬O³£ok |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/20 ¤U¤È 03:55:22²Ä 2672 ½g¦^À³
|
ÁÂÁ·x·x¤j´£¨Ñ¯Î«e°|ªøªº¬Ýªk ¥i¯à¬O¤p§Ì·Q¤Ó¦h¤F¡A¦³¨Ç¨«¤õ¤JÅ] ¤p§Ì¥i¯à³Q§K¬Ì²ÓM§x¦í¤F¡A¥HPÆp¤û¨¤¦y¦Ó¤£ª¾ ¨Æ¹ê¤W¡A¤p§Ì¤]«Ü¦n©_FDA¤§»¡ µ²¦X¼·¤jªº¿Wªù®ø®§ ¤p§ÌÁÙ¬O«Ü¦n©_ ÁÂÁ±z¡I |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/10/20 ¤U¤È 03:32:22²Ä 2671 ½g¦^À³
|
²q·Q¤j:¯Î°|ªø¦b¸Ñª¼«á§Yªí¥Ü»P³¯°|¤h¬Û¦P¬Ýªk! ¥þ²yº¤äÁÞ¤À¤lªvÀù¬Ì] ¯Î±Ò´f¿³¾Ä 2016-02-22 03:33Áp¦X³ø °OªÌ¸â«Ø´I¡þ¥x¥_³ø¾É °w¹ï¨ÅÀù·sÃÄOBI-822¦b¥x¶i¦æ²Ä¤G¡þ¤T´ÁÁ{§É¸ÕÅç¸Ñª¼µ²ªG¡A¥DnÀø®Ä«ü¼Ð¥¼¹F²Îp¾Ç¤WÅãµÛ·N¸q¡A¦ý¥Dn¬ãµoªÌ¡B¤¤¬ã°|ªø¯Î±Ò´f¬Q¤Ñªí¥Ü¡A¯Â´NªvÀø©Ê¬Ì]¨¤«×¨Ó¬Ý¡A¡u§Ú±q¥¼¬Ý¹L³o»òº}«Gªº¼Æ¾Ú¡C¡v¥L»{¬°¡A³o¶µÁ{§É¸ÕÅç¬O¦¨¥\ªº¡A¨Ã¥H¡u«D±`¿³¾Ä¡v§Î®e¦¹¨è¤ß±¡¡C ¨ÅÀù·sÃÄOBI-822¡A¬O¯Î±Ò´f²v»â¤¤¬ã°|¹Î¶¤¶}µoªºÀù¯gªvÀø¬Ì]¡A«á¨Ó§ÞÂà¥xÆW¯E¹©¥Í§Þ¤½¥q¡AOBI-822ªºÁ{§É¸ÕÅçµ²ªG¡A¤£¶È§ñÃö°ê¤º¥Íª«¬ì§Þµo®i¡A¤]¬O°ê»Ú¶¡¶}µo§K¬ÌÀøªk¥Î©ó§ÜÀùªº«n¨½µ{¸O¡A¸Ñª¼«e´N³Æ¨ü¦U¬ÉÆf¥Ø¡C ¯Î±Ò´f»¡¡AOBI-822¬O¥þ¥@¬É²Ä¤@Ó¥HÁÞ¤À¤l»s¦¨ªºªvÀù¬Ì]¡A³o¦¸¥xÆW°Ñ»P²Ä¤G¡þ¤T´ÁÁ{§É¸ÕÅç¡AÁöµM¨Ìì¥ý³]pªº¼Æ¾Ú¥¼¹F¼Ð¡A¦ý¥i¯à»P¨ü¸ÕªÌ¤H¼Æ¤Ó¤Ö¡A¥H²{¦³§ÜÀùªvÀøÃĪ«ªº¼Ð·Ç¤Ó°ª¦³Ãö¡C¦ý¥L»¡¡A¦pªG¥HªvÀø©Ê¬Ì]¨Ó¬Ý¡A¥¦¬O«D±`¦¨¥\ªº¡C ¯Î±Ò´f³zÅS¡A¦b±µ¨üOBI-822·sÃĪvÀøªº¯f¤H¤¤¡A¦³¦Ê¤À¤§¤K¤Q¤·|²£¥ÍIgG¡BIgM§K¬Ì§ÜÅé¤ÏÀ³¡A¤×¨ä¬OIgG¯S§O°ª¡A¹ï³o¨Ç±wªÌ´N¯à¹F¨ì§ÜÀùªºÀø®Ä¡C¦]¦¹¡A¥L»{¬°±N¨Ó¦b¥þ²y¶i¦æ²Ä¤T´ÁÁ{§É¸ÕÅ窺³]p¡A¥un°w¹ï¯à²£¥Í§ÜÅé¤ÏÀ³ªÌ¦C¤J²Îp¡A´N¯à¦¨¥\¡C ¯Î±Ò´fÁ|¬y·P¬Ì]©ÎB«¬¨xª¢¬Ì]¬°¨Ò¡A¦³¨Ç¤H§Y¨Ï¥´¤F¬Ì]¡A«o¨S¦³²£¥Í§ÜÅé¡A¨Ã¤£¥Nªí¸Ó¤ä¬Ì]µL®Ä¡A¦Ó¬OÓ¤HÅé½è¤£¦P¡F¦P¼Ëªº¡AªvÀø¨ÅÀùªº¼Ð¹vÃÄ¡u¶PÀù¥¡]Herceptin¡^ ¡A¥u¾A¥Î¡u²Ä¤G«¬¤HÃþªí¥Ö¥Íªø¦]¤l±µ¨üÅé¡]Her2¡^¡v¶§©Ê±wªÌ¡A³oÃþ¯f¤H¥u¥e¥þ³¡¨ÅÀù±wªÌ¨â¦¨¡A¥L¼ÖÆ[¹w´Á¡AOBI-822·sÃÄ¥¼¨Ó¥un´ÂªvÀø©Ê¬Ì]¶i¦æÁ{§É¸ÕÅç¡A«D¥H¤@¯ëÃĪ«¼Ð·Ç¡AÀ³¯à«Ü§Ö¹LÃö¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/20 ¤U¤È 03:18:13²Ä 2670 ½g¦^À³
|
Cliff ¤j®¦¼w ÁÂÁ±z¼ö¤ßªº¸Ñ»¡ ¦P®É¡A½Ð±Ð±z¹ï³¯°|¤h´N¯E¹©ªº³X½Í¤º®e¡A¦³¦ó¤ß±o ±z²M¤£²M·¡³o¨Ç°T®§ªº¨Ó¥Ñ¡H ¤pªº¤í¯Ê¬ÝÀ´ªºª¾ÃÑ©M·Q¹³¡A¾ú¸g¤@¶g¤´¬O¯íµM ¤pªº¤]²¤²qª¾±z¦³¤W¹F¤ÑÅ¥¤§¯à¡A¬G¦n©_¦¹°Ý ¤£¦n·N«ä¡A¤pªº·Q¨ì¦³ÂIÅܥեؤF¡A±z´N·í¤pªº¨S°Ý¡A¬°Ãø±z¤F ÁÂÁ±z¡A¨¯W¤F ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/20 ¤W¤È 12:06:51²Ä 2669 ½g¦^À³
|
§Úı±o2012/08/08·s»D½Zªº¡uéwªº¯f¤H¡v¡×¡uCR¡BSD¡BPR¡v 2013/06/05©x¤è·s»D½Zªº¡u§e²{¯e¯féw¡v¡×¡uSD¡v¡F¡u¦³¤ÏÀ³ªº¯f±w¡v¡×¡uPR¡BCR¡v¡C ¤W±ªº¨º¤@«hÁ¿±o¤ñ¸û²²¤¡F¤U±ªº¨º¤@«hÁ¿±o¤ñ¸û¥J²Ó¡F·N«ä¬Û®t¤£¦h¡C ¬Ý^¤åª©ªºÁ{§É¸ÕÅ窺ì¤å³Ì·Ç¡G¡]clinicaltrials.gov/ct2/show/NCT01516307?term=OPT-822&rank=1 ¡^ ¡uSubjects with metastatic breast cancer who have achieved stable disease (SD), partial response (PR), or complete response (CR) after at least 1 regimen of anticancer therapy (i.e. chemotherapy or target therapy, either alone or in any combination). Involvement of supraclavicular lymph node is considered metastasis.¡v ¤¤¤åª©ªºÁ{§É¸ÕÅ窺ì¤å¤]¦³§U©ó¤F¸Ñ¡G¡]www1.cde.org.tw/ct_taiwan/search_case2.php¡^ ¡u±wªÌ¶·¬°Âಾ©Ê¨ÅÀù±wªÌ¥B¦b±µ¨ü¦Ü¤Ö¤@½uªº¤ÆÀøÃĪ«(¦p¤Æ¾ÇªvÀø¡B¼Ð¹vªvÀø©Î²üº¸»XªvÀø¡A³æ¿WªvÀø©Î¨Ï¥Î¨âºØ¥H¤WÃĪ«ªvÀø¬Ò¥i)«á¹F¨ì§¹¥þ½w¸Ñ¡A³¡¤À½w¸Ñ¡A©Î¯e¯féwªºª¬ºA¡C¡v ¥t¥~¡A¤µ±á¬Ý¨ìªº¡GGlobo H ¦b¥Òª¬¸¢Àùªº²§±`ªí²{¡C 2016 Oct¡G¡uAberrant expression of tumor-associated carbohydrate antigen Globo H in thyroid carcinoma.¡v¡]onlinelibrary.wiley.com/wol1/doi/10.1002/jso.24479/abstract ¡^ ¥xÆWªº¬ã¨s¡G°¨°º¡B¥_Âå¡K¦X§@¬ã¨s¡C |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/10/19 ¤U¤È 04:30:41²Ä 2668 ½g¦^À³
|
¹ê»Ú¦¬ªº±wªÌ¤ñ 101¤½§iªºÄYV ºâ²rªº ¤£¹L¤]¥i¯à¬°¤Fn¹F¨ì¦¬®×¤H¼Æ ©Ò¥H¦¬ |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/10/19 ¤U¤È 03:09:48²Ä 2667 ½g¦^À³
|
§Ú¬O²z¸Ñ ¥ý«e±µ¨ü¹L¤@¨ì¤G½uÂಾ©Ê¨ÅÀùªvÀø¥B¹ï³Ì«á¤@½uªvÀø§e²{¯e¯féw©Î¦³¤ÏÀ³ªº¯f±w¡A => ¥ý«e±µ¨ü¹L¤@¨ì¤G½uÂಾ©Ê¨ÅÀùªvÀø¥B¹ï³Ì«á¤@½uªvÀø§e²{ ¡¨¯e¯féw¡¨ ªº¯f±w¡A ¥ý«e±µ¨ü¹L¤@¨ì¤G½uÂಾ©Ê¨ÅÀùªvÀø¥B¹ï³Ì«á¤@½uªvÀø§e²{ ¡¨¦³¤ÏÀ³¡¨ ªº¯f±w¡A ¥H¤W¨âÃþ³£¶i¨ì¤F¸ÕÅç¥h |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/10/19 ¤U¤È 02:26:02²Ä 2666 ½g¦^À³
|
½Ð±Ð¦U¦ì¤j¤j 1.¹êÅç²Õ²£¥Íªº±M£¸©Ê§ÜÅé¸ò¹ï·Ó²Õ²£¥Íªº§ÜÅé¬O£¸¼Ëªº¶Ü.¦³¨Ç¤H»¡£¸¼Ë.¦³¨Ç³ø§i»¡¤££¸¼Ë. 2.¬°¦ó¤½¥qºô¯¸ªº¤½§i2012»P2016¹êÅç¹ï¶H¼W¥[¤F¡§©Î¦³¤ÏÀ³¡¨.©Î¦³¤ÏÀ³¬O§_´N¬O¤j®a½èºÃªº¦a¤è ¥xÆW¯E¹©¨ÅÀù·sÃÄÀò»OÆW¹ª«ÃÄ«~ºÞ²z§½(TFDA)®Ö㥿¦¡¶i¤J²Ä¤T´ÁÁ{§É¸ÕÅç ¤é´Á: ¥Á°ê101¦~8¤ë8¤é ¥xÆW¯E¹©¥Í§ÞªÑ¥÷¤½¥q¤µ¤é«Å¥¬¡A¨äªvÀøÂಾ©Ê¥½´Á¨ÅÀù¬Ì]OBI-822/821(«e¦W: OPT-822/821) ¤wÀò±o»OÆW¹ª«ÃÄ«~ºÞ²z§½(TFDA)®Öã¶i¤J²Ä¤T´ÁÁ{§É¸ÕÅç¡A¥»¸ÕÅç¦Û2010¦~11¤ëÀò½Ã¥Í¸p¦b»OÆW¶i¦æÁ{§É²Ä¤G/¤T´ÁÁ{§É¸ÕÅç¡A°w¹ïÂಾ©Ê¥½´Á¨ÅÀù²Ä¤@½u»P²Ä¤G½u¤ÆÀø«á¡§Ã©wªº¯f¤H¡A¥HÀH¾÷¤À°t¤è¦¡¶i¦æ·sÃÄÁ{§É¸ÕÅç¡A¥»¸ÕÅç¥Ñ2010¦~11¤ë±Ò°ÊÁ{§É¤G´Á¸ÕÅç¡A¤é«e¸g»OÆW¹ª«ÃÄ«~ºÞ²z§½¸g¦w¥þ©Ê³ø§i¬d®ÖµL¸·¡A§Y¤é°_¶i¤J²Ä¤T´ÁÁ{§É¸ÕÅç .¨Æ¹êµo¥Í¤é:105/06/05 2.¤½¥q¦WºÙ:¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.¶Ç¼½´CÅé¦WºÙ:¤£¾A¥Î 6.³ø¾É¤º®e:¤£¾A¥Î 7.µo¥Í½t¥Ñ:¥»¤½¥q¤µ¤é(6/5)10ÂI30¤À©óÂd¶R¤¤¤ß¥l¶}°OªÌ·|»¡©ú¡G ¥xÆW¯E¹©¥Í§Þ¡]4174¡^¤µ(5)¤é«Å§G¡A¸Ó¤½¥q©Ò¬ãµo¤§¨ÅÀù·sÃÄOBI-822/OBI-821¡]«e¬°OPT-822/OPT-821¡^¡A¤w©ó¬ü°êªÛ¥[ô©ÒÁ|¦æªº¬ü°êÁ{§É¸~½FÂå¾Ç·|¡]ASCO¡^2016¦~·|¡A¦b¸Ó¦a®É¶¡6/4¤U¤È14:15¡A¥H¤fÀY²³ø§Î¦¡¡]¬ã¨sºKn1003¸¹¡^µoªí¤F¦¹¤@¥D°Ê¦¡§K¬ÌÀøªk¡A¥Î©óÂಾ©Ê¨ÅÀù¯f±wªºÁ{§É®Ä¯q¤Î§K¬Ìì©Ê¤§¤G/¤T´Á¬ã¨s¼Æ¾Ú¡C¸Ó¬ã¨sÅã¥Ü¡A¹ï©ó¿©±w±ß´ÁÂಾ©Ê¨ÅÀùªº¯f±w¡A¨Ã¥¼¹F¨ìµL´c¤Æ¦s¬¡´Á¡]PFS¡^ªº¥DnÀø®Ä«ü¼Ð¡A¦ý¬Û¸û©ó±µ¨ü¦w¼¢¾¯ªº¯f±w¡A¬ù50%¹ï§K¬ÌÀøªk¯à²£¥Í©úÅã§K¬Ì¤ÏÀ³ªº¯f±w¦¸±Ú¸s¡A¨äPFS«h¥i¨£ÅãµÛ§ïµ½¡C¦Ü©ó¸Ó¬ã¨sªº¦¸nÀø®Ä«ü¼Ð¡BÁ`¦s¬¡´Á¡]OS¡^¥Ø«e¼Æ¾Ú©|¥¼¦¨¼ô¡C ¬ü°ê¥[¦{¤j¾Çª÷¤s¤À®Õ®üÛ}°Ç®a±Úºî¦XÀù¯g¤¤¤ß¨ÅÀùÂå¾Ç»PÁ{§É¸ÕÅç±Ð¨|¥D¥ô¡B¥ç¬°¸ÓÁ{§É¸ÕÅ窺¬ã¨sÂå®vHope S. RugoÂå¾Ç³Õ¤h¤fÀY³ø§i®É«ü¥X¡A¡u¹ï©ó¦¹¤@¥Î©óÂಾ©Ê¨ÅÀù¯f±wªº³Ð·s¥D°Ê¦¡§K¬ÌÀøªk¡A¥Ø«e±o¨ìªº¼Æ¾Ú¤wÅã¥ÜOBI-822/OBI-821ªºÁ{§É®Ä¯q¡C§Ú̱N¥H³o¶µ¸ÕÅç¼Æ¾Ú¡A§@¬°¤U¤@¨B¤T´ÁÁ{§É¸ÕÅç³]pªº¨Ì¾Ú¡A¨Ã±q¤¤§ä¥X¥i¯à¦Û¦¹¤@§K¬ÌÀøªkÀò¯qªº¯f±w±Ú¸s¡C¡v Ãö©ó¤G/¤T´ÁÁ{§É¸ÕÅç ¥»¬ã¨s¬O¤@¦h°ê¡B¦h¤¤¤ß¡BÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº¤G/¤T´ÁÁ{§É¸ÕÅç¡]NCT01516307¡^¡AÀøµ{¬°¦b41¶g´Á¶¡¡Aµ¹¤©¤E¦¸OBI-822/OBI-821ª`®g©Î¦w¼¢¾¯¡A¦ÛÀH¾÷¤À²Õ°_ºâ¡A°lÂ̪ܳø2¦~ªºµL´c¤Æ¦s¬¡´Á¡]PFS¡^¡A¨Ã°lÂÜÁ`¦s¬¡´Á¡]OS¡^³Ìªø5¦~¡C¸Ó¸ÕÅç¦@¦³348¦W·N¹ÏªvÀø¯f±w¡A¥ý«e±µ¨ü¹L¤@¨ì¤G½uÂಾ©Ê¨ÅÀùªvÀø¥B¹ï³Ì«á¤@½uªvÀø§e²{¯e¯féw©Î¦³¤ÏÀ³ªº¯f±w¡A.... |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/10/18 ¤W¤È 03:22:52²Ä 2665 ½g¦^À³
|
ì¨Ó¦p¦¹¡A¤Ó¾_Åå¤F¡A¬õ¤£Åý |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/10/17 ¤U¤È 01:38:46²Ä 2664 ½g¦^À³
|
ÁÂÁ·x·x¤j´£¨ÑªºÀɮסI ²q·Q¤j¡A¤p§Ìɱzªº¦W¦r²q·Q¤@¤U¡I ®Ú¾Ú³¯¨}³Õ°|¤hªº»¡ªk¡A¤p§Ì¦³¥H¤U´XÓ²q·Q¡G 1.¦b°ª§ÜÅé±Ú¸s¨¤W¡A¥´¤F822¤§«á¡A¤@Ӥ뤺¥i¥H§ä¨ì¬YºØ§K¬Ì²ÓM¡A¬O»P¥ÍѨӪº¡A¦ý¤£¬O¨CÓ¤H³£¦³ 2.¥´¤F822¤§«á¡AY¦b¤@Ӥ뤺§ä¨ì³oºØ§K¬Ì²ÓM¡A³o¼Ëªº±wªÌ´N·|²£¥Í°ª§ÜÅé¡C°ª§ÜÅ骺²£¥Í¡A¦³ªº±wªÌ¬O¤@Ó¤ë¡B¨âÓ¤ë¡B¤Ó¤ë¡B¤CÓ¤ë©Î§ó¤[¡AÀËÅç³oºØ¯S§Oªº§K¬Ì²ÓM¡A¥i¥H¦b¤@Ӥ뤺´N¥i¥H½T©w¸Ó±wªÌ¬O§_ÄÝ©ó822¾A¥Î±Ú¸s¡A®É¶¡¤W§ó¦³®Ä²v¡C 3.²£¥Í³oºØ¯S§Oªº§K¬Ì²ÓMªº±wªÌ¡A´N¦Ê¤À¦Ê¥i¥H²£¥Í°ª§ÜÅé¡H 4.³oºØ¯S§Oªº§K¬Ì²ÓM¥u¦³¦b¤HÅé¾D¨ì¥~¨Ó¤J«I®É¤~¸û¤j¶q²£¥Í¡H¥´822·|²£¥Í³oºØ¯S§Oªº§K¬Ì²ÓM¡A¨º»ò¦pªG¸Ó±wªÌ(»P¥ÍѨӪº)¾D¨ì¤HÃþ§K¬Ì¨t²Î¨S¨£¹Lªº²Óµß¯f¬r¤J«I¡A¬O§_¤]²£¥Í³oºØ¯S§Oªº§K¬Ì²ÓM¡H»P¥t¥~¨S¦³»P¥ÍѨӪº¤H¬Û¤ñ¡A»P¥ÍѨӴN¦³ªº¤j¬ù50%ªº¤H¤fªº§K¬Ì¨t²Î¬O§_¤ñ¸û±j¤j¡HY¸I¨ì¥@¬ö¤j¯f¬r¡B²Óµß¡A¦bµLÃÄ¥iÂ媺±¡ªp¤U¡A¦s¬¡²v¬O§_»·°ª©ó¥t¥~50%ªº¤H¤f¡H 5.°·±dªº¤H¥´¤F822¡A¬O§_¤]¬O¤j¬ù50%ªº¤H»P¥ÍѦ³ªº¥i¥H²£¥Í³oºØ§K¬Ì²ÓM¡A¬ù¬Ûµ¥©ó50%ªº¤H¥i¥H²£¥Í°ª§ÜÅé¡HRugo´¿»¡¹L¡A¨Ã«D¨Å骬ªp«Ü®tªº¤H´N¤£·|²£¥Í°ª§ÜÅé¡H 6.¤½¥q¤wª¾¡A°£¤F³¯°|¤hª¾¹D¡AFDAª¾¹D¡A¬ì¾Ç¬ÉÁÙ¦³¦h¤Ö¤Hª¾¹D¡H¤p§Ì©tº|¹è»D¡A±q¨Ó¤£ª¾¦³³o¼Ëªº¬ì¾Ç±`ÃÑ¡A¤½¥q¤T´ÁÁ{§É³]pÁÙ¦b¶i¦æ¤¤¡A³o¼Ëªº·sµo²{¦¤@ÂIÁÙ¬O±ß¤@ÂI¤½¥¬¡A¹ï¤½¥qªºªø»·§Q¯q¬O¦nªº¡H¼ç¦bªºÄvª§ªÌ©Î¼ç¦bªº¦X§@¹Ù¦ñª¾¹D³o¥ó¨Æ¶Ü¡H ¤p§Ì©tº|¹è»D¡A¹ï³¯°|¤hªº»¡ªk¬Û·í¦n©_¡A¬Ý¨Ó«áÄò°ò¥»±ªº¶i®i¬O¶V¨Ó¶Vºë±m¤F¡I |
|
|
·|û¡G¼ï¤¤Áú10141277 µoªí®É¶¡:2016/10/17 ¤W¤È 12:27:35²Ä 2663 ½g¦^À³
|
ÁÙ°O±o¸ò¡]¦Ñ´¤j¡^°Q½×¹L¡A§K¬ÌÀøªk¹ï·~¤ºªº½ÄÀ»¦³¦h¤j¡C ·s»â°ìµL¥i°Ñ¦Ò¡A¬OºÃ¼{ÁÙ¬OºÃ°Ý¡A¥Ø«e¤£±oª¾¡A¦ý½T©wªº¬O¡A²{¶¥¬qªºÂåÀøÅé¨t¦³µÛ¦å¦½²£·~ªº¥]µö¡C ¦p¤w¬O¤ô²`¤õ¼ö¡A§K¬ÌÀøªkªº¦¨¥\µLºÃ¬O³·¤W¥[Á÷¡C ´N¥Ø«e¨Ó¬Ý¡A¾ÞÁaµÛªÑ»ù¤W¤U¤§¤H¸¨¦b¤¤¹ê¡B¤j¤á»Pªk¤H¤§¶¡¡C ¦Ó¤j¤á»Pªk¤H¦]¨ä³¡¦ìÃe¤j¡AµL¶q®ÉÃø¦³§@¬°¡A³o®Éªº¤¤¹ê¤á¤Ï¦Ó©ö°Ê¡A¶¶¶Õ¦Ó¬°¤£Ãø¡]ÂðΪ̤]¦h¡^¡C ¦ý¤¤¹ê¤á¸Ì¤S¥H·~¤º¤H¤h©~¦h¡A³oÁÙ¯u·L§®¡AÃø°Ú¡I¡I |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/10/16 ¤W¤È 10:00:00²Ä 2662 ½g¦^À³
|
»{¦PWalker¤jªº»¡ªk 2¤ëè¸Ñª¼®É¡A¥~±£¸°ï±M®a¤]¬O½èºÃ³o¡A½èºÃ¨º¡A¨ä¹ê³o¨Ç±M®a¥Ç¤F«Ü¤jªº¿ù»~¤Î«Ü¤£ÄYÂÔªººA«×¡A¹ïӮ׳£¨SÔ£¤F¸Ñ¡A´N¥H¥L±M®a·Q·íµM¦Õªº´£¥X½èºÃ¡A¯u¬O»~¾É¤j²³¡A ±i¸³»¡¹L¡A³o¬O¥þ·sªº»â°ì¡A¥]¬A§ë¸ê¤H¡A¯E¹©¹Î¶¤¡A¥~±ªº±M®a¡A¥~³¡ªº±M®a¡A´CÅé³£³£¤£¤F¸Ñ¡A´£¥X½èºÃÁÙ¬OÄYÂÔ£¸¨Ç¤ñ¸û¦n |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/10/16 ¤W¤È 08:14:28²Ä 2661 ½g¦^À³
|
©Ò¥H§Ú»¡ §Ú ¹ï¤½¥q¦³ºÃ¼{¡A¥i¨S¤@¤f«r©w¤½¥q¦³°ÝÃD! |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/10/16 ¤W¤È 08:08:55²Ä 2660 ½g¦^À³
|
³\¤j: §Aªº§µ¤ß¬Ý±o¨ì¡A¦ýÁÙ¬On±µ¨ü¥i¯àªvÀøµL®Äªº¨Æ¹ê! Ra-223 ´N¬O³oÓ·N«ä¡A¦Ü¤Ö¤H®a¦³p2ªº¼Æ¾Ú!¨ä¥Lºô¤Í«Øijªº¤j·§´N¯Ê¥F¹ê½èÃÒ¾Ú! ¥t¥~¤W¦¸¦³´£¨ìKeytruda¡A¥i»¡¬O³o¦¸ESMO³Ì¤j«GÂI¡A¦Ó¥B²{¦bÁͶլO©T©w¾¯¶q§Y¥i (100mg/Q3W)¡Aoff-label¨Ï¥Î3¾¯¤j·§40¸U¥ª¥k!¤£¹L³o¥u¦³P1ªºÃÒ¾Ú¤O¡C |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/16 ¤W¤È 08:03:13²Ä 2659 ½g¦^À³
|
T ¤j ±zªº³¯z, «Ü¦h³£¬O°²³], ¥H®wÂêѬ°¨Ò, ±z¯à¦A¦h¤@Ó°²³]¨Ó«ä¦Ò¶Ü? ¤ñ¦p»¡±i¸³¤@¶}©l»¡, ¨Ì·í®É±ø¥ó¬O¤£¥i¥HÅ@½L, ¦ý¹L´X¤Ñ¤S§ï¤f»¡nÅ@½L, ¬O¤£¬O¦]¬°¸gÅ礣¨¬, ¨S¹J¹L³oºØ¸ê¥»¥«³õ±Y¸Ñªº±¡ªp, ©Ò¥H¦b¤@¨Ç¤Hªº«Øij»P¬ã¨s¥i¦æ©Ê¤U¤~§ï¤f? ¦pªG³o¬O¥Lºë¤ßµ¦µeªº®æ§½, ¥L»Ýn¥ý§_¨MÅ@½L¦A§ï¤f¶Ü? ³o¸Ì¦³¦h¤Ö¤H°µ¹L±Y½Lªº¦M¾÷³B²z? ¤j®a³£¥i¥H§â°²³]»¡±o®Ô®Ô¤W¤f, ¦ý¦³¤@¤Ñ±z¬OÂħQ¾÷ªø®É, ±z¬O§_·|§â¸¾÷°¸¨¦bªe±¤W? ESMO ¤]¬O¤@¼Ë, ¦pªG²{¦b±¡ªp¬O³¯¨}³Õ©Òzªºª¬ªp, FDA ¤wª¾¾å¼Æ¾Ú, ´Nµ¥¯E¹©¸É¥R¼Æ¾Ú, ¦A¸É°µ¤@¨Ç¼Æ¾Ú, ¦pªG¤½¥q¬O±zªº, Ãø¹D¤£·|·Q¥ý§â³o²£«~¤¶²Ðµ¹¤j®a, Å¥¨ú¨ä¥L¥ý¶iªº·N¨£? Booth ¯à¤¶²Ð¦h²`¤J? ´eµÛÀY°µ´N¤@©w¬O¥¿¸Ñ¶Ü? ¹ï©ó¼Ú¬wªºÃö«Y, ¤£¬O¤]¸Ó«Ø¥ß¶Ü? §Ú̪º±Ð¨|¨t²Î·|±Ð¾É§ÚÌ°²³]»P¨DÃÒ, ¦ý²{¹êªÀ·|¤W, °²³]«Ü®e©ö, ¨DÃÒªºÃø«×«o¥i¯à«Ü°ª, ¦b³oºØ±¡ªp¤U, ÃhºÃ, ¥Í®ð»P¤£«H¥ô¬O¥¿±`ªº, ¦ý½Ð§O§Ñ°O, ¨º¨Ç³£ÁÙ¥u¬O°²³], ¤£¤@©w¬O¨Æ¹ê |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2016/10/16 ¤W¤È 07:30:36²Ä 2658 ½g¦^À³
|
T¤j: ¦b§AÂ_°T¤§«e §Æ±æ¯à¬Ý¨ì§Ú¤W¦¸ªº°ÝÃD À°¦£¦^ÂФ@¤U~ÁÂÁÂ. ·Q½Ð±Ð(¤£¦n·N«ä¸ê½è¾q¶w,©Ò¥H¦A½T©w¤@¤U) §Aªºªí¹FÀ³¸Ó¬O¥H¤U³oÓ·N«ä [¦¨°©¦³®Ä,»k°©µL®Ä ³o¼Ëªº»¡ªk¥i¯àÁÙ¤ÓªZÂ_] °©Âಾ«á°©Àf³Q¯}Ãa´N·|¦³««Øªº¾÷·| ²z½×¤WÅJ223´N·|¦³®Ä(°±¸g©Î¶Pº¸»XªvÀøªº¤k©Ê¥i¯àÀø®Ä§ó§C) ¥u¬O«ÜÃøª¾¹D®ÄªG¦p¦ó ¹ï¶Ü? ¤]ÁÂÁ§A¹ï¯E¹©ªºª÷¥É¨}¨¥ ¸ê¥»¥«³õ¬O¥ûÀIªº §ó¦óªp¸ê°T¤£¹ï¯¯ »P¸êª÷¦¨¥»¤£¹ï¯¯ °J¤ß¬è±æ¤½¥q¥H¸Û«H¬°¥» §V¤OÂÔ·V½ñ¹êªº¨«¦n¨C¤@¨B. |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/10/16 ¤W¤È 03:04:01²Ä 2657 ½g¦^À³
|
¤@¨Ö¦^µª§Ú©Ò¿×ªº¸Û«HºÃ¼{ 1. ²{¦bªºªÑªFµ²ºc¡An°²³]¤j¦h¼Æ¤H¬O¦b¤WÂdIPO¶i³õ¡A·í®É²{¼W20KªÑ¡A±q¸ê¥»¥«³õ¨ú±o62»õTWD¡A³o¨Ç¿úÀ³¸Ó¬O¥R¹ê¤½¥qÀç¹B¡A®³¨Ó¶R®wÂêѴN¬O¦³°ÝÃD¡C 2013/10¤½¥q·s»D½Z: www.obipharma.com/index.aspx?lang=chi&fn=news_content&no=24 ¥xÆW¯E¹©¦¹¦¸²{ª÷¼W¸ê¡A¥Dn¬°Ñºª`¨ÅÀùªvÀø©Ê¬Ì]OBI-822Á{§É¸ÕÅçpµe¡Cºôù¤@¬y±M·~¤H¤~¡B¨}¦nªº¬ãµoºÞ²z¡A´£°ª©Ò¦³¶}µopµe¦¨¥\²v¡A¥ç¦Ò¼{°t¦X¬ãµo¦¨ªG¡A°£¤F¦b¤¤¬ü¤Î¨È¤Óµ¥«n¥«³õ¦¨¥ßÀç¾P¹Î¶¤¥~¡A¤]¤£±Æ°£»P°ê»ÚÃļt¦X§@¡A¥H¨ú±o³ÌÀu±ÂÅv±ø¥ó 2. ½Ð°Ý¤W±²{¼W¥Øªº°£¤F¬J¦³ªºIND¸ÕÅçÄ~Äò¶i¦æ¡A¨ä¥L¦³¬Æ»ò«¤j¶i®i? 3. ¤U±¬O¤µ¦~ESMOªºindustry sponsored symposium¦Cªí¡A½Ð°ÝOBI-¯{¤j¿úªº¥Øªº? www.esmo.org/Conferences/ESMO-2016-Congress/Exhibition-Satellite-Symposia/Industry-Sponsored-Satellite-Symposia ·|ÃÙ§U¦¹Ãþ«¬·|ijªº¼t°Ó¤£¥~´XºØ: A. °ê»Ú¤jÃļt¡A¤w¸g¦³¦h¶µÃĪ«¤W¥«¡A·s¤W¥«ÃĪ«´£¨Ñ·s°T¹ªÀyÂå®v¨Ï¥Î¡A¤w¤W¥«¦h¦~ÃĪ«´£¨Ñ§ó·sÀø®Ä¸ê°T±j¤Æ¥«³õ!¨Ò¦p (BMY, Merck, Novartis, Pfizer, Lilly...) B. ¤¤«¬Ãļt(Mid-cap)³q±`¬O·sÃÄè¤W¥«¡A±NÁ{§É¸ÕÅ禨ªG®i²{¨ÃÅýÁ{§ÉÂå®v»{ÃÑ·sÃĪ«(¨Ò¦pExelixisªºCabo)¡A©Î§Y±N¤W¥« (¨Ò¦p PUMA ªºneratinib¡A AriadªºBrigatinib)¡A¤W±¨âÓÃij£¤w§¹¦¨Á{§ÉP3¡AFDA ¤]¤w¸g±µ¨üNDA¤F! ¬Æ©ÎLillyªºAbemaciclib¡AÁöP3ÁÙ¥¼§¹¦¨¡A¦ý³oÓÃĤw®³¨ìBTD¡A¥unP3§ó·s¸ê®Æ°÷¦n¡AÀH®É¦³¥i¯à°eNDA¡C ªáÂI¤ß«ä¥i¥H¬Ý¨ì¨ä¥L¤½¥qªá¿ú¬O¦³¹D²zªº!¦Ó¥B¤j³¡¤À¦b¤j·|³£¦³§e²{·sdata¡A®b½ÐPI¡Bco-PI«Ü¦X²z! ¦pªG¬O¨S¦³abstract¥i§ë(©Î§ë¤F¨S³Q±µ¨ü)¡A·QÃn¥úÃÙ§U¡AboothÅu¦ì§Y¥i! §O§Ñ¤F¡A¤½¥qÁÙ¨SÀò§Q¡Aªáªº¬O§ë¸ê¤Hªº¿ú¡Aì©l¤jªÑªF¤Î¸g²z¤H(Áö«ùªÑ³Ì¦h¡A¦ý¦¨¥»»·§C©ó´²¤á)²{¦³«ùªÑ¥i¯à³£¬O¹s¦¨¥»ªº(¨Ò¦p¸³¨Æªøªº^Äݺû¨Ê¸s®q°ÓAlpha«Ü¥i¯à´N¤w¸g±N³Ìªì¦¨¥»®³¦^¤F)(¯Î§¨qªº«ùªÑ¤£¤]¬O¦p¦¹) ªáªÑªFªº¿ú°µ¤½Ãö®b½ÐPI¡Aco-PI¡A¬Æ¦Ü¯Î°|ªø¨ìESMO¡AÀ³¸Ón¦³¹ê½è®Ä¯q!¬Ý¤£¨ì®Ä¯q§Ṳ́pªÑªF¤£¯à»¡¸Ü? ·íµM§Ú¤]¥i¥H¹³¬Y¬Y¦bESMO«e°²³] 1. ¤½¥q¦³¦nªº§ó·sdata¦b¤â¡A¥i¯à¥i¥H°eNDA¡A©Ò¥H¿ìindustry sponsored symposium RE: ³o§óÁV¡A¸ê°T¤£¹ïµ¥¤U¸g²z¤H¶R½æªÑ²¼´N¤ñ´²¤á§Ö¤@¤â¡A¥xÆWÁö¦³ªk³W¡A¦ý¤º½u±q¥¼¤î·²! 2. ¤½¥q¤£ª¾¹D§ó·sªºdata RE: ¨º¿ì³oindustry sponsored symposium´N¹³§Ú¤W±ªº½×z¬O®ö¶O¿ú ©Ò¥H¤£½×þ¤@ºØ¡A³£¥Nªí¸gÀçºÞ²z¦³°_¤HºÃÄu¤§³B!¦n°Õ¡A¦³¤H¤Sn§ðÀ»»¡§Ú¥u·|§åµû¤F! ¦p´X¦ì°ª¤â©Ò»¡¡A²{¶¥¬q¤½¥q¤£¥²¤]¤£¸Ó¦³¤Ó¦h°Ê§@¡A¦n¦n§â¸Ó¶i¦æªº¸ÕÅç°µ§¹¡A ¼Æ¾Úº}«G¡A¦ÛµM¥þ²y·|»EµJ¡A¤¤¸Î´N¬O«Ü¦nªº¨Ò¤l! §Ú¤§«e¤]´£¹L¤½¥q¥i¥H¦Ò¼{¶i¦æ¤@¨ÇcomboªvÀø¤p«¬¸ÕÅç¡A¬Æ©Î°£¤Fcyclophosphamide¡A¦A¥[¤W¨ä¥Limmu preconditioningÃĪ«(¹³CAR-T¨Ï¥Îfludarabine)¬Ý¬ÝÀø®Ä¬O§_§óÅãµÛ(²£¥Í§ÜÅé±Ú¸s¤ñ¨Ò¬O§_¼W¥[)! »¡ÁÀ¸Ü¥s¤£¸Û¹ê¡A§Ú»¡ªº¸Û«HªººÃ¼{¬O¤£¤@¼Ëªº!§Æ±æ³o¼Ë¦³¦^µª¬°¤°»ò§Ú©Ò¿×ªº¦³ºÃ¼{¡C «Ü©êºp¡A³o½g¦^À³«á·|¤@¬q®É¶¡Â_½u¡A¼È®É¤£°µ¨ä¥L¦^À³! |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2016/10/15 ¤U¤È 08:33:50²Ä 2656 ½g¦^À³
|
W®v¡GESMO¬O¾Ç³N¡DESCO¤~¬Oµoªí·|¡D ¬OnÅý¥þ¥@¬ÉÂå®vª¾¹D822·sÀøªkªº ¤½¥q¦³説¤£·|µo«°Tªº ²{¦b¤½¥q¤£¬O¥Î¶¡±µ³¯³Õ¤hÅý§Ú©ñ¤ß¤F¶Ü¡H ¤j®anµ¹¤½¥q¹Î¶¤¥[ªo¡D |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/15 ¤U¤È 08:15:58²Ä 2655 ½g¦^À³
|
T&T said: µ¥¤F´X¤Ñ¤]¨S¬Ý¨ì¤½¥q»¡©ú¦bESMO·|ijªº¦¬Ã¬! ªáªÑªFªº(¤j)¿ú¦bESMO¿ìsatellite symposium¹ê¦b¬O§Ú¯à¤O¤£¯à²z¸Ñªº¨Æ! ³o¤~¬O§ÚµLªk²z¸Ñªº¨Æ, T ¤j, ±z¬Ý¹L¥þ¥@¬Éþ®a¤½¥q¿ì§¹ Symposium ´N¶}°OªÌ·|©Î·s»D½Z³¯z¦³¨º¨Ç¦¬Ã¬? §ÚÆZ·Q¬Ý¬Ý¦³¨º¨Ç®×¨Ò |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/10/15 ¤U¤È 07:19:54²Ä 2654 ½g¦^À³
|
T^T¤jÁÂÁ±z¦Ê¦£¤§¤¤¤W¨Ó¸ò¤j®a¤À¨É¡I ¹ï©ó§Ú³oºØ¤£¬O¦æ¤ºªº¤H¡A¦³«Ü¦hªF¦è¥i¥H¾Ç²ß¤ÎÁA¸Ñ¡C ¤£½×2017¦~¬O¥¢¸¨ÁÙ¬O§Æ±æªº2017¡A ¤]½Ð±zÄ~Äòµ¹§ÚÌ«ü¾É¤À¨É¡I §Ú̪ººÖ®ð¡I |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/10/15 ¤U¤È 07:15:50²Ä 2653 ½g¦^À³
|
T¤j:³¯¨}³Õ¥ý¥Í³£»¡¤F,ÁÞªº»â°ì¯Î°|ªø¬O¥@¬É¤W²Ä¤@,²Ä¤G¦WÁÙ®t±o«Ü»·,§Ú·Q«H§A«Ü±M·~,¦ý´¢¼¯FDA¹ïOBI822ªººA«×¬O§_¸ÓÂÔ·V¨Ç,²¦³º³o¬O¥þ·s¤F»â°ì!µû½×ªº®ÉÔ¤£¥ýÙ^Ùg§O¤H,«ç»ò·|³Q§O¤HÙ^Ùg©O?¹ï³\¦h¯E¤Í¦Ó¨¥,¤½¥qªº¸Û«H«Ü«n!T¤j¤£©ú¨s²z´N¤jÁnÄWÄW¤½¥q¸Û«H¦³°ÝÃD,³o¹ï§Ú̳o¨Ç«Ü¤ä«ù¤½¥qªº¤H¦Ó¨¥,T¤j¤£¸Ó¹Dºp¶Ü?? ³Ì«á:§Ú¬°¤§«eµL²zªºµo¨¥¦VT¤j§APºp!sorry |
|
|
·|û¡GT^T10142245 µoªí®É¶¡:2016/10/15 ¤U¤È 06:48:50²Ä 2652 ½g¦^À³
|
ÅF¨«¬O¤£¦Ü©ó¡A¥u¬O¨S¨ºÓ®É¶¡°µµL¿×ª§ÅG!¤£Á¿²zªº¤H§ðÀ»¡A·í¯º¸Ü¬Ý´N¦n!¦³¤H§âmetaphor·í§@sarcasticism´Nºâ§Úªí¹F¯à¤O¤Ó®t! §Ú·íªìASCO & ESMO«e«áªºµo¨¥¨ì¤µ¤ÑÁÙ¬O¥i¥HÀËÅç¡Acliff¤]¬Ý¥X§Ú·íªì»¡atezoªºCR©MOBIªºNED¬O¤£¦P¼h±ªºª¬ªp!µ¥¤F´X¤Ñ¤]¨S¬Ý¨ì¤½¥q»¡©ú¦bESMO·|ijªº¦¬Ã¬!ªáªÑªFªº(¤j)¿ú¦bESMO¿ìsatellite symposium¹ê¦b¬O§Ú¯à¤O¤£¯à²z¸Ñªº¨Æ! ¤£¹L2017¹ï¯E¹©§Ú¬ÝˬO«Üȱo´Á«Ýªº¤@¦~¡A¦Ü¤Ö¦bCTºô¯¸¥ÎOBI¬d±oªº4ÓÁ{§É¸ÕÅç¡A¦³3Ó©ú¦~¥i¯à¦³µ²ªGµoªí¡A¯Ê¥Fsolid evidence¬O¤½¥q²{¦bªº®zÂI¡A´Á«Ý2017·|¬OÂà¾÷ÂI!·íµM¦³evidence¤]¦s¦b·ÀI´N¬O¤F!¦Ü©óªÑ»ùªºªi°Ê±q¨Ó¤£¬O§Úªº°Q½×«ÂI! clinicaltrials.gov/ct2/show/NCT02132988 ¡ANCT00857545¡ANCT01516307¡ANCT02310464 ¤£¹L²Ä¤@Ó NCT02132988¡AÀ³¸Ó¬O°¨°º¶i¦æªºIIT¡A«e±cliff´£¨ÑªºPDFÀɸ̡AP12©ú¸üIITªº¬ã¨s¥ØªºThe primary focus is on improving and expanding patient care of an already approved drug. °¨°º²{¶¥¬q¯à®³¨ìÃĶi¦æ¤HÅéÁ{§É¡A²q´úI«á¤j©@«Ü¦³power!(IRBn¦P·N¥¼¤W¥«ÃijoÃö©M¯E¹©´£¨ÑÃĪ«³oÃö¹ï«Ü¦hPI³£¬O¤£¥i¯àªº¥ô°È) |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/10/14 ¤W¤È 08:18:12²Ä 2651 ½g¦^À³
|
ÁÂÁÂcliff¤j²M·¡ªº¤ÀªR¸ê°T.¸Ñ»¡ªº«D±`²M·¡ ·P®¦¦A·P®¦ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/14 ¤W¤È 06:57:27²Ä 2650 ½g¦^À³
|
Cliff ¤j®¦¼w ÁÂÁ±z¤@¤j¦¡A´N¬°¤j¹Ù°µÄYÂÔªº±M·~¸Ñ»¡ ÁöµMªÑ»ù§C°g¡A¤j¹Ù¤ß±¡©Î¨ü¼vÅT µM¦Ó¦³±zªº½Î½Î±Ð»£¡A¤j®aÀ³¸Ó³£·|ı±o«Ü©¯ºÖ ½Ð±`¤W¨Ó¹ªÀy¤j®a ÁÂÁ±z¡I ÁÂÁ¤j®a¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/14 ¤W¤È 06:26:28²Ä 2649 ½g¦^À³
|
ÄP¤¸¤j ±i¸³»¡¡G¡u³o¦¸Á{§É¨ÅÀù¥|´Á¦¬®×¨S¦³¬D¯f±w.¡v§Úı±o±i¸³©Ò«üªº¬O¡u¨S¦³¨Æ¥ý¿z¿ï¦³GHªº±wªÌ¨Ó¦¬®×¡v¡F¤£¹³Herceptin¬O¿z¿ïHER2(+++)¥H¤Wªº±wªÌ¦¬®×¡C ¡u«ö·Ócliff¤j»¡ªk¬O¦³¥i¯à©µÄò£¸´Á¬D¸ûÀuªº¯f±w¡v¡A§Úªº·N«ä¬O´£¿ô¤j®a¡A¨Ì·Ó822ªº¤@´Á»P¤G´Áªº³]p¬O°w¹ïÂಾ©Ê¨ÅÀù¤w¸g¸g¹L¤ÆÀø©Î¼Ð¹vªvÀø«áéwªº±wªÌ©Ò°µªº¡uºû«ùÀøªk¡v¡A¤£¦P©óÂಾ©Ê¨ÅÀù²Ä¤@½uªvÀøÃĪ«¡F¤£¹³Herceptin¬O°w¹ïªì³Q¶EÂ_¬°Âಾ©Ê¨ÅÀù¡A©|¥¼¥Î¹L¥ô¦ó¤ÆÀøªº±wªÌ¡A¤]´N¬O³W¹º§Æ±æ¦¨¬°Âಾ©Ê¨ÅÀù²Ä¤@½uªvÀøÃĪ«¡C Herceptinªº¦¬®×¹ï¶H¥i°Ñ¦Ò³o¤@½g¡G¡uwww.nejm.org/doi/full/10.1056/NEJM200103153441101#t=articleMethods¡v ¡uMethods Patients¡G Women with progressive metastatic breast cancer that overexpressed HER2 who had not previously received chemotherapy for metastatic disease were eligible for the study¡K¡K¡v¯f±¡¤´¦b¶i®i¤¤ªºÂಾ©Ê¨ÅÀù¥B¹L«×ªí²{HER2ªÌ¡]¤j©ó+++ªÌ¡^¥B©|¥¼±µ¨ü¹L¤ÆÀøªvÀøªÌ¡K¡K¡A©Ò¥H¤@¥¹Herceptin¸ÕÅçµ²ªG¦¨¥\«K¥i·íÂಾ©Ê¨ÅÀùªº²Ä¤@½u¥ÎÃÄ¡C ¡u¦pªG¦³¬D¯f±wÁ`¦s¬¡´Á¬O§_¤]·|±¹ï½èºÃ¡v¡A¤£¬O¬D¿ï¯f±w¡A¤]¤£·|²£¥Í½èºÃ¡A¥un¦p²q·Q¤j¤j»¡ªº¡G¡u¤£ºÞ¦¬®×¦p¦ó , ¥un¨â²Õ¥[¤J«eªºI´ºµL¤°®t§O , ¥B¸ÕÅç«á¨â²Õ¹FÅãµÛ®t²§ , À³´NµL°ÝÃD°Õ¡v®t§O¬O¦b©ó¸ÕÅç³]p¦¬®×ªº±Ú¸sºØÃþ¡A·|¼vÅT¨ì¥¼¨Ó·sÃÄÃÒªº¾AÀ³¯g¡C ©Ò¥H¡G 1.®³822»PHerceptin¬Û¤ñ¸û¡A¤ñPFS¡B¤ñ¾P°â³W¼Ò¡B¤ñ¡K¡A¨ä¹ê¬O¤£¬ÛºÙªº¡]Âû»L¤ñ¤H»L¡^¡CÀ³¸Ó®³888¸òHerceptin¤¬¬Û¤ñ¸û¤~¹ï¡]¨È¬w»L¤ñ¬ü¬w»L¡F¦P¬°³æ®è§ÜÅé¡B³Q°Ê§K¬ÌÀøªk¡^¡C»P822¹ïµ¥ªº¥D°Ê§K¬ÌÀøªk¡AOBI¬O¿W¨B¡AµL¤H¥i¤ñ¡C 2.§â¥½´ÁÂಾ©Ê¨ÅÀù¥«³õ³W¼Òª½±µ®M¥Î¦b822¨¤W¡A¤£µL°ª¦ô¤§¶û¡C 3.±N¨ÓY822¶¶§Q¨ú±oÃÄÃҮɡAnª`·N¬Ý¬Ý©Ò®Ö㪺¾AÀ³¯g¡]Indication¡^¬O¾A¥Î©óþ¨Ç±Ú¸s¡H¦A¨Ó¦ôp¥«³õ¤j¤p¤ñ¸û¥¿½T¡C |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/10/13 ¤U¤È 12:20:34²Ä 2648 ½g¦^À³
|
ÁÂÁ²q·Q¤j |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/13 ¤U¤È 12:17:43²Ä 2647 ½g¦^À³
|
Cliff ¤j®¦¼w ÁÂÁ±zªºµû½× ¬Ý±zªº¤å³¹ , »Ýn«~À|¦A¤T , ¤ÏÂзN·| , ¤ß¹Ò¦³¦pªY½àÃÀ³N«~ , ¤ßÀR«ä»· ¯E¹©2017ÁöµM"¥i¯à¬OÀª§¼ªº¤@¦~" "©ú¦~ASCO·|¤£·|¦³¾÷·|¤W¥x¡A§Ú»{¬°¦³¾÷·|¡A¦ý¤£¨£±o¨Ó±o¤Î¡A¤£n¹L«×´Á«Ý" ¨Æ±¡¤£n¹L«×´Á±æ , ´N¤£·|¹L«×¥¢±æ ¤pªº¬Ýªk»P±z¹p¦P ¨Ì·Ó±zªº¼Æ¾Ú®Éµ{±À¦ô , ÁÙ¦³QQ¤j¤j´£¨Ñªº¤½¥q±Àºâ ¤pªº±À´ú , °ò©ó«O¦u¦Ò¶q , ¨Æ¥óÁ`¼Æ©Î¦b180¥H¤W , ¤½¥q¤~¦³¥i¯à¸Ñª¼ 2017 ¦~¤¤«e«á , ©Î¸û¦³¥i¯à½µP µM¦Ó³oºØ¤£¬O¾Þ¤§¦b§Úªº¼Æ¾Ú, «ç»òÅÜ¤Æ , «ÜÃø¹w´Á, ¤½¥q¤@©w·|¨ÌOSÁ`¼ÆªºÅܤÆ, ¨Ó¨M©w¸Ñª¼®ÉÂI ¦Ó¦b¸Ñª¼¤§«á,°²³]¹LÃö(¹ê»Ú¤W¥¼ª¾) , ©Î±N§áÂ५³õªº¬Ýªk , ¤½¥qÀ³·|ÀH«á´£¥XBTD¤ÎTFDAªºÃÄÃҥӽР, ©Î³\ÁÙ¦³¥i¥H¤p½T©¯ªº¦a¤è ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! ÄP¤¸¤j¤j ¤£ºÞ¦¬®×¦p¦ó , ¥un¨â²Õ¥[¤J«eªºI´ºµL¤°®t§O , ¥B¸ÕÅç«á¨â²Õ¹FÅãµÛ®t²§ , À³´NµL°ÝÃD°Õ ¶È¨Ñ°Ñ¦Ò ÁÂÁ±z! |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/10/13 ¤W¤È 11:21:04²Ä 2646 ½g¦^À³
|
cliff¤j.§A¦n ·PÁ§Aªº¸ê°T.½Ð±Ð§A ±i¸³¨Æªø»¡¡G³o¦¸Á{§É¨ÅÀù¥|´Á¦¬®×¨S¦³¬D¯f±w.«ö·Ócliff¤j»¡ªk¬O¦³¥i¯à©µÄò£¸´Á¬D¸ûÀuªº¯f±w.³oÓ®t§O·|«D±`¤j.¦pªG¦³¬D¯f±wÁ`¦s¬¡´Á¬O§_¤]·|±¹ï½èºÃ ¤p§Ì¿éªº°_.¥u·Qª¾¹D¯u¬Û¬O¬Æ»ò ¤]½Ð²³¤j¤j«ü±Ð |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/10/13 ¤W¤È 12:55:55²Ä 2645 ½g¦^À³
|
Cliff ¤j¤j: ·PÁ±zªº«ü¾É, ³o¼Ë´N¦³¸û²M´·ªº½ü¹ø¤F, ¤£·|¦Û¤v¦b¨º·Q±o¸£³U¥´µ²¤]¾ã²z¤£¥XªF¦è¨Ó. Åý±z¥Î¤F¨º»ò¦hªº®É¶¡¸Ñ»¡, ¥´¤F¨º»ò¦hªº¦r, ¯u¬O¤Ó¤£¦n ·N«ä, ºF·\. ¦pªG¤£¬O±zªº´£ÂI, §ÚÁÙ¨S·Q¨ìBio-Japan¸ò Bio-Europe ¸ò¥xÆWªº¥Í§Þ®i¬OÄÝ©ó¦P©Ê½èªº®iÄý, Ãø©Ç¦b§ë¼v¤ù¤Wªº¼ÐÃD¬O¡¨¡K.°Ó°Èµo®i¬¡°Ê¡¨. ¯u¬O¾|¶w¡K. ¯à¦³È±oµ¥«Ýªº¦n¤½¥q¬O©¯¹Bªº., §ó©¯ºÖªº¬O¦³¹³±z, ¦Ñ¥v¤j, ¤p©_¤jµ¥¦h¦ì¤j¤j̪ø´Á¥H¨Ó, ¤£Â÷¤£±ó«ùÄò«ü¾É¥[«ù. °£¤F·P¿E, ·PÁÂ, ÁÙ¬O·P¿E, ·PÁ¡K. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/12 ¤U¤È 05:48:17²Ä 2644 ½g¦^À³
|
QQ¤j¡A»P±z¤Á½R ¡uEffective Sugar Nucleotide Regeneration for the Large-Scale Enzymatic Synthesis of Globo H and SSEA4¡v¡]pubs.acs.org/doi/full/10.1021/ja4075584 ¡^ ¬Ý¥k°¼ªºMetrics¡G¡uReceived 23 July 2013¡FPublished online 17 September 2013¡v±q±µ¨ü¨ì¥Zµn¬ù¸g2Ó¤ë¡C ¡uLapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor¡VPositive Metastatic Breast Cancer¡v¡]jco.ascopubs.org/content/27/33/5538.long ¡^ ¡uReceived April 16, 2009. ;Accepted June 25, 2009.¡v¬ù¸g2Ó¦h¤ë¡C ¡uUnderstanding survival analysis: Kaplan-Meier estimate¡v¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC3059453/ ¡^ ¡uReceived 2010 Oct 8; Accepted 2011 Jan 15.¡v¬ù¸g3Ó¦h¤ë¡C ¡uPhase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer¡v ¡]theoncologist.alphamedpress.org/content/16/8/1092 ¡^ ¡uReceived September 7, 2010. Accepted March 26, 2011. First published online in THE ONCOLOGIST Express on May 14, 2011. ¡v ³o¤@½g¤ñ¸û¤[¡A¦¬¨ì¤å³¹¡]2010/7¡^¶}©l¦P¾«¼f®Ö¡Aªñ6Ó¤ë«á³Q±µ¨ü¡]2011/3¡^¡A¦A¸g¹L¬ù50¤Ñ«á¥Zµn©ó½u¤W´Á¥Z¡]2011/5¡^¡C«e«á¬ù¾ú10Ó¤ë¤~¥Z¥X¡C¥i¯à¬O¸É¥R¤@¨ÇÁ{§É¸ÕÅ窺¸ê®Æ§a¡H §@ªÌÄ榳¤@¬qÁn©ú¡uThe content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.¡vpeer reviewers ´N¬O¦P¾«¼f½ZªÌ¡C ³q±`¼f½ZªÌYµo²{ì¤å¤£°÷²M·¡¤§³B·|n¨Dì§@ªÌ´£¨Ñ»¡©ú©Î¸É¥R¸ê®Æ¡A³o¤@¨Ó¤@©¹ªº¼W§Rװų£·|¯Ó±¼®É¶¡¡C °£«D»P´Á¥ZÄݩʤ£¦X©Î¤º®e¤FµL»ùÈ¡A§_«h¦h¬°°h¦^קï©Î¸É¥R¸ê®Æ¡C·íµM¤ñ¸û·V«ªº§@ªÌ¡A·|¦b§ë½Z«e¥ýµ¹¦P¾«Åv«Â¥ýקï¹L¡A´N¬O±z±q¤C¤ë¥Í§Þ®iÅ¥¨ìªº¡CÁޤƾǻâ°ìªº°ò¦¬ã¨s¤å³¹Yµ¹°|ªø¥ý¼f¹L¡A§Úı±o¥úÀô·|¼W¦h¤@ÂI¡CÁ{§ÉÂå¾Çªº¤å³¹´N¤£²M·¡¡C ¡uBio Japan Oct. 12~14. ¤Î¤UÓ¤ë¼w°êªº Bio-Europe¡v³£¬O·í¦aªº¥Í§Þ®i¡A¸ò¥xÆWªº¥Í§Þ®i¤@¼Ë¨Ñ¦U¸ô²£·~¬ÉÂ\Åu¦ì¡A¥´¥´ª¾¦W«×®ÄªG´¶´¶¡C³Ìª½±µªºÁÙ¬O¸~½FÂå¾Ç·|¡Aª½±µ¦V¸~½F¬ìÂå®v§e²{¸ÕÅçµ²ªG¡CY¨S¦³·s¤º®e¥i¤W¥x¡A´N¥u¦n¦Û¤v¥Ó½Ð³õ¦a¦Û¿ì¬ã°Q·|¡A®ÄªG·íµM®z¤@ÂI¡]§O§Ñ¤F822¬O©|¥¼¤W¥«ªº¬ãµo¤¤·sÃÄ¡A¥x¤UªºÂå®vÅ¥§¹«á´N¬O¼W¥[¤º¥\¡A¤F¸Ñ¥Ø«e¶i«×¡A³»¦h°Ñ»P°Q½×¡^¡C ¦Ü©ó¦³·N½Í±ÂÅvªºÃļt¡A§Úı±o¤£·|§â³oºØ¤j«¬¤½¶}ªº³õ¦X¡]¦pESMO¡B¥Í§Þ®iµ¥¡^·í§@¬O«ÂI¡A¸Õ·QYn½Í±ÂÅv¡A·íµMn¥t¬ù®É¶¡¡A¥Ñ¤½¥q§@¤@¹ï¤@ªº·¾³q¡A§Ú°Ý§Aµª¡A§A°Ý§Úµª¡A«ç¥i¯à¦b¤@Ó´X¦Ê¤H¾x«¡«¡ªº³õ¦X¡A¦YÓ±ßÀ\¡AÅ¥¨î¦¡Â²³ø¡A·|«á·Qµo°ÝÁÙ±o¸ò¤@°ï¤H·mµÛÁ|¤â¡K¡K ¬ì¾Çªº¤º®e´Nn¥H¬ì¾Çªº¤è¦¡¨Ó«ä¦Ò¡A¥ú¬O·Å±¡³Û¸Ü±¡·P¤ä«ù¬O©_©Çªº¡C¥un¼Æ¾Ú°÷¦n¡A¥þ²yªº´CÅé¦ÛµM·|»EµJ¹L¨Ó¡A®Ú¥»¤£»Ýn¯S§O«Å¶Ç¡A²{¦b´N¬Onµ¥¡C©¹«áÁÙ¦³«Ü¦hÂå¾Ç·|¡B¥Í§Þ®i¡AÁ|¿ì®É¶¡¤£¦P¡B·|ijÄݩʤ£¦P¡B°Ñ¥[ªº¨Ó»«¤]¤£¦P¡A¥H¤½¥qÆ[ÂI·íµM¾¨¶q§â´¤¾÷·|°µ«Å¶Ç¡A¦ý¬O¤£¥Nªí¨C¦¸³£È±o°Ñ¥[¡A¬Æ¦Ü»{¬°¨C¦¸³£·|´¦ÅS·s¼Æ¾Ú¡CÁ|2017 ASCO¬°¨Ò¡ALate breakingªººI¤î´Á¬O3/19¡A¦pªG¼Æ¾Ún¨ì©ú¦~¤W¥b¦~¤~°÷º}«G¡An»°µÛ®³power 80%ªº¼Æ¾Ú¥hµn³õ¡AÁÙ¬Onµ¥¨ì90%¦A´¦ÅS¡H©Ò¥H©ú¦~ASCO·|¤£·|¦³¾÷·|¤W¥x¡A§Ú»{¬°¦³¾÷·|¡A¦ý¤£¨£±o¨Ó±o¤Î¡A¤£n¹L«×´Á«Ý¡A®{¥Í¦Û¤v»P¤½¥q§xÂZ¡A§OÀÉ¥i¥HÀò§Qªº¾÷·|¦hªº¬O¡A¤@¬N¦a±¡ºü¤Æ«D©ú´¼¤§Á|¡C2017¦³¥i¯à¬OÀª§¼ªº¤@¦~¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/10/12 ¤U¤È 02:46:01²Ä 2643 ½g¦^À³
|
Cliff ¤j¤j: ¦b¥Í§Þ®i®É, «Ü©¯¹B²{³õ¦³¸I¨ì§E³Õ¤Î´å³Õ. ¦L¶H¤¤®Ú¾Ú¥L̪º»¡ªk, OS¥X¨Óªº®É¶¡±À¦ô¥i¯à¦~©³¨ì©ú¦~¤W¥b¦~., ©Ò¥H¥Ø«e¨S¦³·sªº¼Æ¾Ú¬O«Ü¦X²zªº¨Æ±¡. §Z±_Àù³¡¤À, Y¥H§Z±_Àùªº´c©Ê¤Î¥D°Ê§K¬ÌÀøªkªº»¼©µ®ÄªG, ¥Ø«e°¨°ºªºÁ{§É¦¬®×³´¤Jªñ°±º¢¬O§_¤]³zÅS¥X¨Ç°T®§ ? ®Ú¾Ú¯E¹©9¤ë¥÷·ç¤h«H¶Uªk»¡ªº§ë¼v¤ùp50, ±µ¤U¨Ón¥hªº¥]¬A¥Ø«e¥¿¦b¶i¦æªºBio Japan Oct. 12~14., ¤Î¤UÓ¤ë¼w°êªº Bio-Europe. ˬO¬ü°ê12¤ë¥÷ªº¨ÅÀù¤j·|¥¼¦C¨ä¤W¦³¨Ç¥O¤H©_©Ç¤£¸Ñ ¡K. ¤ñ¸û¦b·Nªº¬O©Ò¿×ªº´Á¥Z³ø¾É, ¤@ª½¨S®ø¨S®§. ¦b¥Í§Þ®iªº®ÉÔ, ·í®Éªº»¡ªk¬O¤w¸g¦b¾ã²z¸ê®Æ, ¥¼¨ÓÁÙn°e¦P¾«¼f®Öµ¥µ¥, ¤~·|°e¥X. ¥Ø«e¤w¾ú¸g3Ó¤ë. ¯à§_¦V±z½Ð±Ð¬O§_ª¾±x¦b³o³¡¤À§ë½Zµ¥ªº¬yµ{¤Î®É¶¡³W¹º ? »Ýn³o»ò¤[¶Ü ? ÁÙ¬O§ë½Z³£³Q©Úµ´©Ò¥H¨S®ø®§¶Ü ? ¹ê¦b¯Ç´e. Àµ½Ð«ü¾É. ¦bPD-1 PD-L1³°³°ÄòÄò°{«Gµn³õªº¼Æ¾Ú±µ³s³ø¾É¤U, ÁÞ¬ì¾Çªº¦¨ªG822«o¨S¦³¯à¨£«×, ¦ü¥G²T¨S¦b¥D¬y¤¤ ?? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/12 ¤U¤È 01:29:13²Ä 2642 ½g¦^À³
|
¦Ñ¥v¤j©l²×§NÀR¤¤¥ß¡A¥O¤HÃø±æ¶µI¡C ESMO ¬O¼Ú¬w¸~½F¬ìÂå®v¤@¦~¤@«×ªº¤j«ô«ô¡A»P¬ü°êªºASCO»»»»¬Û¹ï¡A³o¦¸¤½¥q¥¼¹³2016 ASCO¤@¼Ë¤W¥x³ø§i¡A¦Ó¬OÁ|¿ì¡uIndustry Sponsored Satellite Symposia¡v¡A·f³õ¤lºûô¤H®ð¡A®ÄªG¦p¦ó¦³«Ý¤é«á°lÂÜ»P¤½µû¡A¦ýªí¥Ü¤½¥q¬O¦b·N¦Ó§V¤Oªº¡C¬ã°Q·|¤¤ªº¤TÓ¥DÃD±qÃD¥Ø¤W¨Ó¬Ý¡]µù1¡^¡A¤´¥HReview ASCOªº¼Æ¾Ú¬°¥D¡A¨S¦³¿ËÁ{²{³õ·íµMµLªk¤@·§¦Ó¥þ¡A¦ý¬O¦pªG¨ÅÀù¼Æ¾Ú³¡¤À¯uªº¨S¦³·s¼Æ¾Ú§e²{¡F§Z±_Àù³¡¤À¤]¥¼µÛ¾¥¡AÓ¤Hı±o¬Û·í¦X²z¥B¬O¹w®Æ¤§¤¤¡A¦]¬°mOS¼Æ¾ÚY©|¥¼¦¨¼ô¡A¦ó¨Ó¥¢±æ¤§¦³¡C ¤¤¤å·s»D½Z¡]µù1¡^¡G¡u¡K·|¤¤±N®Ú¾ÚOBI-822¡]Adagloxad Simolenin¡^Á{§É¸ÕÅçµ²ªG¡AÀ˵øGlobo ¨t¦C§Üì¡þ¦bÂಾ©Ê¨ÅÀù»P¨ä¥¦Àù¯gªº¼Æ¾ÚÂǦ¹±´°Q¥D°Ê¦¡§K¬ÌÀøªkªº¥¼¨Ó¡C¡v ^¤å·s»D½Z¡]µù1¡^¡G¡u¡Kwill review the data on targeting Globo Series antigens in Metastatic Breast Cancer and other cancers with the investigational active immunotherapy Adagloxad Simolenin (formerly OBI-822) and examine the future of active immunotherapy in oncology.¡v¤¤^¤åª©¬Û²Å¡C ¦ý¦b^¤åAgenda¡]µù2¡^¡G¡uReview the data on targeting the globo series in metastatic breast cancer with the investigational active immunotherapy adagloxad simolenin and examine the future of immunotherapy in oncology.¡v¹ï°ê»Ú¤½¶}ªº^¤åÁܽШç¨Ã¥¼´£¨ìn§â¡u¨ä¥LÀù¯g¼Æ¾Ú¡v¡]§Z±_Àù¡H¡^ªº¼Æ¾Ú§e²{¥X¨Ó¡A¬ã°Q·|«e¤@¶g®É´N¤wµo²{¡C¦³«í¤j©ó10/7¤]´£¹L¡u¡K§Z±_Àù³¡¤ÀÁÙ¦³¬ÛÃö²Ó¸`»P°¨°º°Q½×¤¤,©Ò¥H½Ð¤j®a¤Á¤Å¹ïESMO¼Æ¾Ú¤½¥¬°µ¹L¦hªº´Á«Ý¡K¡v MMH-OPT-822-OC001¡G ¤½¥q·|¤£·|¤½¥¬§Z±_Àù¤G´ÁÁ{§É¸ÕÅç¼Æ¾Ú¡HȤ£È±o¤½¥¬¡HÓ¤Hı±o¦³«ÝÆ[¹î¡C ¦]¬°³oÓÁ{§É¸ÕÅ窺ÄÝ©Ê¡]investigator initiated trial¡FIIT¡^¡]µù3¡^¡]µù4¡^¤£¦P©ó¥Ñ¤½¥q¥D¾ÉªºÁ{§É¸ÕÅç¡]Industry sponsored trial¡GIST¡^¡C©Ò³]pªº¬I¥´pµe¡B¾¯¶qµ¥²Ó¸`¡A¬O§_·|Åý³Ì«á¥X¨Óªº¸ÕÅçµ²ªG²Å¦X¤½¥qªº§Q¯q¬O¦³«Ý°Óºeªº¡A¦L¶H¤¤±i¸³´¿´£¹L°¨°º¨ºÃ䦳¥L̪º·Qªk¤ª¤ª¡K¡C¨Ã«D¸ÕÅçµ²ªG¤@µL¬O³B¡AÀ³¸Ó¤´¦³°Ñ¦Ò¤§³B¡A¥u¬O´N¤½¥q§Q¯qªº¨¤«×¡A¤@Ó¡u¤£¬O¥H¥Ó½ÐÃÄÃÒ¬°¥Øªº¡v¦Ó³]pªºÁ{§É¸ÕÅç¡A¥¦ªºµ²½×¯à¤£¯à¥R¤À®i²{³oÓÃĦb§Z±_ÀùªºÀø®Ä¡H¾ú¸g¤µ¦~¸Ñª¼ªºµhW¥N»ù¡A¤½¥qȤ£È±o¦Aµo¥¬¤@ÓÅý¥~¬É¡]´CÅé¡BªÅ¤è¡K¡^¥i¥H¦A¨£Á_´¡°wªº¤£§¹¬ü³ø§i¡HÓ¤Hı±o¤£n¤½¥¬¬°¨Î¡A¥un®³¨Ó°Ñ¦Ò´N¦n¡Aµ¥¨ì¤T´Áªº§Z±_Àù¸ÕÅç³]p§¹¦¨®É¡A¦A¤½§i¡u822ªº¤T´Á§Z±_ÀùÁ{§É¸ÕÅçn¶}©l¤F¡v¡A³o¼Ë´N¥i¥H¤F¡C ¤£¹L¡A´N¾Ç³N¬ã¨sªº¨¤«×¡A¤]´N¬O¥HÂå°|°ü²£¬ìªº¨¤«×¡A³o¥i¬O¿W¨B¥þ²yªº¤@¤j¬ã¨s¡A¥i¥H¥Î¦bÂå°|µûŲ¥[¤À¡B´£°ªÂå°|¤Î°ü²£¬ì¦b°ê»Úªºª¾¦W«×¡K¡A«D±`¥i¯à·|¦b«áÄòªºÂå¾Ç·|³õ¦X¥H®Ñ±©Î¤fÀY¤è¦¡§e²{¡A©Ò¥HY¥¼¨Ó¬Ý¨ì³ø§i¥XÄl®É¡A±À´ú¥HÂå°|³oÃäµo¥¬ªº¾÷·|¤ñ¸û¤j¡C IIT»PISTªº®t§O½Ð¦Û¦æ¤U¸ü¡uIIT made easy¡v ³o¥»¤p¥U¤l¡]µù5¡^¡AŪ¤FPDF page 9/86¡X12/86«á´N·|©ú¥Õ¡A¥ú¥Î±¡·P»P·Q¹³ªº¤£¬O¿ìªk¡C³o¥»¤p¥U¤l¦W¦C¤F¤T¦ì§@ªÌ¡A¨ä¤¤¤@¦ì¬O¡uProfessor K. Arnold Chan¡v¡A¥L¬O¥x¤j¬y¦æ¯f¾Ç»P¹w¨¾Âå¾Ç¬ã¨s©Òªº³¯«ØÞm±Ð±Â¡C ¸Ì±ÁÙµo²{¤F¤@¥y«Ü¦³·N«äªº¸Ü¡Gpage 3/86¡G Carl Sagan¡G¡uAbsence of evidence is not evidence of absence¡v¨S§ä¨ìÃÒ¾Ú¤£¥NªíÃÒ¾Ú¤£¦s¦b¡C ·Q°_¤p©_¤j´¿¸g¸ÑªR¹L¡u¦]ªG¡v»P¡u¬ÛÃö¡v¡A¨Sµo²{¦]ªGÃö«Y¤£¥Nªí¦]ªGÃö«Y¤£¦s¦b¡H¡I¹ï·ÓRugo¸Ñª¼«áªºµ²½×»P«Øij¡A»á³ôª±¨ý¡C µù¡G 1.¤¤¤å©xºô¡G¡uwww.obipharma.com/index.aspx?lang=chi&fn=news_content&no=84 ¡v ^¤å©xºô¡G¡uwww.obipharma.com/index.aspx?lang=eng&fn=news_content&no=32 ¡v 2. Agenda¡G¡uapothecomgroup.com/activeimmunotherapy/button2.html ¡v 3. 2015/06/05ªÑªF·|--Ý»¡©úPD229¨Æ¥óªº¨º¤@¦¸¡G²Ä45-50¤ÀÄÁ¤§¶¡±i¸³ªº¦^µª©ú½T´£¨ì°¨°º§Z±_Àù¤G´ÁÁ{§É¸ÕÅç¬O¤@Óinvestigator initiated trial¡C 4. Stellarªº·s»D½Z¤]´£¨ì¡u¡K It is also being evaluated for the treatment of ovarian cancer in an investigator-initiated Phase 1/2 clinical trial in Taiwan.¡v¡uwww.marketwired.com/press-release/stellar-biotechnologies-announces-collaboration-with-amaran-biotechnology-inc-otcqb-sbotf-1861978.htm¡v 5.¤U¸ü¡uIIT made easy¡v¡G¡uwww.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwi4-dOmktLPAhVH22MKHd2dAtcQFggcMAA&url=http%3A%2F%2Fwww.quintiles.com%2F-%2Fmedia%2Ffiles%2Fprotected%2Fiit-made-easy-2015-2.pdf%3Fla%3Den&usg=AFQjCNH5IXTd-GZwKlS25v3m5t-1MK0VGQ ¡v¬ÝPDF page 9/86¡X12/86¡C |
|
|
·|û¡G¦³¹Ú³Ì¬ü10141895 µoªí®É¶¡:2016/10/12 ¤U¤È 01:11:58²Ä 2641 ½g¦^À³
|
¨¯W¥xÁÞ¤j¤F¡A¨C·íªÑ»ù¤U¶^®É¡AÁ`¬O¹ª»R¤j®a¡A¥B¥ß½×¦³¾Ú¡AµÛ¹ê¤£®e©ö!! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/12 ¤U¤È 12:30:58²Ä 2640 ½g¦^À³
|
ÁÂÁ½n¶¯¤j¡A³ÌªñÀ£¤O¯uªº¤ñ¸û¤j¡A§Ú·Q¥ð®§¤@¬q®É¶¡¥R¥R¹q¡A¨ì³B®È¹C¡A¬Ý¬Ýµ¡¥~ªºÂŤѡA¬Ý¬Ý¥|¶gÀô®üªº¥xÆW¡C |
|
|
·|û¡G¶Â³Ç§J10142064 µoªí®É¶¡:2016/10/12 ¤U¤È 12:15:32²Ä 2639 ½g¦^À³
|
¦Ñ¥v¤j ¤¤ªÖªü ...... Æg³á ~~ |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/10/12 ¤W¤È 11:55:07²Ä 2638 ½g¦^À³
|
¦^Cliff¤jªº¸Ü §Ú³Ìªñªw¦besketamine¤¤ ºë¯«ª¬ºA§e²{dissociative ±z¤F¸Ñªº ÁöµM¦ÕÃäÅ¥¨ìªº¸ê°T«Ü¦h ¦ý¬JµM¬OÅ¥»¡ §Ú´N¦Û¤vťť¦Ó¤£¦h»¡¤F §Ú²{¦b¥uÃö¤ß¤½¥qªº°Ó·~¯à¤O ¤½¥q¦p¦ó¹üÅã³oÓ822ªº»ùÈ¡H 822¦n¤£¦n¤£¬O§ÚÌ»¡¤Fºâ¡A¦Ó¬O¨º´X¦ì¤jô¤j¤jñ¤U¥h¤~ºâ §Ú°Ý¦Û¤v §ÚÄ@·Nµ¹¤½¥q¦h¤Ö®É¶¡Åý¥Lªí²{¤½¥qªº°Ó·~¯à¤O¡H ¦pªG¤½¥q°í«ùn¦Û¤v®IÀYW·F §ÚÄ@·Nµ¥¦h¤[¡H§Ún¥Î¦h¤Ö«ùªÑµ¥¤U¥h¡HȤ£È±o¡H |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/10/12 ¤W¤È 11:54:55²Ä 2637 ½g¦^À³
|
¥xÁÞ¤j¡AÀ£¤O§O¤Ó¤j°Ú...¯E¤Í³£À´¦Ïªº»ùÈ¡A¥u¬O§â¦Ï©ñ¥X¥h³z³z·¡A®É¶¡¨ì¤F¡AÁÙ¬O±o§ì¦^¦Ï°é¸Ì¡A¥B¥i¯à¥i¥H¦A¦h§ì´X°¦¤j¦Ï¤p¦Ï¡A¦Ü¤Ö§Ú¨Ã䪺¯E¤Í³£¬O³oºØ·Qªk...¼F®`ªº¤H¤£°µ§@µu½u¤]¬O¤âÄoÃø@¡A¤£µM§ë¸ê¤H³£¦sªÑ¥u¶i¤£¥X¡A¥xªÑ¦¨¥æ¶q³£°®²U°Õ...Àç·~û¥u¦n¥h¶}pµ{¨®... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/12 ¤W¤È 11:19:13²Ä 2636 ½g¦^À³
|
ASCO KOL interviews_Dr. Hope Rugo¡þDr. James C. Paulson ¤ù«¬Ý: ¨â¦ì°ê»Ú±M®a ¹ï OBI 822ªºµû½×»P«Øij ¬Û·í¤¤ªÖ (¦³¤¤¤å½Ķ) www.obipharma.com/index.aspx?lang=chi&fn=news_content&no=79 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/12 ¤W¤È 12:00:45²Ä 2635 ½g¦^À³
|
¦pªG¤U¦C¬O¯uªº¬°¦ón¬ÝÃa¯E¹©? ¬JµM¬O¯uªº¦ó¨Ó¹L«×¼ÖÆ[? A¯Î°|ªø¥ô¾ªº¤¤¬ã°|¬ãµo¹Î¶¤¦bÀù²ÓM©MÀù¤Æªº·F²ÓM¤Wµo²{¤TÓ¯S®íªºÁޯ׽èSSEA3¡BGlobo H¡B SSEA4¡A¬O¥¿±`²ÓM©Ò¨S¦³ªº¡A¦Ó¥B¦b16ºØÀù¯g³£µo²{¦³Áޯ׽誺¦s¦b¡C¤j³¡¥÷¦³³o¤TÓ¯S®íªºÁޯ׽è,¦³¨ÇÀù¯g¦³¨âÓ¯S®íªºÁޯ׽è B ¯E¹©°Ñ¥[2016 ASCO ¨Ã¤½§i¥t¥O¤H®¶¾Äªº¹Ïªí¼Æ¾Ú P13 P14 P15 P16 P17 C MSCI §â¯E¹©¦C¤J¦¨¥÷ªÑ D ¬ü°êÁ{§É¸~½FÂå¾Ç·|7¤ë25¤é¥X¥ZÂå¾Ç³q°T¡A¯S§O¤¶²Ð¤»¤ëªìASCO¦~·|©Òµoªí¨ã®i±æ©Êªº¨ÅÀù·sÀøªk¡F¥xÆW¯E¹©©Ò´£¥XªºOPT-822/ OPT-821²Ä¤G/¤T´ÁÁ{§É¸ÕÅ禨ªG¡A¥ç¦b¸Ó¥Z³ø¾Éªº¤TºØ¨ÅÀù·sÀøªk¤§¦C¡C E OBI 822 °ª¦w¥þ©Ê °ª¥Í¬¡«~½è °ª®aÄÝ·ÓÅU¤è«K©Ê F ¥xÆW¯E¹©¥D¤O²£«~ OBI-822 ¤G/¤T´ÁÁ{§É¸ÕÅçpµe¨j¦b¤µ¦~ 2 ¤ë¸Ñª¼¡F¹ï©ó³o¦¸¸Ñª¼µ²ªG¡A±M®a«w»{¦b¬ì¾Ç©MÁ{§É¤W§¡¤wÀò±o·§©À©ÊÅçµý(Proof of concept)¡F³o¬O¤½¥qµo®i«nªºÂà±ÊÂI G ³o¤@¦~¨Ó¡A¯E¹©¬¡ÅD©ó¦U°ê»Ú·|ij©M¥Í§Þ®i¡A¥Ñ¦¹¤w»P 40 ®a¥H¤W°ê»Ú¤Î°Ï°ìÃļt±µ¬¢¡A¨ä¤¤¤w¦³¼Æ®a»P§Úñq«O±K¨ó¬ù¡A¥¼¨Ó±N¶i¤@¨B°Q½×±ÂÅv»Pµ²·ù¨Æ©y¡C H OBI-833 ¤w°w¹ïªÍÀù¡BGÀù¡B¤j¸zª½¸zÀù©M¨ÅÀù¤wÂಾ¯f±w¡A¦b¥xÆW¤Î¬ü°ê®i¶}¤@´ÁÁ{§É¸ÕÅç¡A¥Ø«e¤w§¹¦¨²Ä¤@²Õ(cohort 1)¤§¦¬®×¡A¹wp¦b¤µ¦~¦~©³§¹¦¨¤T²Õ¦¬®×¡FOBI-833/834 pµe±N©ó 10 ¤ë§¹¦¨¬r²z¸ÕÅç¡A¨Ã©ó 11 ¤ë¥Ó½Ð·s¼WÁ{§É¸ÕÅçpµe®Ñ¡A¹wp©ó2017 Q1 ®i¶}Á{§É¤@´Á¸ÕÅç¡C I OBI-822 ¤µ¦~¤]±N±Ò°Ê·sªºÀù¯g¾AÀ³¯g¤G´ÁÁ{§É¸ÕÅçpµe¡A¥]§tªÍÀù¡BGÀù¡B¤j¸zª½¸zÀù¡B¤Î¨xÀù¡C J ±q OBI-822 Á{§É¸ÕÅç©ÒÀò±oªº·§©À©ÊÅçÃÒ±oª¾¯f¤HÁÞ§ÜÅ骺²£¥Í©M§Ü¸~½F¤ÏÀ³¦³«D±`±jªº¥¿ÃöÁp©Ê¡A¦]¦¹¥xÆW¯E¹©±N¥þ¤Oµo®i³æ®è§ÜÅé OBI-888¡A¦¹§ÜÅéÃĪ«°£¤F¤w¥Ó½Ð¦h°ê±M§Q¡B¿n·¥±M§Q§G§½¤§¥~¡A¥Ø«e¤w¶i¤JÁ{§É«eÃIJz¬r²z¸ÕÅç¥H¤Î§ÜÅé¶q²£¶}µo¡A¨Ã¦P®É®i¶}Á{§É¤@´Á¸ÕÅ窺³]p¡C K OBI-858 2015¦~·~¤w§¹¦¨¬r²z¸ÕÅç¤Îì®ÆÃĥͲ£¡A¨Ã®i¶}ì®ÆÃĦw©w©Ê¸ÕÅç¡A¤½¥q¨Ã·Ç³Æ´M¨D¦X§@¹Ù¦ñ¡A¦@¦P¶}µo¡C LÁÞ´¹¤ù OBI-868 ¤w§¹¦¨³]p¤Î»sµ{Àu¤Æ¡C®Ú¾Ú²z½×ÅçÃÒªº¹êÅçµ²ªGÅã¥Ü¡A±N´¹¤ùÀ³¥Î©ó OBI-822 ¤Î OBI-833 ¯f±wÀøµ{¤¤ªº§ÜÅéÀË´ú±N§ó¨ã²£«~Àu¶Õ¡A¨Ã±N¥H¦¹§@¬°pµeµo®i«ÂI M ¤½¥q¬ãµo¹Î¶¤¦b·sÃĶ}µo¨ã¦³Â×´Iªº°ê»Ú¦¨¥\¸gÅç¡A¤w¸g§¹¦¨OBI-822 ¦b¥xÆWªº¤G/¤T´ÁÁ{§É¸ÕÅç¡A¥Ø«e³W¹º¦V»OÆW¹«~ÃĪ«ºÞ²z¸p(TFDA)¥Ó½Ð¦³±ø¥óªº¤W¥«³\¥iÃÒ¡A¨Ã§Q¥Î¤G/¤T´Áªºµ²ªG¡A«·s³W¹º¦V¬ü°ê FDA ¥Ó½Ð¥þ²y²Ä¤T´ÁÁ{§É¸ÕÅç¡C ¦pªG¤U¦C¬O¯uªº¬°¦ón¬ÝÃa¯E¹©? ¬JµM¬O¯uªº¦ó¨Ó¹L«×¼ÖÆ[? |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2016/10/11 ¤W¤È 08:46:48²Ä 2634 ½g¦^À³
|
Cliff ¤j,¦hÁ¤F. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/11 ¤W¤È 12:21:05²Ä 2633 ½g¦^À³
|
§Ú»{¬°¤£n¶W¹L500¤H¸û²z·Q¡A«nªº±M®a¾ÇªÌ»P«n¤jÃļt±M·~¤Hû¡A¼Ú¬üÂå¾Ç¤¤¤ßÀù¯g¬ã¨s¤Hû¨Ó°Ñ¥[´N¨¬°÷¤F¡A¦]¬°®É¶¡¦³¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/11 ¤W¤È 12:09:17²Ä 2632 ½g¦^À³
|
Cliff¤j¤j Bella Center¦³¥|¶¡Â§°ó¡A®e¶q±q310-930¤H¤£µ¥¡AÓ¤H»{¬°³o¦¸¬O»P¼t°Ó±ÂÅv¦³Ãöªº±Ð¨|¬ã°Q·|¡A·|¦³¯S©wªºÁܽйï¶H¡A³õ¦a¤]¤£¤¹³\¹L¦hªº¤H¼Æ¡C |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/10/11 ¤W¤È 12:02:11²Ä 2631 ½g¦^À³
|
´Ü¨Øcliff¤j®i²{ªº°ª«×»P®ð«×,·P®¦! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/10 ¤U¤È 11:45:17²Ä 2630 ½g¦^À³
|
·x·x¤j¡A¤p§Ì¤~¬O¤£¹ï¡A¥Îµü¤£·í¡A¾G«¦V±z»P¦U¦ì¤j¤j¹Dºp¡A¤U¤£¬°¨Ò¡C T^T¤jªº½T¨ã¦³±M·~I´º¡A¬O¯à´£¨Ñ§Ṳ́£¦PªºÆ[ÂIªº¤H¡A©Î³\è¶}©l°Ñ»P®É¤£¶¶ºZ¡A¦ý¥un¯àÅý¤j®aªø´¼¡A§Ú·Q³£¤£¬OÃa¨Æ¡C·PÁ·x·x¤j¡B·PÁ¤j®a¡C ¥t¥~¡A¤p§Ì¦n©_ESMO¬ã°Q·|ªº³õ¦a¥i®e¯Ç´X¦ì°Ñ¥[ªÌ¡H¤@¤p®É«e¡AÀ°¦£µù¥UªºPatrica Holley»¡¥i®e¯Ça lot of people¡A¦Ó¥B¥Ø«e¤´¦³ªÅ¦ì¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/10/10 ¤U¤È 11:34:37²Ä 2629 ½g¦^À³
|
Cliff¤j, ¤p§ÌÀ´¤F ·PÁ¡I |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/10/10 ¤U¤È 11:17:57²Ä 2628 ½g¦^À³
|
·q·RªºCliff¤j:¤p§Ìı±o³e¹ý¤½¥qªº·N§Ó¨Ã¤£¬OÅF,§ó¦óªpT¤j¤]ªí©ú¨S²M·¡¤F¸Ñ¨ÓÀs¥h¯ß´N§å§P¤F!¦p¦³±o¸o~¥H«á¤p§Ì·|·V¨¥!ÁÙ½ÐCliff¤j®ü²[!!! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/10 ¤U¤È 10:31:48²Ä 2627 ½g¦^À³
|
Cliff ¤j®¦¼w ÁÂÁ±z³á «¢¡I³ßÅw±z²{¦bªº·®æ¡A±M·~»P²`«×»ô¸¡AÁô³ë¦@«ÕÀq¤@¦â ¨ØªA¤§¦Ü ¸g±zªº«ü¾É¡A¤pªº¤]¦³¤@©wªº§â´¤«×¤F ¨¯W±z¤F ¦A¦¸·PÁ±z¡I ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/10 ¤U¤È 09:52:00²Ä 2626 ½g¦^À³
|
Iriswu¤j¡G ±i¸³ªº½T»¡¹L¶W¹L80%ªº±wªÌ¥´822 ·|²£¥Í§ÜÅé¡A¬Æ¦Ü¶W¹L°|ªø»¡ªº¤ñ¨Ò¼Æ¦r¡F¥L¦n¹³¤]»¡¹L¸Ó§ÜÅé¬O«üGH§ÜÅé¡F¦ý§Ú̵Lªk¶i¤@¨B¤F¸Ñ©Ò²£¥Íªº§ÜÅé®Ä»ù¬O¦h¤Ö¡H³Ì«á¬Ý¨ìSlide¤W¬O§â®Ä»ù´¿¹F¨ì160ªº®³¥X¨Ó¤ÀªR¡A©Ò¥H¡u¦³²£¥Í§ÜÅéªÌ´N¦³Àø®Ä¡v ³o¥y¸Ü¨s³º¬O«ü¦h¤Ö§ÜÅé®Ä»ù¡H ¤@¯ë·L¥Íª«¾Ç¤W§PÂ_¦³¨S¦³¨ü·P¬V¡A¹³Åð¼ßµß·P¬V¡A·P¬V«e/«á§ÜÅé®Ä»ù40-->¡Ù160¡A¦¨¥|¿®t¶Z¥H¤Wºâ¶§©Ê¡F±ö¬rTPHA´ú¨ì80ºâ¶§©Ê¡F¸Ñª¼¤ÀªRùجO§_ªu¥Î40-->160¦¨¥|¿®t¶Z¥H¤WªÌ¬°¼Ð·Ç¡H¤£ª¾¹D¡C ¬O¤£¬O§ÜÅé¶q¤£°÷¡HY¬O¡AÀ³¸Ó·|è¶}©l¦³®Ä¡A«á¨Óº¥´c¤Æ¡C¸ò±q¥¼²£¥Í¦³®Ä§ÜÅé·|¦¦´N¶}©l´c¤ÆªÌÀ³¸Ó¦³¤£¦Pªí²{¡C ²q·Q¤j¤j¡G §Ú«ç»ò¥i¯àª¾¹DÃöÁä¨M©w¦]¤l¬O¬Æ»ò¡H¦pªG§Ú¯àª¾¹D´N¦n¿ì¤F¡A¥i¥H¼gµ¹¤½¥q°Q½×¡A¬Æ¦Ü¥i¥H¸ÕµÛ¼gµ¹Rugo¸ò¦o½Ð¯q¡A¬Ý¦o¬O§_Ä@·N§â¸Ü»¡²M·¡¤@ÂI¡A¡K°ÝÃD¬O¡A§Úºâþ®Ú½µ¡]ÁöµM³Ìªñªº½µ«Ü¶Q¡^¡H¯u¥¿À´ªº¤H¡]§Q¯A¤j¡BT^T¤j¡K¡^¨Ó¹L¤F¡A¤]³QÅF¦^¥h¤F¡C ©_©Ç¡A¦Ñ¥v¤j«ç»ò³o»ò¦wÀR©O¡H ¤p©_¤j¡G 1.¡uSD-->NED ªí¥Ü822Àø®Ä´¶³q¡FPR-->NED ªí¥Ü822Àø®Ä¤£¿ù¡v³o¬O§Úªº¥DÆ[·Pı¡A§Ú·Q»¡ªº¬O¡A³o¨Ç¨ü¸ÕªÌ¦b¦¬®×«e¤w¸gºâ¬Oª¬ªp¤ñ¸û¤£¿ùªº¡C¨ä¹êSD©ÎPD³£¬O¹ï¥ý«e¶Ç²ÎÀøªkªº¤ÏÀ³µ²ªG¡A¸ò«áÄò·|¤£·|¤]¹ï822¦³¬Û¹ïµ¥ªºªvÀø¤ÏÀ³¡AµL¤H¯à¹w¥ýª¾¹D¡CÁÙ¦³¡A¹ï¤£¦Pªº±wªÌ¦Ó¨¥¡A¥Ò¬OSD¡A¤A¬OPR¡Aþ¤@¦ìªº¸~½F¤Ø¤o¸û¤j¡H¨Ã¨S¦³¤@©w³W«h¡C¦]¬°SD¬O¥ÎÃÄ«eªº¥Ò¸ò¥ÎÃī᪺¥Ò¤ñ¸û¦Ó±o¡FPR¬O¥ÎÃÄ«eªº¤A¸ò¥ÎÃī᪺¤A¤ñ¸û¦Ó±o¡C 2.¨S¦³¾ú¸g¨º»ò¦hӤ몺®É¶¡¡Am, fu ek42ji m,4¡A¤]¨S¦³·s¼W¨º»ò¦h¨Æ¥ó¡A¦]¬°¤£¬Onewly updated¡C¥t¥~¡A¤£¦Pªº®É¶¡ùØ¡A¨C¦ì¨ü¸ÕªÌ¤U¤@¤ÀÄÁªºrisk of event¬O¤£µ¥¤ñ¨Òªº¡C4~5¬O±À´ú¨Óªº¡C³oÓ»¡¤£²M¡A¡uµ¥¦X¾Aªº®É¾÷¦A¡K¡K¸Ñ¶}¸£³Uªºµ²¡v¡G¦P·N¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/10/10 ¤U¤È 01:34:50²Ä 2625 ½g¦^À³
|
Cliff¤j¡A¤p§Ì¤]¦³°ÝÃDµo°Ý ·Q¤F¦Ñ¥b¤Ñ¡A·Q¨ì¸£³U¥´µ²¡AÀµ½ÐCliff¤jÄÀºÃ¡I ²Ä¤@Ó°ÝÃD¡A±z»¡¡G ¡u³Q¦¬®×«e-->822ªvÀø«á¡G SD-->NED ªí¥Ü822Àø®Ä´¶³q PR-->NED ªí¥Ü822Àø®Ä¤£¿ù CR-->NED ªí¥Ü¡H¡H¡v ¤p§Ì쥻ªº»{ª¾¡A°²³]®t¤£¦h¯fªpªºMBC±wªÌ¡A¸g¹L¤ÆÀø©Î¼Ð¹vªvÀø«á¡A§e²{¤FSD¡BPR¡BCR¤TºØªvÀø«áªºª¬ºA¡A¬O¤£¬O¸~½Fªº¤j¤pSD¡ÖPR¡ÖCR(CR´ú¤£¨ì)¡H¨º»ò¦b¸g¹L822ªºªvÀø«á¡AY¦P¼Ë³£Åܦ¨NEDªºª¬ºA¡ASD¬O±q¤ñ¸û¤jªº¸~½FÁY¨ìNED¡AÃø«×¬O¤£¬O¤ñ¸û°ª¡H¦]¦¹ªí¥Ü822Àø®Ä¤£¿ù¡FPR¬O±q¤ñ¸û¤pªº¸~½FÁY¨ìNED¡AÃø«×¬O¤£¬O¤ñ¸û§C¡H¦]¦¹ªí¥Ü822Àø®Ä´¶³q¡F¦Ü©óCR-->NED¡A¬O¤§«e¤ÆÀø©Î¼Ð¹vªvÀøªºÀø®ÄÁÙ¬O822ªºÀø®Ä«ÜÃø§P©w¡A¦]¦¹822ªºÀø®ÄÃø¥H§P©w¡H ¤£ª¾¤p§Ìþ¸Ì§Ë¿ù¤F¡A·Q¤£¥X³o¦]ªGÃö«Y¡AÁÙ½ÐCliff¤jÄÀºÃ¡C ²Ä¤GÓ°ÝÃD¡A±z»¡¡G ¡u¨C¤ë¬ù4~5¦ì¡AÁö¤£¤¤¥ç¤£»·¨o¡C¡v ¡u¨CÓ¤ë¥X²{ªº¨Æ¥ó¼Æ¡A¬Onon-proportional harzard cure rate model¡A¥Hµeª½½u¨Ó¦ôºâ¤£·Ç¡C¡K..¡v «á±³o¤@¥y¸Ü¡A¤p§Ì¤×¨ä·Q¤£³q¡C ¨C¤ë¬ù4~5¦ì¡A¬O«ü±q2015/10¨ì2016/9¤j¬ù11Ӥ몺®É¶¡¡A°£¤F¤w¸gª¾¹Dªº85ÓOS¨Æ¥ó¥~¡A¦@¦³·s¼Wªº¤j¬ù44~55Ó·sªº¨Æ¥óµo¥Í¡H ÁÙ¬O³Ìªñ³o¤@¨âÓ¤ë©Î¨â¤TÓ¤ë¡A¨C¤ë¬ù4~5¦ìªºOS¨Æ¥óµo¥Í¡H ¡u¨CÓ¤ë¥X²{ªº¨Æ¥ó¼Æ¡A¬Onon-proportional harzard cure rate model¡v ¤p§Ì¬Û·í¦n©_¬Æ»ò¼Ëªº¨Æ¥ó¼Æ¦CÅܤơA·|¬Onon-proportional harzard cure rate model¡A ¬O«ü2015/10¨ì2016/9³o11Ӥ몺®É¶¡¡AOSªº¨Æ¥óµo¥Í¼Æ¡A¦´Áµo¥Íªº¤ñ¸û¦h¡A³ÌªñÅܱo¤ñ¸û½w¶Ü¡HÁÙ¬O¡K¡K ¤p§Ì¯uªº·Q¨ì¸£³U¥´µ²¤F¡AÁÙ½ÐCliff¤jÀ°¦£¸Ñ¶}¡I ¤£¹L¤p§Ì·Q²Ä¤GÓ°ÝÃD©ÎªÌ¤£¦n¦^µª¡A©Îµ¥¦X¾Aªº®É¾÷¦AÀ°¤p§Ì¸Ñ¶}¸£³Uªºµ²¡I ÁÂÁ±z¡I |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2016/10/10 ¤W¤È 10:51:36²Ä 2624 ½g¦^À³
|
cliff¤j,¤p§Ì°O±o¸Ñª¼«áªº²Ä¤@¦¸ªk»¡·|,±i¸³´¿»¡¹L¶W¹L80%ªº±wªÌ¥´822 ·|²£¥Í§ÜÅ骺,¦pªG±z´£¨ì¥´¤F822¬O§_¥i²£¥Í§ÜÅé¬OÃöÁä,¬O¥u¯à°÷²£¥Í¨¬°÷ªº§ÜÅé¶Ü? ¦]¬°²z½×¤W80%¥H¤WÀ³¸Ó¤w¸gºâÆZ°ªªº¤ñ¨Ò,¬O¦]¬°¶q¤£°÷©Ò¥HÀø®Ä¤£¨Î,±N¨Ó¥²¶·¿z¿ï²£¥Í¨¬°÷§ÜÅé¶qªº±wªÌ¶Ü? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/10 ¤W¤È 10:14:45²Ä 2623 ½g¦^À³
|
Cliff ¤j®¦¼w ¤µ¦¦A²Ó²Ó«~À|¤j¤å ¤¤ªÖ¥Ã¦^ÅU¹L¥h¡A´£ºõ®²»â¤Þ»â¥¼¨Ó ¤×¨ä¨º¥y¡u¡u ¯à²£¥Í§K¬Ì¤ÏÀ³ªºÃöÁä¨M©w¦]¤l¡v¬O¬Æ»ò©Ò¾ÉPªº¡v¡A³Ìµo¤H¬Ù«ä ¤pªº·Q¡A¤j®aÀ³¦h¦³©Ò«ä¦Ò ©Î³\¤j®a«ª©ó±M·~¾ÇÃѸgÅç¡A©Î¦³·Qªk¦ýÀRÀq¡A¤pªº¦Ü¤µ¤´¤@ÀYÃú¤ô Áx´±½Ð°Ý±zª¾¹D¸Ô±¡¶Ü¡H¡I Y¦³¡A¥i§_½Ð±z¤À¨É¡AÅý¤j¹Ù±o¥H¿s¨ä¶ø ¤j®a³£ª¾¹D¡A±z¬°¤åÄYÂÔ¡A©Î³\±zª¾¹D¡A¦ý©Î«ÝÃÒ¹ê¡AÅý±z¼ÈÁô¤£µo ¤pªº·Q¡A¤pªº¤@ª½¬O¬Ý±z¤j¤å¾Ç²ß¦Óªø¤jªº¡A±R·q·P®¦¤§±¡·¸©ó¨¥ªí ¤pªº¤£´±¸ò±z»¡¡A¦³®É¯}¨Ò¤@¤U¡A©Î³\¤H¥Í·|¬Ý¨ì¤£¤@¼Ëªº·´º ¤pªº¯uªº¤æÁx¤F¡A¡] °QÄÇ ¡^ ÁÂÁ±z¡I ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/9 ¤U¤È 10:02:10²Ä 2622 ½g¦^À³
|
·PÁ Cliff ¤j®¦¼w ªº«ü¾É¤Î±Ð»£ ·Q¤Ó¦h¥i¯à¤]¬O¤pªº¤@ºØ¤ò¯f ±zªº¤j¤å¥Rº¡õ²z·N¹Ò ¤pªº¸ê½èÁöÃøÀ´ ¦ý¤]½ÐÄ~Äò¤Þ¾É¤pªº ÁÂÁ±z¡I ¤pªº»Ê·P¤¤º |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/9 ¤U¤È 08:31:09²Ä 2621 ½g¦^À³
|
Mrs.Serenity¦b³Q¦¬®×¤§ªì¡A¯f±¡¬O³B©óþÓ¶¥¬q¡HCR¡HPR¡HSD¡H§Ú¥u±qFacebook¬Ý¨ì ¡ustable with stage 4 breast cancer¡vªº±Ôz¡Cºâ¬OCR? ©ÎSD? °ò¥»¤W·|³Q822¦¬®×ªº¤H¡A¥²µM¬O¸g¹L¤ÆÀø©Î¼Ð¹vªvÀø«áéwªº¤Wz¤TÃþ±wªÌ¡A¥un¡uéw¡v§Y¨Ï¬O¤´¦b¨Ï¥ÎhormoneªÌ¤]¦¬¡C «·s¼fµø822ªº¹êÅç³]p¡A§Y¨Ï¤µ¦~2¤ë¸Ñª¼¹F¼Ð¡A¦¨¥\¥i¥Ó½ÐÃÄÃÒ¡A¥¼¨Ónª½±µ¥Î¦b¡u©|¥¼Ã©w¡vªºªì¶EÂ_ªº¥½´Á¨ÅÀù¨¤W¡A¬O§_¤´»Ý¦A°µ¤@¦¸Á{§É¸ÕÅç¡H¦]¬°¦¬®×¹ï¶H¤£¦P¡AÀø®Ä¬O¥¼ª¾ªº¡C ¦]¬°¥D°ÊÀøªk»ÝnÅé½è¸û¨ÎªÌ¡A¸g¥´ÃÄ«á¦Û¨n¯à²£¥Í§ÜÅéªÌ¤~¦æ¡A©Ò¥H®³¨Ó±Ï«æ¥Î¦b¤´¦b´c¤Æ¤¤ªºªì¶EÂ_¨ÅÀù¥½´Á¯f±w¡A¤£¤@©w·|¦³®Ä(§Y¨ÏÅ餺Àù²ÓM¦³GH¤]¤£¤@©w¦³®Ä)¡A¦]¬°n¯à¼µ¹L©µ¿ð®ÄÀ³´Á¡]®û¼í´Á¡^ ¦ý³Q°ÊÀøªkªº888´N³æ¯Â±o¦h¡A¥unÀù±wªÌÅ餺Àù²ÓM¦³GHªí²{¡A¤£½×¨ä§K¬Ìª¬ªp¦p¦ó¡Aì«h¤WÀ³·|¦³®Ä¡A¥i¥H®³¨Ó±Ï«æ(¨S¦³©µ¿ð®ÄÀ³)¡A¦ý¥¦¥u°w¹ïGH¡]+¡^ªÌ¤~¦³®Ä¡C ©Ò¥Hþ¨Ç±wªÌ¬OÄÝ©ó©Ò¿×ªºÅé½è°÷¦n¡A¤]´N¬O»¡¨ã¦³þ¨Ç±ø¥óªº±wªÌ·|¹ï¥D°Ê§K¬ÌÀøªkªº822°_¤ÏÀ³¡A»·»·¤ñ¦oÅ餺Àù²ÓM¦³¨S¦³ªí²{GH¨Ó±o«n¡C ³o¼Ëªº»¡ªk®³¥h¸ò±i¸³»¡ªº¡u¦³²£¥Í§K¬Ì¤ÏÀ³ªÌ´N¦³Àø®Ä¡v¤ñ¹ï-->²Å¦X¡C¡]¨º¨ÇGHªí²{¶q¤£¦hªº±wªÌ¬°¦ó¤]·|¦³®Ä¡H§Ú²q¦oÌ¥i¯à¬O¥HSSEA-3/SSEA-4ªºªí²{¬°¥D¡A·íµM¤@¼Ë¥i¥H¦³Àø®Ä¡^ ®³¨Ó¸ò¡u¹ï·Ó²Õ¥u¥´Cyclophosphamide¤]¬¡«Ü¤[¡v¤ñ¹ï-->²Å¦X¡C¡]¥un§K¬Ìª¬ªp°÷¦n¡A¸g¥ý«e¤ÆÀø©Î¼Ð¹vªvÀø«á¹F¡uéw¡vªº±wªÌ¡AÁöµM¥uÄò¥´Cyclophosphamide¤´µM¦³¾÷·|¯à¦A¼µ¤W´X¦~¡^ ®³¨Ó¸ò¡uRugo¦bASCO³ø§iªºµ²½×»P«Øij¡v¤ñ¹ï-->²Å¦X¡C §K¬Ì¨t²Î¤£¨ÎªÌ¡A§Y¨ÏÅ餺Àù²ÓM¦³GH seriesªí²{¡A¥´¤F822¤]¨S¦³§ÜÅé¤ÏÀ³¡A©Ò¥HµL®Ä¡C ³Q¦¬®×«e-->822ªvÀø«á¡G SD-->NED ªí¥Ü822Àø®Ä´¶³q PR-->NED ªí¥Ü822Àø®Ä¤£¿ù CR-->NED ªí¥Ü¡H¡H 822¦¬®×ªº¤H¡A¬O¸g¹L¤ÆÀø©Î¼Ð¹vªvÀø«áéwªºCR¡BPR©ÎSD±wªÌ¡A¸ÕÅç¬O³]p¦b³o¼Ëª¬ªp¤Uªº±wªÌ¡A¸g822¬I¥´°µ¡uºû«ù©ÊÀøªk¡v«á¡A°lÂܦo̯àºû«ù¦h¤[ªº®É¶¡¤£·|´c¤Æ¡A©Ò¥H®³PFS§@¬° primary endpoint¡A§Ú²{¦bı±o¬O¦X²zªº¡A·íªì¤£¥i¯à¥Î¤ÏÀ³²vORR¥h¬ÝÀø®Äªº¡AORR¬O´XÓPD-1·sÃĦb¸I¾À«á¡AÂàÓÅs©Ò±Ä¨úªº´À¥N©Ê«ü¼Ð¡C²{¦b822¸Ñª¼¥¼ªG¤~¦^ÀY§åµû¹êÅç³]p¿ù»~.....¦ü¦³»~·|¤§¶û¡C ¤Ï¦Ó¦^ÅUº}«Gªº¤@´Á¸ÕÅç³ø§i¡A¦¬®×®Éªº27¦ì·í¤¤¡]¼Ë¥»¼Æ«Ü¤Ö¡I¡^¡A¦³15¦ì¤w¬ONED¡A¥t12¦ì¬Ostable disease¡]ºâ¬OSD¡H¡^¡A©Ò¥H³y´N¬Û·í¦nªº«áÄò°lÂܼƦr¡A©Ò¥H¤G´Áªº³]p¨ä¹ê´N¬O»P¤@´Á³]p¤@¯ß¬Û©Ó¡C¥u¬O¦h¤FPR¤]¦¬¡C©Ò¥H¤£À³¦A§â¤@´Á³ø§iªº¬ü¬ü¼Æ¦r¦ûº¡¤ßÀY¡A«ä¦Ò·|¥´µ²ªº¡C §Ú²{¦bı±o¤£¬O¹êÅç³]p§âPFS¿ù³]¬°primary endpoitªº°ÝÃD¡A¦Ó¬O¨Æ¥ý¤£ª¾¹D¡u¯à²£¥Í§K¬Ì¤ÏÀ³ªºÃöÁä¨M©w¦]¤l¡v¬O¬Æ»ò©Ò¾ÉPªº¡A©Ò¥HDr.Rugo¹ï¸Ñª¼µ²ªGªºµ²½×¬O¡G¡u¥¼¨ÓÀ³§ä¥Xþ¨Ç±Ú¸s·|¹ï822²£¥Í§K¬Ì¤ÏÀ³¡v¡A¦Ó«D¥u¦Ò¼{±wªÌÅ餺Àù²ÓMªí±·|¤£·|ªí²{GH¡]¦p¦¹¬O§_¤]²Å¦X¤FASCOªºµ²½×¡G¡uTreatment response appears to be independent of tumor biological subtype and Globo H expression levels¡vªº»¡ªk¡H¡^ «áª¾«áı¡AJ¨¥¶Ã»y¡AÅwªï«ü¥¿¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/7 ¤U¤È 10:03:20²Ä 2620 ½g¦^À³
|
ÁÙ¯u¤jªº¤ñ³ë¤Ó´Î¤F¡A¨S¿ù´N¬O¿ï¶µ¤G¡A¥t¤@º²Õ¦±Ãø«×n§ó°ª¤~¯àÀò±o«C·ý¡A±q¯E¹©2016 ASMO¤½§iªº¤º¤å¨Ó¬Ý®æ§½¤w¤£¬O¥u¦b¨ÅÀù³æ¤@Ó¾AÀ³¯g¡A¦Ó¬O¾ãÓOBI822¨t¦CªºÂX±i¡A§Z±_Àùªº¬D¾ÔÃø«×·¥°ª¡A¥u¬OnÃÒ©úOBI822¨t¦C¾AÀ³¯gªº¼s«×»P²`«×¡A¤Ñ¯§¥xÆW¡C |
|
|
·|û¡GÁÙ¯u10138289 µoªí®É¶¡:2016/10/7 ¤U¤È 09:09:16²Ä 2619 ½g¦^À³
|
¥xÁÞ¤j, ¤@Óºq¤â°Ñ¥[ºq°Û¸`¥Ø, ²Ä¤@¦^¦X¿ï¤F"¤ÑÅ£"ªººq, ¦ýµû¼f»¡§Aªº¿ïºq«Ü¦n, ¦ýÁÙ¤£°÷¼ô½m, ¦^¥h¦A¥[±j, §A¤@©w«Ü¦³«e³~ªº, ¨ì¤F²Ä¤G¦¸°ÑÁÉ, ºq¤â¤Sn°Ûºq¤F, ¥L³o¦¸·|°Û 1. ¦P¤@ººqªº¼ô½mª© 2. ¦P¤@ººqªº¼ô½mª©+¥t¤@º²Õ¦± ¦pªGnÅýµû¼fÅåÆA, À³¸Ó¬O²Ä¤G¿ï¶µ..²Õ¦±, ¦ýºq¤â¬O§_¯u¯à¬D¾Ô°ªÃø«×ªººq¦±, ´N½Ð«ø¥Ø¥H«Ý .... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/7 ¤U¤È 03:45:21²Ä 2618 ½g¦^À³
|
ÁÙ¯u¤j 1§Ú¬O¨Ì¾Ú¯E¹©¤½§i°Ñ¥[2016ESMO¤º¤å¥h¶Ã²qªº¡A¤£n¤Ó¬Û«H¡A¦pªG¬O§A¬Ý¨ì¤º¤å´£¨ì¡G¨ä¥LÀù¯g¼Æ¾Ú¡A¨ä¥LÀù¯gÅý§A·Q¨ì¨º¤@ÓÀù¯g? 2¤Q¤G¤ë¨ÅÀùÁ{§É¼Æ¾Ú·|¥þ³¡ÅýªÑªFª¾¹D¡A³o¬O ªÑªF¤j·|¦³ªÑªF´£°Ý¤½¥q¦^µª¡A¤½¥q¤]½ÐªÑªF¬d¸ß¥¼¨Ó·|¦³¨º¨Ç«nªº°ê»Ú·|ij¡C»{¯uªºªÑªF³£¥i¬d¸ß¨ì³o¨Ç·|ij¥l¶}®É¶¡¡C 3½×¤åÁÙ¨Sµoªí¬O¤£¥i¥H¦VªÑªF¤½§i¡A³o¬O°ê»Ú ºD¨Ò¡A@¤ßµ¥«Ý¤½¥q¤½§i¡C§Ú¬O¥H¤½¥q¤½¶}ªº¸ê°T·í¬°³Ì«n¸ê°T¨Ó·½¡C |
|
|
·|û¡GÁÙ¯u10138289 µoªí®É¶¡:2016/10/7 ¤W¤È 12:31:37²Ä 2617 ½g¦^À³
|
¥xÁÞ¤j»¡ªº¹ï, °¨°º§Z±_Àù¹êÅç¬O±Ä¶}©ñ¦¡³]p(¤p§Ì§Ñ°O¤F, ¤£¥Î¦Aµ¥¸Ñª¼), ¥i¥HÀH®É°lÂܯf±wª¬ªp, ¦bESMO ´±®³¤WÂi±, À³¸Ó¬O¦³¨äȱo±´°Qªº¦a¤è ... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/6 ¤U¤È 11:39:08²Ä 2616 ½g¦^À³
|
4¤½¥q°Ñ»P2016 ESMO¤½§i¤¤¦³´£¨ì¡A®Ú¾Ú822Á{§Éµ²ªG¡AÀ˵øGlobo ¨t¦C§Üì¦bÂಾ©Ê¨ÅÀù»P¨ä¥LÀù¯gªº......¡A822¦³°µÁ{§Éªº°£¤F¨ÅÀù¥~ÁÙ¦³§Z±_Àù¡A©Ò¥H½×z2 §Ú·|²q§Z±_Àùªºì¦]¡A¦p²q¿ù½Ð¥]®e¡A¦p²q¹ï¤]¬O¦X²z±À´ú¡C 5 «e«h¶K¤å½×z3 ²q¿ùªº¥i¯à©Ê«Ü¤j¡Aťť´N¦n 6§Úªº«ä¦Ò¬OÅÞ¿è¬O822¦b¤£¦PÀù¯gªº¤ñ¸û(¦p¨ÅÀù»P§Z±_Àù)¡A¥t¥~¤@Ó¬O¤£¦P¨t¦C¦b¬Û¦PÀù¯g»P¨ä¥LÀù¯gªº¤ñ¸û( 822»P833) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/6 ¤U¤È 11:17:12²Ä 2615 ½g¦^À³
|
²q·Q¤j¤j 1 ª¾¦Wªº¸~½F°ê»Ú·|ij´N¨º´XÓ¡A²q¤]²qªº¥X¨Ó¡A¥þ²yªº¥Í§Þ¤½¥q³£¥þ¤Oª§¨úÃn¥ú«×¡A¯E¹©¤]¤£¨Ò¥~¡A¬Û«H§Úªº¬ã§P¡A¯E¹©¤@©w·|°Ñ¥[¤Q¤G¤ëªº¸t¦wªF¥§¶ø¨ÅÀù¬ã°Q·|»P©ú¦~¥|¤ëªºAACR¡C 2 §Ú¦A¦¸Å¥¤»¤ëªÑªF¤j·|¤½¥qªº½×z»P¦^µª ½T©w¤µ¦~¤Q¤G¤ë·|§¹¦¨OBI822ªº¸Ñª¼¡A±q ¤½¥qªº¤½§i¤¤Ó¤H¬ã§P§Z±_Àù¼Æ¾Ú·|¦b2016ESMO ´¦ÅS¡A¤ñ¸ûOBI822¦b¨ÅÀù»P§Z±_Àù²£¥Í§ÜÅ骺®t²§¡C 3 2017 AACR¨ì©³n¤½§i¤°»ò¡AÓ¤H¬ã§P¬OOBI833¤@´ÁÁ{§Éªì¨B¼Æ¾Ú»POBI822²£¥Í§ÜÅ骺®t²§°µ¤ñ¸û¡C ¥H¤W¤À¨É¡Aťť´N¦n¡A¥i°Ñ¥[¤½¥qºô¯¸¤½§i»P¤»¤ëªÑªF¤j·|¬ÛÃö¸ê°T |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/6 ¤U¤È 09:48:21²Ä 2614 ½g¦^À³
|
¥xÁÞ¤j¤j ½Ð±Ð±z ¤½¥q°Ñ¥[³o¨Ç·|ijªº°T®§¡A¬O±zªº±À´ú¡AÁÙ¬O¨Ó¦Û¤½¥q ¥»¨Ó¤U¤È¥h¹q¤½¥q¡A¦ý¨S³sµ¸¤W ¤½¥q¦n¹³ÁÙ¨Sµo¥Íªº¨Æ±¡¡A¤f·³£«Üºò «¢¡I¤p§Ì«Ü©È³Q¦C爲¤£¨üÅwªïªÑªF Y±z¤£«K¦^µª¡A¤]¨SÃö«Y¡A¤p§Ì¯àÅé½Ì¨CÓ¤H³£·|¦³©ÒÃø³B ÁÂÁ±z¡I |
|
|
·|û¡GÁÙ¯u10138289 µoªí®É¶¡:2016/10/6 ¤U¤È 04:49:01²Ä 2613 ½g¦^À³
|
Ó¤H»{¬°¨ÅÀù¼Æ¾Ú¤j³¡¤À¼Æ¾Ú·|¦b¤µ¦~©³§¹¦¨ ©ú¦~4¤ëÀ³¸Ó·|¨ÅÀù+§Z±_Àù¼Æ¾Ú .. 2015¦~°¨°º¬ö©ÀÂå°|Àù¯g¬ã¨s°ê»Ú¬ã°Q·|·|ij³ø¾É, ¦³¤@¬q¸Ü ... "ªñ¦~¨Ó¡A¸~½F¬ÛÃöºÒ¤ô¤Æ¦Xª«§Üì¤w¦¨¬°·s¤@¥NÀù¯g§K¬ÌªvÀøªº¬Ì]¼Ð¹v(¹Ï¤G)¡C¥»°|°üÀù¬ì±i§Ó¶©¥D¥ô¬ã¨s¹Î¶¤¥ÑÁ{§ÉÀËÅ餤¡Aµo²{¤j¬ù70¦Ü80%ªº§Z±_ÀùӮרä¸~½F²ÓM¦³Globo H¤ÎGb5µ¥ÁÞÃþ§Üìªí²{¡C¥HGlobo H¬°¼Ð¹v¦Ó¶}µoªºÀù¯g¬Ì]¡A¦b¥Ø«eÁ{§É¸ÕÅ窺µ²ªG¤]Åã¥Ü¥X¯à»¤¾É²£¥Í§ÜGlobo Hªº§ÜÅé¡A¦Ó³o¤]³Q»{¬°±N¯à¿Eµo¤@¨t¦Cªº§K¬Ì¤ÏÀ³¤Î§Ü¸~½F®ÄÀ³¡C" §ë¸ê·ÀI¤´n¦Û¦æµû¦ô |
|
|
·|û¡GD10142776 µoªí®É¶¡:2016/10/6 ¤U¤È 03:39:06²Ä 2612 ½g¦^À³
|
ÁÂÁÂ¥x¿}¤jªº°T®§ ¤p§Ì¨ü¯q¦h¦h |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/6 ¤U¤È 03:33:19²Ä 2611 ½g¦^À³
|
©ú¦~¥|¤ë¤@¤é¨ì¤¤éÁÙ¦³¤@Ó°ê»Ú·|ijAACR 2017 ¡A¯E¹©¤]·|°Ñ¥[¡A·|¯d¤@³¡¤À¼Æ¾Ú¦b³oÓ°ê»Ú·|ijµoªí¡A¤j³¡¤À¼Æ¾Ú·|¦b¤µ¦~¤Q¤G¤ë¤W¦¯µoªí§¹¦¨¡A·|¤£·|¦b¤Q¤ë¤¤¨ì¤Q¤G¤ë©³ ¤½§i¤@¨Ç«¤j°T®§? ¤j®an±K¤Áª`·N¤F¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/6 ¤U¤È 01:57:47²Ä 2610 ½g¦^À³
|
ÁÂÁ²q·Q¤j´£¨Ñªº±À½×¡Aªº½TÁÞÃĬO·s»â°ì¡A¤½¥q»PªÑªF³£¦bºN¯Á¡A´X¤Ñ«á¤j®a¹ïÁÞÃĪºÀø®ÄÀ³·|§ó²M´·¡A¦ý³Ì¨Îªº¼Æ¾ÚÓ¤H²q´ú·|¯d¦b³Ì¦nªº´Á¥Zµoªí¡A¤Q¤G¤ë¤W¦¯¸t¦wªF¥§¶ø¨ÅÀù¬ã°Q·|ªº¼Æ¾Ú·íµ²§À¡A©¡®É¥þ²y±M®a¹ïÁÞ¤k¥þ»ª±N¤F¦p«ü´x¡AOBI822¸Ñª¼¤½§i¤]¥þ³¡§¹¦¨ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/6 ¤U¤È 01:18:32²Ä 2609 ½g¦^À³
|
¥xÁÞ¤j¤j ¤p§Ì¬O¼ÒÀÀ«Ü¦h , «Ü¦h²Õ¦X , ²{¦b¥Î¬Ýªº , ¤j·§´N¥i¬ù¦ô¹F¼Ð§_? ±zªº°ÝÃD , ¤p§Ì«Ü·Qµª ¤£¹L¤p§ÌÁÙ¦bµ¥¤@Óµª®× , ¬Ý¬Ý¬O§_©M¦Û¤vªº·Qªk¦³®t¶Z , ¦ý¤]¥i¯à¦]¬Y«n¦]¯À¦ÓµLªk±o¸Ñ ¥H¤½¥q¸Ñª¼µ¹ªº¨Æ¥ó²v 22.3% , 28.2% ·í°ò·Ç ¥Î³oӨƥó²v¤ñ , ¦Ó¨Æ¥ó¼ÆY°÷¤j , P ȬO¦³¹F¼Ð¥i¯à ( ¬Ý¼Æ¾Úªº±Æ¦C , ¦³®É¤@¨âӨƥó¼Æ´N¨M©w¤j§½ ) , ¦ýpower¥i¯à·|®t¤@¨Ç ¤]´N¬O»¡ , Y¨â²Õªº¨Æ¥ó²v¤ñ¤j , Ó¤H¥DÆ[»{¬°¹F¼Ð¤£Ãø , ©Ô¶V¤j , ¶V©ö¹F¼Ð , ¥Bµ¥«Ý®É¶¡¤]¥i¦]©Ô¶V¤j¦Ó¶V§ÎÁYµu ¤W¦¸¸gÀÙ¤é³ø¶À°OªÌªº³ø¾É»¡ , ¤½¥q·|´£¥XBTDªº¥Ó½Ð , §Ú¦b·Q , ¾ÌÂǪº¬O¤°»ò , ·íµM¬On¦³¹w´Áªº¦n¼Æ¾Ú , ¥Ó½Ð¤~¦³·N¸q ©Î³\þ¤Ñ¤½¥q«Å§G¥Ó½ÐBTD®É , ¥i¯à´N¬O¹F¼Ð®É? ¥H¤W¥DÆ[¬Ýªk , ©Î»P¨Æ¹ê¬Û¥h¬Æ»· ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! ¡@ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/6 ¤U¤È 12:25:50²Ä 2608 ½g¦^À³
|
²q·Q¤j¤j 1 ¨Æ¥ó¼Æ¶V¦h , power ·|§ó°ª 2 ¨â²Õªº®t¶Z¶V¤j , p È·|¶V¤p , power ¶V¤j ²q·Q¤j¤j¨C¤Ñ³£¦b¼ÒÀÀ±À¦ô ¹ïP13 ¤@©w«Ü¦³·P ´N¦n¹³¤@³¡¾÷¾¹ºN¤[¤F ¹ï¨ä¤º³¡µ²ºc ·|¤ñ¤@¯ë¤H¯àÁaÆ[¥þ§½ ¨Ì¾Ú²q·Q¤j¤j¬ã§P P13 ³Ì²× ¹F¼Ðªº¾÷²v ? ( ) A 1-25 % B 26-50% C 51-75% D 76-99% |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/6 ¤W¤È 11:39:30²Ä 2607 ½g¦^À³
|
¥xÁÞ¤j¤j ¤p§Ìªº·Qªk¬O³o¼Ëªº ¤§«e¼ÒÀÀªº¼Æ¾Ú , ¥Dn¬O´£¨Ñ¤j¹ÙÌ°Ñ¦Ò §Ú·Q , ¨CÓ¤H¹ï©ó¨â²ÕOS¨Æ¥ó¼Æªº¹w¦ôÈ , À³¦h¤£¤@¼Ë ·í¤j®a¹w¦ô«á , ®³¨Ó»P¼ÒÀÀªº¼Æ¾Ú¹ï·Ó, ¬Ý¬O§_¥i¹F¼Ð , ³o¬O¥Dn¥Î·N ¦ý¤j®a¦Û¤vªº¹w´Á¼Æ , ¬O§_»P³Ì²×¤½¥q¤½§iªº°ß¤@¹ê»ÚȶKªñ , ´N·|¼vÅT¦Û¤vªº§ë¸ê§PÂ_ °²¦p±z¬O¤½¥qªº¨Mµ¦ªÌ ¦Ó¥B¥uª¾¨â²Õ¨Æ¥óªºÁ`¼Æ , ±z·|¦p¦ó³B²z Á|Ó¨Ò ·í¨â²Õ¨Æ¥óªºÁ`¼Æ¬°100®É , §Ṳ́@©w¤£´±Â½µP ¦ý·íÁ`¼Æ¨Ó¨ì 160 ©Î 180 ©Î 200 ®É , §ÚÌ¥i¯à´N·|°Ñ°u¦U¶µ¤wª¾ªº¸Ñª¼¼Æ¾Ú , ¨Ó§PÂ_¥i¯à¹F¼Ð»P§_ , ¦A¨M©w¬O§_½µP ³o¬O¤p§Ì»{¬°nµ¥«Ýªº²z¥Ñ ·íµM¨Æ¥ó¼Æ¶V¦h , power ·|§ó°ª ¦ý§ó«nªº¨M©w¦]¯À , ¤p§Ì»{¬°¬O¨â²Õªº®t¶Z , ®t¶Z¶V¤j , p È·|¶V¤p , power ¶V¤j ³o¬O¤p§Ì«D±M·~ªº²Ê²L¬Ýªk , ¦³½Ð¤j®a«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/6 ¤W¤È 10:06:34²Ä 2606 ½g¦^À³
|
²q·Q¤j¤j 1 ÁÂÁ«e½ú«ü¶}¥Ü,¨Ã¼ÒÀÀ¬Û·í¦hªº²Õ¦X¥i¥H¹F¼Ð( power ,HR , P value ),Ó¤H·Qªk¬O¥un¶e¨ì¤@²Õ¯E¹©«K¥i¤½§i ¦p¦¹¥i¥HÅýÃĺɧ֤W¥«, ²q·Q¤j¤j´£¨ìªº¨º¤@²Õ power ¤]«Ü°ª86.6% ¥t¥~95 75 ³o¤@²Õ ¬O 90.2% nµ¥ªº«n²z¥Ñ¤§¤@¬OÅýpower§ó°ª ? ¹ï¶Ü ? power ¶V°ªP value·|¶V°ª? 2 2016 ASCO P14 ¥´§¹¤E°w104¤H¨º¤@±i§ë¼v¤ù PFS °ª¹F22.5Ó¤ë,¦P®É¥X²{¦bP14 ( §¹¦¨¥þµ{¤E¦¸ª`®gªº¯f±w) »P P16 (°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù≥1:160)ªº±Ú¸s ,NED ·|¤£·|´NÂæb¸Ì±,§ÚÁÙ¦b«ä¦Ò³oÓ°ÝÃD? ³o¤@±iªºÁ`¦s¬¡´ÁÀ³¸Ó§ó¾_¾Ù 3 °ªIgM §ÜÅé®Ä»ù ªº¬ì´¶Äõ ±ö¬ù¦s¬¡¦±½u,¯E¹©¤»¤ëªk»¡´£°Ý®É¦³µªÂз|¤½§iIgM §ÜÅé®Ä»ù¤ÀªR §Ú³ßÅwJ«ä¶Ã·Q ,¦³¨Ç¥i¯à¬O°¾¨£, ťť´N¦n, ¥u¬O´£¨Ñ«ä¦Ò¤è¦V ,©ß¿j¤Þ¥É |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/6 ¤W¤È 08:09:24²Ä 2605 ½g¦^À³
|
Cliff ¤j®¦¼w Y¤pªº¦³»Ýn¸É¦Ò ±z·|µ¹¤pªº C+ , C++ , C+++ , C++++ ,ÁÙ¬O C+++++ , ©Î³\ÁÙ§ó¦hªº+ ©O? ÁÂÁ±zªºµ¹¤À! ¥xÁÞ¤j¤j °²¦p¬Oopen label , ·íµM´N®e©ö¦h¤F °ÝÃD¦b©óª¬ªp¥¼©ú®É , ¦p¦ó¨Mµ¦ ¤@¯ë¤H¦h·|¥Î÷í«O¦uªº§@ªk , ÁöµMµ¥«Ý®É¶¡ªø¨Ç ³o¬O¤p§ÌÓ¤Hªº°¾¨£ , µLÃö¨Æ¹ê ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/6 ¤W¤È 06:52:48²Ä 2604 ½g¦^À³
|
¦A«×¥B¥J²Ó©CÄZ¦^¨ý Cliff ¤j®¦¼wªº¦ÒÃD»P¸Ñµª»¡©ú¡A¯u¥i¿×¥Î¤ß¨}Wªº¸m¤J¦æ¾P§r ¤p§Ì¤£¥Î¤ß¡Aªí¿ù±¡¡A¶¾¨Ê·í°¨²D¡Aêɤj¤F ¤À¼Æ±oÓ¤jE¡AÁÙ¦nÁÙ¨S±oÓ¤jF ²{±o¨ÄÂI¥Î¥\¨Ç¡A¬Ý±Ð±Â¯à¤£¯à¸Éµ¹ÓC¡Aµ¹Ópass¡A«hÄݸU©¯ ¤@¤j¦´N»yµLÛ¦¸¡A½Ð¤j®a¨£½Ì ÁÂÁ¤j®a¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/5 ¤U¤È 02:43:19²Ä 2603 ½g¦^À³
|
²q·Q¤j¤j §Ú´£¨ì 136 : 95 ¥X²{ªº¾÷²v¬O 0 Sorry §Ú§Ñ°O³]©w®É¶¡ Ó¤H¬O¥H¤p©_¤j2017¦~2¤ë¬°³]©w®É¶¡±À´ú ¥X²{136 : 95 ªº¾÷²v¬O 0 ¤½§i¼Æ¾ÚÀ³¸Ó¬O¦³ªá³ô§éª½¶·§é¡A²ö«ÝµLªáªÅ§éªKªºì«h,§_«h¦Aµ¥¤¦~ ¨â²Õ¤j³¡¤À³£µo¥Í¨Æ¥ó ¤]´N¤£·|¦³ÅãµÛ®t²§¤F,´x´¤best timing ²Å¦X¬ù©w´N¤½§i¤~¬O¤Wµ¦ p13 ¦]¬°¬O¦³§K¬Ì¤ÏÀ³»P¨S§K¬Ì¤ÏÀ³²V¦Xpºâ ,Pȯà¤p©ó 0.05 HR ¯à°¨ì0.72 ¥ª¥k ´N¤w¸g«Ü¦n¤F , ÁÙ¦n¦³¤T±i«Ü´Îªº ·í¦õÃÒ P14 P16 P17 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/5 ¤U¤È 12:58:24²Ä 2602 ½g¦^À³
|
¿òº|¹ï·Ó²Õ: G P12¹ï·Ó²ÕM PFS 10 Ó¤ë ,¦A¬Ý¬Ý P13¹ï·Ó²Õ MOS ¦p¥Hª½½u¹ºªk²q´ú¬ù¦A36-40Ó¤ë ( ¤ñÈ3.6--4) »P¹êÅç²Õ¤ñȦ³«Ü¤j®t²§ ³o¤]ÃÒ©úOBI822 OS ¸ûÀu¶Õ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/5 ¤W¤È 11:36:36²Ä 2601 ½g¦^À³
|
D ¦A¬Ý¬ÝP12¨â²Õ§e²{³ÂªáªÈÄñ PFS µLÅãµÛ®t²§, P13 ¨â²Õ OS ¶}¤f¦b²Ä16Ó¤ë«á³v¨B©Ô¤j ¨ì32Ó¤ë ¶}¤f¤w¬Ý¥X§ó©úÅã©Ô¤j,§K¬ÌÀøªkªº¯S©Ê¥HOS ¨Óµû¦ôÀø®Ä³Ì¦X²z ,¬ü°êFDA¹ï³oºØ·sÀøªkªº¯S©Ê¤w¥R¤À´x´¤ E PFS ¶Vªø OS ¬O§_´N¶Vªø §Ú»{¬°¹ïÁÞ¤À¤l·sÃĤ£¤@©w¾A¥Î,¥h¦~¦³¤@Áû¨ÅÀùÃĦ]PFS«GÄR³Q®Öã ¤j®a¥i¥H¬Ý¬ÝOS ¬O¦h¤Ö Ó¤H»{¬°¦nªº¥Í¬¡«~½è,°ª¦w¥þ©Ê,¬I¥´·ÓÅU¤è«K,¦³Àu²§ªºOS,¤£¶QªºÃÄ»ù,¯àº¡¨¬¥¼³Qº¡¨¬ ªºÂåÀø»Ý¨D, ¤~¬OÀù¯g¯f±w»P®aÄݹڴK¥H¨Dªº¨}ÃÄ,¤]¬O²Å¦X¬ü°êFDA»ùÈÆ[»P³Ì·Q®Ö㪺ÃĪ« F ¦³ÃöPFS OS ¤ñÈ ¬OÓ¤H¦n©_¹ïOBI822ªº±À´ú, ¤£¬O¥ô¦ó§K¬ÌÀøªkªºÃĪ«³£¬O¦p¦¹, ¦³¿³½ìªº¤j¤j¥i¥H®³2016 ASCO §ë¼v¤ù¨Ó±À¦ô¬Ý¬Ý ,°ª¤âÀ³¸Ó¯à±À¦ô¦h¤Ö¤HNED ¥H¤WPFS OS ¤ñȬOÓ¤H¦n©_¹ïOBI822ªº±À´ú½M²q, ¶È¬O´£¨Ñ«ä¦Ò¤è¦V ťť´N¦n §ó¥¿: §K¬Ì¤Ï¼u >>> §K¬Ì¤ÏÀ³ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/5 ¤W¤È 10:51:27²Ä 2600 ½g¦^À³
|
²q·Q¤j A ¨Ì¾Ú2016 ASCO§ë¼v¤ù P16 °Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù≥1:160 ªº¹êÅç²Õ112¤H PFS 12.1Ó¤ë ¤ñ¶PÀù¥ ¦n100% ¦³²£¥Í§K¬Ì¤Ï¼uªº112¤H PFS 12.1Ó¤ë OS/PFS ¤ñȤñì¥ý²q´úªº3¿ÁÙn¤j«Ü¦h (¬ù 5.6 -6¿ ) ¦A¬Ý¬ÝP17 ·|µo²{²£¥Í§K¬Ì¤ÏÀ³¯f±wªº´Á¤¤Á`¦s¬¡´Á (interim OS)¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160) OS ¬Û·í«GÄR (¹ºª½½uMOS ¦³¾÷·|¨ì¹F 68 _ 72Ó¤ë) B 136 : 95 ¥X²{ªº¾÷²v¬O 0 C Power ¬O©w80% ©Î ¬O90%? ¥H¤U²Õ¦XPower·|¹F90% 95 75 90.2% 95 78 96% 95 80 98% 95 82 99.1% ¥H¤W½M²q ¶È¬O´£¨Ñ«ä¦Ò¤è¦V ťť´N¦n |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/5 ¤W¤È 07:53:59²Ä 2599 ½g¦^À³
|
¹ï¤£°_ §ó¥¿¤@¤U 2.94 ¡G 20.6 À³§ï¬° 2.94 ¡G 2.06 ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/5 ¤W¤È 07:49:23²Ä 2598 ½g¦^À³
|
Cliff ¤j®¦¼w ¤pªº¦¬¨ì§ª«¤F, ÁÂÁ±z ±z»¡±z¤£²z¸Ñ ,³o¤£¬O±zªº°ÝÃD ,¦Ó¬O¤pªº¿ù»~pºâ©M²q´ú©Ò¤Þ°_ ¸Ü»¡¡u¤µ¤é0 ¡ã9¤¤¡A³Ì«Óªº¼Æ¦r¬O5 2.79 ¡G 2.21 ¬O²{¤µ½L ³Ì¦n·íµM¬O 2.5 ¡G 2.5 ¡A¬Æ©Î 2 : 3 ¬O§_¥i¥H¦p·N µ¥¼ô¤F´Nª¾¹D¤F¡v ¤pªº»¡©ú¦p¤U: 1.¥H5¬°°ò·Ç, ¦]¤´»Ý¦A¸Ñª¼, ¦Ó°²©w 5 = E²Õ + C²Õ(¤pªº¥i¯à»~¸Ñ±z¯u¥¿ªº·N«ä? 5©Î³\¥u¬OE ©ÎC ªº¼Æ¥Ø?) 2.²{¤µ½L ©Î§ï¬°"¤wª¾½L"¸û¯à¤Á¦X¹ê»Ú, ¥B2.79 ¡G 2.21¬O¿ù»~ªº, À³§ó¥¿¬°2.94 ¡G 20.6(5*50/85 : 5*35/85) 3.¨ä¥L2.5 ¡G 2.5 ¡A¬Æ©Î 2 : 3¤§»¡,¡@¬O¨ä¥L¨C¤ë°²³]È(E²Õ »P C²ÕªºOS¼Æ) ¥Ø«e¶Z2015/10¤w¦³11Ó¤ë, Y¥Î2.5 ¡G 2.5ªº°²³]ȵû¦ô, 2.5*11ªº¼¿n ¨ú¬°28 ¦]¦¹E²Õ »P C²ÕªºOS¼Æ¤À§O¬° 78 ; 63 ¥Î¥xÁÞ¤jªº¼Æ¾Ú power 82---65---81.7% 83---66---83.2 % 84---67---84.3% 85---68---86.1% 86---69---87.5% 87---70---88.8% 88---70---87.1 % 89---70---85.3% 95 ¡V 72 - 80.2 % ¥[¤W¤pªº¤@²Õ 81---64---80 % ©Ò¥HY¨â²ÕOSªºµo®i¬O¥H2.5:2.5§e²{, ©Î³\¼Æ¾Ú¤w¹F¦¨¼ô Y¥Î2 : 3ªº°²©w ,´N§ó¤£¦b¸Ü¤U¤F ¦]¦¹²{¦b°ÝÃD,¦b©ó¥ÎþÓ°²©w¼Æ¾Ú¨Ó¨Mµ¦¸û¦X²z Y«Ü«O¦u,¥Î¸Ñª¼ªº¼Æ¾Ú(§Y2.94 ¡G 20.6), ¤pªººâ¹L, Pn¤p©ó0.05, ¥i¯àOS¼Æn¨ì 136 : 95 ¤~¦³¾÷·| ÁÙnµ¥Ô ((136+95-50-35)/5)-11¡@= 18Ó¤ë ¤pªº·Q¡@ 822ªº«pªø§À®ÄÀ³·|þ»ò®t¶Ü? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/4 ¤U¤È 11:49:22²Ä 2597 ½g¦^À³
|
²q·Q¤j¤j¦B³·Áo©ú¤ß«ä²Ó¿°¡A¨¯W¡u¤ß¡vW¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Both are from the horse¡¦s mouth. ¤ÏËn½Ð±Ð±z¡G ¡u¤µ¤é0 ¡ã9¤¤¡A³Ì«Óªº¼Æ¦r¬O5 2.79 ¡G 2.21 ¬O²{¤µ½L ³Ì¦n·íµM¬O 2.5 ¡G 2.5 ¡A¬Æ©Î 2 : 3 ¬O§_¥i¥H¦p·N µ¥¼ô¤F´Nª¾¹D¤F¡v ¤p§Ì¾q¶w¡AÀµ½Ð²q·Q¤j¤j«üÂI¡A·PÁ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/4 ¤U¤È 06:08:17²Ä 2596 ½g¦^À³
|
Cliff ¤j®¦¼w ¤pªº©ú¥Õ¤F µª®×À³¦b¡u¾Ú±x¡v¤G¦r¤WÀY ÁÂÁ±z¤F |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/4 ¤U¤È 04:50:03²Ä 2595 ½g¦^À³
|
Cliff ¤j®¦¼w ±z¯uªº¤ñ¤pªº«Ó¤Ó¦h ¤pªº¯uÆj¡A"¾|"¤F¥b¤Ñ¡A¨ÌµMµL¤°¦¬Ã¬ ¡u¾Ú±x¶É¦V¨S¦³¡v¡A¡u Áö¤£¤¤¥ç¤£»·¨o¡C¡v ¬O±zªº±À´ú¡AÁÙ¬O¤Í¤Hªº±Àºâ¡H¡]·íµM¤pªº¤£¬O°Ý"¤Í¤H"¬O½Ö¡^ ©êºp¡A¤pªº©Î¤£¸Ó¦¹°Ý Y¤£¤è«Kª½±µ¦^µª¡A¶¡±µ¤]¦æ¡A¤£µª¡A¤pªº¤]¯àÅé·|Ãø³B ¹ï¤£°_¡AÃø¬°±z¤F ÁÂÁ±z¡I ¤]ÁÂÁ¤j®a¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/10/3 ¤U¤È 11:11:04²Ä 2594 ½g¦^À³
|
Cliff¤j ÁÂÁ±zªº¸Ñ»¡¡I Ãö©ó²Ä¤@ÃD¡A¦A¦^ÀY¬Ý§ë¼v¤ù¡Aªº½T¦³¦¹±Ôz¡I ¤p§Ì·íªì·|¿ïAªºì¦]¡A¬O±q¤T´ÁÁ{§É¦¬®×¥i¯àªº¶i¦æ¤è¦¡±À´ú¡A¯f¤H¥´¤@¡B¨â°w«á¡A §ÜÅé®Ä»ùY¯à¤j©óµ¥©ó40¡A¥Nªí822¹ï¦¹¯f¤H´N¦³§@¥Î¡A¥ç¥Nªí¦¹¯f±wÅ餺¦³¨¬°÷ªºGlobo H§Üì¡A ¨º»ò¡A¨C¤@¦¸ªº®Ä»ù²z·í³£·|¤j©óµ¥©ó40¡I¤£¹L¡A¤p§Ì¦ü¥G·Q¿ù¤è¦V¤F¡I ¦A¦¸ÁÂÁ Cliff¤jªº¸Ñ»¡¡I¤]ÁÂÁ±zÅý¤j¹Ù̦³½ì¤S¦³²`«×ªº¸£¤O¿EÀú¡A³Ìªñ¤p§ÌÀY¸£³£§Ö¥ÍÄäF¡ã ²q·Q¤j §Æ±æ±zªº°·±dª¬ªp¤]¯à¸òºë¯««³«³ªº±z¤@¼Ë100¤À¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/3 ¤U¤È 10:00:56²Ä 2593 ½g¦^À³
|
²³¤j¤j¡G I.¦b2016 ASCO¤fÀY²³ø¤¤(Slide No.15 and 17)¡A´£¨ì¡u§ÜÅé®Ä»ù>160¡vªº¨º¤@Ó¦¸¸s¡A³oӮĻù>160ªº¼Æ¾Ú¬O«ü¡G ³o¤@ÃD§Ú»{¬°¬O¡]B¡^¦b³Q°lÂܹLµ{¤¤¡A¥un´¿¸g¥X²{¹L¤@¦¸anti-GH®Ä»ù¡Ö160ªÌ¡A´N·|³Q¦C¤J³o¤@Ó¦¸¸s¡C ³o¤@ÃDÀ³¸Ó¤ñ¸û¨S¦³ª§Ä³¡A¤½¥qª©ªºSlide P.16ì¤å¬O¡uIgG titer ratio¡Ù1¡G160 anytime after baseline¡v¡F¤U¤è½Ķªº¤¤¤å¬O¡u°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù¡Ù1¡G160¡v¡FP.17¤S¥X²{¤@¦¸¡C ÁÙ¦³Slide P.20¤U¤èªº¤¤¤å¬O¡u¡K±µ¨ü¬Ì]¥B¦bªvÀø´Á¶¡´¿¥X²{¹ï OPT-822²£¥ÍIgG§ÜÅé®Ä»ù¡Ù1¡G160 ªº¯f±w¡K¡v¡A ¥i¥H°Ñ¬Ý¡uwww.youtube.com/watch?v=_znW_DxOkRI&feature=youtu.be¡v¡G²Ä36¤À15¬í³B¡]P.16¡^¤Î²Ä40¤À27¬í³B¡]P.20¡^¡A³£¬O«ü¡u¡K´¿¥X²{¡K¡v¡C II. ¬Y¨ü¸ÕªÌ¦bOS°lÂܹLµ{¤¤¡A¤@ª½³B©óNEDª¬ºA¡A¦ý¬O¡K¡K¤£©¯¦Û±þ¦¨¥\¡A¨º¦¹¨ü¸ÕªÌ¼Æ¾Ú¦bK-M¹Ï(OS¹Ï)¤¤¡A¸Ó§@¦p¦ó§e²{¡H ¡]A¡^¸òÃĮĵLÃö¡AÂk¬°PD¡C ¡]B¡^Âk¬°³]¸ê®Æ¡]censored¡^¡C ¡]C¡^±N³oµ§¼Æ¾Ú²¾¦Ü¥tµù¡A¤£p¤JOS²Îp¤ÀªR¡C ¡]D¡^ºâ¬OOS¹Ï¤Wªº¤@Óevent¡A§Y¹êÅç²Õª\ªÌ¼W¥[¤@¦ì¡C That would a miserable case¡Aif it is true.§Æ±æ³oºØª¬ªp¨S¦³µo¥Í¹L¡C ³o¤@ÃD§Ú¦b¤T¶g«e´£¥X¨Ó®É¡A§Ú¤@ª½Ä±±o²@µLºÃ°Ý¦aªº¡A¥²µM¬O¡u¡]D¡^ºâ¬OOS¹Ï¤Wªº¤@Óevent¡A¡K¡K¡v¡F ¦]¬°OS¼Æ¾Ú¬Onpºâ±qÀH¾÷¤À²Õ¶}©l¨ì¡u¥ô¦óì¦]¤`ª\¡vªº¤é´Á¬°¤î¡]¡Kfrom the date of randomization to the date of death from any cause. ¡K¡^¡A¦³¨âºØ±¡§Î·|³Q¦C¤Jcensored data¡G¡]1¡^¥¢¥h°lÂÜ¡]¦Ü¤Ö°lÂܨ⦸¥¢±Ñ¡^¡]2¡^¦bdata cut-off®É¤´¦s¬¡¡C ¤£¹L«á¨Ó·Q·Q¡A¦³¨Ç³ø§i¤ÀªR·|¥H¡]C¡^ªº¤è¦¡³B²z¡A©Ò¥H¡]C¡^¤]¦³¥i¯à¡C ÁÙ¦³¡A¥t¥~¤@ӥѦ¹l¥Íªºª¬ªp¡C¥»¨Ó¡]D¡^ªº¿ï¶µ¬O¡uºâ¬OOS¹Ï¤Wªº¤@Óevent¡A§Yª\ªÌ¼W¥[¤@¦ì¡C¡v¡A«á¨Ó¦Û¤vµe³D²K¨¬¥[¤W¡u¹êÅç²Õ¡v¤TÓ¦r¡A¦]¬°ª½Ä±¤W/±¡·P¤W»{¬°NED¥²¨Ó¦Û¹êÅç²Õ¡AµM¦ÓªG¯u¬O¦p¦¹¶Ü¡H ¦b¦¬®×ªº±ø¥ó¤¤¡A¨ü¸ÕªÌ¬O±µ¨ü¹L¦Ü¤Ö¤@¦¸ªº¤ÆÀø«á¹F¨ìCR¡BPR©ÎSDªÌ¡C¦³¨S¦³¥i¯à¤@¦ìCRªÌ³Q½s¤J¹ï·Ó²Õ¡AÁö¥¼ª`®g822¡A¦ý¤@¸ô´X¦~°lÂܤU¨Ó¡]¥i¯àÁÙ¨p¤U¨Ö¥Î¨ä¥Lªº°¾¤è¡A¤]¥i¯à¨S¦³¦A¨Ö¥Î¨ä¥LÀøªk¡^«Ü©¯¹B¦a³£ºû«ù¨}¦nª¬ªp¡A³Ì«á¹F¨ìNED¡H§Úı±o²z½×¤W¦³¥i¯à¡F¨º¹ê»Ú¤W©O¡H¾Ú±x¶É¦V¨S¦³¡C ÁÙ·Q¨ì¤@Óª¬ªp¡A¦]¬°¨C¦ì¶i³õ®É¶¡ÂI¤£¤@¡A©Ò¥H¤¦~ªºOS°lÂÜ´Á©|¥¼¥þ³¡©¡º¡¡A¨Ï±o¨ü¸ÕªÌºÝ©|¥¼¸Ñª¼¡A¦pªG¥¿¦n¦Û¤v©Î¿ËªB¦n¤Í³£¨S¦³¤H¬Ý¥²´I¡]ª`®g³B¦³¨S¦³¬õ¤@¤j¶ô¡H¡^¡A¨º¦oÌ¥i¯à¤´¤£ª¾¹D¦Û¤v¨s³º¬O³Q½s¤Jþ¤@²Õ¡A¤£ºÞ¬ONEDªÌ©Î«DNEDªÌ¡A¨ººØ¤£½T©wªºµ¥«Ý·P¬O«Ü·Î¼õªº¡C¡]¡K¬Ý¥²´I¦³À°§U¡K¡^ ¥t¥~¡A¹ê»ÚPDªÌ¡A¦bPFS¹Ï¤W¬O¤@Óevent¡F¦ý¦bOS¹Ï¤W©O¡H¥un¤@®§©|¦s´N¤£ºâ¤`ª\¡A¹ïOS¹Ï³£¬O¥¿±°^Äm¡C¥H¹ê»ÚPD¤H¼Æ¨Ó¦ômOS¨Ã¤£¦n¥Î¡C°ò¥»¤W¤£¥²¥HPD ¤H¼Æ¥h¦ôOS¤H¼Æ¡A¨C¤ë¬ù4~5¦ì¡AÁö¤£¤¤¥ç¤£»·¨o¡C ¥H¤WÓ¤HÆ[ÂI¡AÅwªï«ü¥¿¡C ÁÂÁ²³¤j¤j¡C |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2016/10/3 ¤U¤È 09:57:03²Ä 2592 ½g¦^À³
|
Cliff¤j, I==>B II===>B |
|
|
·|û¡GÁÙ¯u10138289 µoªí®É¶¡:2016/10/3 ¤U¤È 09:54:04²Ä 2591 ½g¦^À³
|
Cliff¤j, I-->B II-->C |
|
|
·|û¡Gµ¾ÂF10142999 µoªí®É¶¡:2016/10/3 ¤U¤È 09:44:16²Ä 2590 ½g¦^À³
|
Ó¤H·Qªk¡G B C |
|
|
·|û¡Gmetrostar10141472 µoªí®É¶¡:2016/10/3 ¤U¤È 08:10:25²Ä 2589 ½g¦^À³
|
§Ú¨S¦³ÂùB ÁÙ¦n³o¥i¥H¿ïÂùB ©Ò¥H 1.B 2.B |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/10/3 ¤U¤È 07:57:34²Ä 2588 ½g¦^À³
|
Cliff¤j ¤p§Ì¤]¨Óª±ª± A(°Q½×®É¡A¦A»¡¤p§Ìªº©å¨£¡^ D ²q·Q¤j Cliff¤j¦n«Ó |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/10/3 ¤U¤È 07:56:57²Ä 2587 ½g¦^À³
|
Cliff¤j ¤p§Ì¤]nÀ½´ê¤@¤U B C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/3 ¤U¤È 07:52:09²Ä 2586 ½g¦^À³
|
¬JµMCliff¤j®¦¼w§ïµª®× ¤p§Ì¤£´±¹HI ¤p§Ì§ï¬° BD ¦n«Ó |
|
|
·|û¡GLIN10137582 µoªí®É¶¡:2016/10/3 ¤U¤È 07:39:51²Ä 2585 ½g¦^À³
|
Cliff¤j ¢¹⇒B ¢º⇒B |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/3 ¤U¤È 07:32:43²Ä 2584 ½g¦^À³
|
©êºp¡A§ó¥¿¤@¤UÃD¥Ø¡G¤Ö¤F¤@Ó¡]D¡^ªº½s¸¹¡C II. ¬Y¨ü¸ÕªÌ¦bOS°lÂܹLµ{¤¤¡K¡K ì¤å¡G¡]B¡^ºâ¬OOS¹Ï¤Wªº¤@Óevent¡A§Y¹êÅç²Õª\ªÌ¼W¥[¤@¦ì¡C §ó¥¿¡G¡]D¡^ºâ¬OOS¹Ï¤Wªº¤@Óevent¡A§Y¹êÅç²Õª\ªÌ¼W¥[¤@¦ì¡C ÁÙ¦³¡A³o¬O¤F¸Ñ¤j®aªº·Qªk¡A¥u¬O¡u¤p¤p·N¨£½Õ¬d¡v¡A¤£¬O¦ÒÃD¡A»¡¦ÒÃD¤Ó¨I«¡C ©Ò¥H¦A¦hµ¥´X¦ì¦^µª«á¦A¨Ó°Q½×¦n¤F¡C |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/10/3 ¤U¤È 07:15:21²Ä 2583 ½g¦^À³
|
A B |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/10/3 ¤U¤È 06:05:36²Ä 2582 ½g¦^À³
|
Cliff ¤j: I: B II: B |
|
|
·|û¡G³p»»10141999 µoªí®É¶¡:2016/10/3 ¤U¤È 05:34:32²Ä 2581 ½g¦^À³
|
Cliff¤j I= (B) II=(B) |
|
|
·|û¡Gªø½u10139882 µoªí®É¶¡:2016/10/3 ¤U¤È 05:16:37²Ä 2580 ½g¦^À³
|
Cliff¤j ¢¹⇒B ¢º⇒B |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2016/10/3 ¤U¤È 05:04:15²Ä 2579 ½g¦^À³
|
Cliff¤j I-->B I I-->C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/3 ¤U¤È 04:43:24²Ä 2578 ½g¦^À³
|
¹ï¤£°_¡A¤p§Ì§Ñ¤FµªÃD ÂùB (±Ð±Âµ¹ÂùB¡A¤pªº¤£´±¤£±µ¨ü¡^ ¦n«Ó |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/10/3 ¤U¤È 04:43:18²Ä 2577 ½g¦^À³
|
¦Ñ¤j ¤p¦ÒÅo¡I I=>(B) II=>(B) |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/3 ¤U¤È 04:34:53²Ä 2576 ½g¦^À³
|
Cliff¤j®¦¼w±Ð±Â¤p¦ÒÅo¡I ¤£¹LÃD¥Ø¦³¨ÇÃø ¤pªº©Èµª«D©Ò°Ý¡AÃø¬°±¡ ¤p§Ì¤]¨Ó¸É¤@ÃD ¦³½Ð¤j¹ÙÌ¿ãÅD§@µª ÃD¥Ø¬°¡G Cliff¤j®¦¼w¡A¦n¤£¦n¡H«Ó¤£«Ó¡H «¢¡I¤p§Ì¥X±o²³æ§a¡I |
|
|
·|û¡G¤p¤á10140918 µoªí®É¶¡:2016/10/3 ¤U¤È 04:29:34²Ä 2575 ½g¦^À³
|
¤£¦n·N«ä, קï¤@¤Uµª®×. I=>(B) II=>(C) |
|
|
·|û¡G¤p¤á10140918 µoªí®É¶¡:2016/10/3 ¤U¤È 04:25:29²Ä 2574 ½g¦^À³
|
ÅTÀ³Cliff¤j, I=>(B) II=>(B) |
|
|
·|û¡GBH56710142562 µoªí®É¶¡:2016/10/3 ¤U¤È 04:12:55²Ä 2573 ½g¦^À³
|
I=>(B) II=>(B) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/3 ¤U¤È 03:27:04²Ä 2572 ½g¦^À³
|
I B II C |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/10/3 ¤U¤È 03:10:26²Ä 2571 ½g¦^À³
|
I=>(A) II=>(B) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/10/3 ¤U¤È 02:32:35²Ä 2570 ½g¦^À³
|
ªÑ»ù«Ü´e®É¡A¨Ó°µÓ¤p¤p·N¨£½Õ¬d¡G I.¦b2016 ASCO¤fÀY²³ø¤¤(Slide No.15 and 17)¡A´£¨ì¡u§ÜÅé®Ä»ù>160¡vªº¨º¤@Ó¦¸¸s¡A³oӮĻù>160ªº¼Æ¾Ú¬O«ü¡G ¡]A¡^¥X²{¦b¸Ó¨ü¸ÕªÌ¨C¤@¦¸³Q°lÂÜÀˬdanti-GH®Ä»ù³£¡Ö160ªÌ¡C ¡]B¡^¦b³Q°lÂܹLµ{¤¤¡A¥un´¿¸g¥X²{¹L¤@¦¸anti-GH®Ä»ù¡Ö160ªÌ¡A´N·|³Q¦C¤J³o¤@Ó¦¸¸s¡C II. ¬Y¨ü¸ÕªÌ¦bOS°lÂܹLµ{¤¤¡A¤@ª½³B©óNEDª¬ºA¡A¦ý¬O¬Ý¨ì´CÅé¹ï¸Ñª¼¼Æ¾Úªº¸ÑŪ¬O¡u¥¢±Ñ¡v¡A¹ï¤½¥q«H¤ß¤j¨ü¥´À»¡F¦A¬Ý¨ì°|ªø»X¨ü¤£¥Õ¤§Þ³Q¢Ã㾡A¤ß±¡¦Ü¬°Æ{´e¡A¤£©¯¦Û±þ¦¨¥\¡A¨º¦¹¨ü¸ÕªÌ¼Æ¾Ú¦bK-M¹Ï(OS¹Ï)¤¤¡A¸Ó§@¦p¦ó§e²{¡H ¡]A¡^¸òÃĮĵLÃö¡AÂk¬°PD¡C ¡]B¡^Âk¬°³]¸ê®Æ¡]censored¡^¡C ¡]C¡^±N³oµ§¼Æ¾Ú²¾¦Ü¥tµù¡A¤£p¤JOS²Îp¤ÀªR¡C ¡]B¡^ºâ¬OOS¹Ï¤Wªº¤@Óevent¡A§Y¹êÅç²Õª\ªÌ¼W¥[¤@¦ì¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/3 ¤U¤È 01:07:45²Ä 2569 ½g¦^À³
|
¥@»¡·s»y 1 §â¤G¤ë¤½§Gªº Top-line Results ¸Ñª¼¼Æ¾Ú·í¥þ³¡¬O¤@ºØ°g«ä,§ó¬O¤@ºØ°¾¨£ ,¸Ñª¼¬O¤@Ó³sÄòªº¹Lµ{,¯E¹©¨ÅÀù ÃĮڥ»ÁÙ¨S¸Ñª¼§¹¦¨¦p¦ó½×¦¨±Ñ 2 ·|¼vÅTMOSªº ¬O¹ê»Úªº PD ¤H¼Æ, 2016 ASCO P12 ¤½§i ¹êÅç²Õ ¨Æ¥ó¼Æ159 ¤H ¦pªG´«¦¨¹ê»Úªº PD ¤H¼Æ ·|¬O¦h¤Ö¤H ¥H70% ¨Óºâ ¹ê»Úªº PD ¤H¼Æ ¬ù 112¤H 3 P13 ¹ï·Ó²Õ MOS °²³]¥H36Ó¤ë²q´ú ¦s¬¡¦±½u¬ù¦b2016¦~ 2¤ë¼Æ¾Ú¤w¸gmature¨ì¦ì, ²{¦b¦bµ¥¨â²Õ¤ñ¸û«á HR , power , P value ¬O§_¹F¼Ð ´N¥i¤½§i (¤£½×¹êÅç²Õ¦s¬¡¦±½u¦³¨S¦³¨ì50% ¦ì¸m ) 4 Åý¯E¹©³Ì·P¿³¾Ä»P¹ª»Rªº¬O 2016 ASCO P13 P14 p16 p17 ÁÙ¦³©¹«á·|³°Äò¤½§iªºÁ{§É¼Æ¾Ú §â¤G¤ë¤½§Gªº Top-line Results ¸Ñª¼¼Æ¾Ú·í¥þ³¡¬O¤@ºØ°g«ä §ó¬O¤@ºØ°¾¨£ ¥H¤W¤À¨É¥i¯à¤]¬O°¾¨£, ťť´N¦n, ¥u¬O´£¨Ñ«ä¦Ò¤è¦V |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/3 ¤W¤È 07:02:43²Ä 2568 ½g¦^À³
|
¤j¹Ù¦¦w¡I ¬Q¤é´£¤ÎCliff ¤j®¦¼wªºIgM§K¬ÌºÊ´ú«ù«í¥\¯à µM¦p¦ó¦b822¦LÃÒ ¥O¤H·Q°_¤ý£«¬Â¤j¤jªº¨â¦ì©¯¹B±wªÌ ¥Ñ²¾Âà®Éªº 5 cm¸g¥ÎÃÄ´î¦Ü3¡ã3.5 cm §Ú̪¾¹D¡A§K¬ÌÀøªk·|ÃĮĦ³©µ¿ð«ù¤[ªº²{¶H ¨Ì¾Ú³ø¾É¡A¦³¤H¬Æ¦Ü£¸¡B¤G¦~«á¤~¹FCR ¤£ª¾³o¨â¦ì©¯¹B±wªÌ¡A©ó¡u ¶q ¡vªºµû¦ô¤W¡A¬O§_¦³©ÒÅܤơA¥ç§YÅܤj ¡BÁY¤p©Îºû«ù ¦³µª®×·íµM¦³§U©ó§PÂ_¡A¦ý§Ú̹ê¦b¤£¦n·N«ä¦A½Ð¤ý£«¬Â¤j¤j¸Ñµª ¤p§Ì´£¥X¨Ó¨Ñ¤j¹ÙÌ°Ñ¦Ò ¤]³\¤j®a¶°«ä¼s¯q¡A©Î¥t¦³£¸µf®ð¶H ¤p§Ì·R»¡¸Ü¡A¤]½Ðì½Ì ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/2 ¤U¤È 05:30:49²Ä 2567 ½g¦^À³
|
«·s·Å²ß²³¤j¤jªº¨ô¤å ¦³µÛ¸ò¥H©¹¤£¦Pªº»{ª¾ ¤×¨äCliff ¤j®¦¼wªº¤j¤å, ´X¥i¶°µ²¦¨¥U¦¨¬°OBI-822 ¤j¥þ ¤å³¹©w©Ê¡B©w¶q¬Ò¦³, ¤Þ¸g¾Ú¨å, ©Î¯SµÛ«¶qªº§e²{ ´N¦p¯Î°|ªøªº http://pubs.acs.org/doi/pdf/10.1021/ar5004187 Figure 11 ( ¦³½Ðª`·NÁa¶b¨è«× ) ©ú¥Ü Globo-H−KLH−QS21 and Globo-H−DT−C34,¦b¹«Åé²£¥ÍGlobo-H¨t¦C§ÜÅé IgG ©Î IgM ªº¶q Åý§Ṳ́jP¤F¸Ñ¤GªÌ²£¥Í§ÜÅé¶qªº®t¶Z©M½ü¹ø ¦P®É¤]ª¾¹DGlobo-H−KLH−QS21 ¥HIgM¬°¥DIgG¬°»²; Globo-H−DT−C34«h¬Û¤Ï ÁöµM¦b¤j®aªº»{ª¾¤¤, IgGÆF¬¡¨ã°O¾Ð©Ê, À³¤ñIgM¬°¨Î ¦ýCliff ¤j®¦¼wªº¥t½g¤j§@ ¡y ¡]ÁöµMÁÞ§Ü쥼¯à²£¥Í«Ü¦h¨ã¦³°O¾Ð©ÊªºIgG¡^¡A¤£¹L´`Àô¤¤ªº§ÜÁÞÃþªºIgM³Q±ÀÂ_¬O§K¬ÌºÊµø¨t²Îªº¾÷Âà¡A ¦¨¬°¥ý¤Ñ©Ê§K¬Ìªº¤@û¡A±À´ú¤é«áY¦³·s²£¥Íªº§Üì¡]Àù²ÓM¡^¡A±o¥H¦A±N¥¦Äè·À¡C ¡z ¦P®ÉÁ|¶Â¦â¯À²ÓM½Fªº¤HÅé¬Ì]¸ÕÅç¦^·¹¤À²Õ§@¤ÀªR ¡y ¡]¤À¦¨¦s¬¡5¦~¥H¤W¡B¦s¬¡2-5¦~¡B¦s¬¡<1¦~¤Î¹ï·Ó²Õ¦@¥|²Õ¡^¡AÀˬd¨ä¦U²Õ±wªÌ¦b²Ä0¶g»P²Ä¥|¶gªºIgM¬Û¹ï¿@«×ÅܤơA µo²{¦s¬¡5¦~¥H¤Wªº¨º¤@²Õ¡A¨ä²Ä¥|¶gªºIgM¿@«×³Ì°ª¡A¨ã¦³²Îp±oÅãµÛ·N¸q¡C ¬O§_¦s¬¡±o¶V¤[ªº±wªÌ¡A¨äÅ餺·í®É³Q»¤µo¥X¨Óªº°ª¿@«× IgM ¬OÃöÁä¡H ¡z ¤½¥q¸Ñª¼«á»¡, §ÜÅé¶q¶V°ª, Àø®Ä¶V¦n Cliff ¤j®¦¼w¦b2015/1/4 ´N¤w¹wª¾, §i¶D¤j®a¤F ¥t´N833²Ä¤G¥N»P²Ä¤@¥N ( GH-DT/C34 ©M GH-DT/QS21 ) ªº¤ñ¸û https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574961/figure/fig03/ ÅãµM¦b¹«Åé 833²Ä¤@¥N¨Ã¨SÀu822¦h¤Ö ( ¯Â¹«Åé¼Æ¾Ú¤ñ¸û ) ¦ýCliff ¤j®¦¼w »¡ ¡y ´N²£¥Í¸û¦hIgG¼Æ¶q¦Ó¨¥¡AD (GH-DT)Àu©óKLH (GH-KLH)¡F¥BDT¨Ï¥Î¤w¤[¡Aéw©Ê¦n ¡Aµ²ºc³æ¯Â¦n»s³y¡A¦¨¥»§C·G¡FKLHn¶i¤f¡A¦¨¥»¸û°ª ¡z ¸Ñ¤F¤p§ÌªººÃ´b Cliff ¤j®¦¼wªº¤j¤å ¦h¨ì¤p§Ì²´ªá«ä¶w ¨ä¥L¦p ¯»¶ê»¡ ; Áx©T¾J°§C¤Fªº§K¬ÌºÊ´ú®ÄªGµ¥,¤£¤Î°O¸ü ³o¬O¤p§Ìµ§°O ¦³«Ý¤j¹ÙÌÄ~Äò¸É¥¿ §óÁÂÁÂCliff ¤j®¦¼w¦h¦~¨Óªº±Ð»P¾É, Y¤p§Ìªºµ§°O¹L«×¤Þ¥Ó, ¥ç½Ð¤@¨Ö«ü¥¿ ÁÂÁ±z! ¤]ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/2 ¤U¤È 05:22:50²Ä 2566 ½g¦^À³
|
¥xÁÞ¤j¤j ÁÂÁ±z ¤p§Ìªº·Pı ¸Ó¸ÕÅç¬JµM¬O®ê¶ëªk ©Î´N¥uÂê©wHCC±wªÌ? Y¯àÂX¤Î¥LªÌ ©Î¤]¯à»P822Áp¦XªvÀø? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/2 ¤U¤È 05:15:35²Ä 2565 ½g¦^À³
|
§@ªÌµoªíµû½×»PºÃ´b¸Ñµª: www.nownews.com/n/2016/09/27/2250720 J¦Ä¡G§Ú̪º¬ã¨s¡A§ÚÌ»{¬°¥Nªí¤F¤@ÓªvÀø¸~½Fªº·s²z©À¡A¦³²z½×¤Wªº·N¸q¡Cìµo©Ê¨x²ÓM¨xÀù¬OÀËÅç³oÓ«ä¸ô³Ì¦nªº¼Ò«¬¡A§Ú̬ð¯}¤F¤j¨xÀùÀø®Ä®tªº²~ÀV¡A³o¬O¤@Ó¶i¨B¡A¦ýÂ÷²×·¥¥Ø¼ÐÁÙ«Ü»·¡A»Ýn§Ú̳o¤@¥N¤H¤D¦Ü¤U¤@¥N¤H°í«ù¤£¾Ó¦a§V¤O¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/2 ¤U¤È 04:38:15²Ä 2564 ½g¦^À³
|
§ó¥¿ ³o½gµoªí¦b´Á¥Z e Life ¤W ¤£¬O¦bCSCO ·|ij¤Wµoªí ¦]¬°¬O pilot clinical investigation ¤H¼Æ¤£»Ý«Ü¦h ¨ü¸Õ¨xÀùÁ{§É´Á§O? ¤£¬O«Ü²M·¡? ½×¤åÃD¥Ø: A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/10/2 ¤U¤È 02:33:27²Ä 2563 ½g¦^À³
|
walker ¤j ²q·Q¤j ¦b«DÀH¾÷¹ï·Ó¸ÕÅç·í¤¤¡A³oÓµ²ªG¬Ý¤W¥h«Ü¤£¿ù¡A¤¤¦ì¥Í¦s´Á¦³¤F·¥¤jªº´£°ª¡C ( «DÀH¾÷¤À¬£¦³®Ä) ¤ñ¸û¿ò¾Ñªº¬O¡A¥Ñ©ó¼Ë¥»¶qµo¥ÍÅÜ°Ê¡AÀH¾÷¹ï·Ó¸ÕÅ窺µ²ªGÅã¥Ü¨âªÌ¨S¦³¥Í¦s´Á¤Wªº©úÅã®t²§ ( ÀH¾÷¤À¬£¨S¦³®Ä ) kknews.cc/zh-hk/health/ljr9g9.html ³o½g¬ã¨s¦b2016 CSCO µoªí ( ¤£¬OASCO ¤£n¥H¬°§Ú¼g¿ù) Ó¤H»{: ÄYÂԫפ£¨¬ Á{§É¼Ë¥»¤£¨¬ Á{§É³]p¤£²M·¡ ¥Ñ©ó¼Ë¥»¶qµo¥ÍÅÜ°Ê¡AÀH¾÷¹ï·Ó¸ÕÅ窺µ²ªGÅã¥Ü¨âªÌ¨S¦³¥Í¦s´Á¤Wªº©úÅã®t²§ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/2 ¤W¤È 10:07:41²Ä 2562 ½g¦^À³
|
ÁÂÁÂwalker¤j ´£¨Ñªøª¾ÃѪº°T®§ ì¨Ó³o¤£¬O¥Î¦Yªº,¦Ó¬O¤@ºØ®ê¶ëªk,ºÙ¬° ¡u¹v¦V¸~½F¤º¨Å»Ä³±Â÷¤l©M²BÂ÷¤lªº°Ê¯ß´¡ºÞ¤ÆÀø®ê¶ë³N¡v¡A²ºÙ¡uTILA-TACE¡v http://news.wenweipo.com/2016/09/24/IN1609240018.htm |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/10/2 ¤W¤È 08:36:06²Ä 2561 ½g¦^À³
|
¤¤°ê¤j³°ªº·sÀøªk ¦³¤H¬Û«H¶Ü¡H Àù²ÓM³Q³°Âå¥Í¾j¦º¤F ÃöÁä¬O¤pĬ¥´ ¡]¤¤¥¡ªÀ¥x¥_25¤é¹q¡^¤¤°ê¤j³°®ý¦¿¤j¾Ç¸~½F¬ã¨s©Òµo²{¡u¾j¦º¡vÀù²ÓMªº·sÀøªk¡AÃöÁä¦b©ó¨Ï¥Î¤pĬ¥´¡A¨Ã¦b¸²µå¿}ÄȾj©Î¯Ê¥Fªº«e´£¤U¡AÀù²ÓM·|§Ö³t¦º¤`¡C www.cna.com.tw/news/firstnews/201609250267-1.aspx |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/10/1 ¤U¤È 11:12:50²Ä 2560 ½g¦^À³
|
¶¢±oµL²á¡A¤£¦pÅý§Ú̦h»{ÃѤ@¨Ç¥ç¼Ä¥ç¤Íªº¦n·fÀÉ Immune Escape to PD-L1/PD-1 Blockade http://www.medscape.com/viewarticle/868372 Y¤j®a¦³¤ß±o¡A½Ð¤À¨É±zªº¨ô¨£ ÁÂÁ¤j®a¡I |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/10/1 ¤U¤È 07:11:47²Ä 2559 ½g¦^À³
|
¤½¥qªº¦^ÂÐ: ÁÂÁ±z¹ï¯E¹©ªºÃöª` ±z´£ªº«Øij ³£¦b¤½¥q¥J²Óµû¦ô¤¤ ¤Z¦³§Q©ó¯E¹©µo®iªºµ¦²¤ §Ú̳£·|ºÉ¥þ¤Oª§¨ú µ¥¤T´Á¦³¨ãÅé¶i®i¨Ã²Å¦X¤½§i±ø¥ó®É §ÚÌ·|©M§ë¸ê¤j²³¤À¨É ¦AÁ ¥xÆW¯E¹© 20160926 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/30 ¤W¤È 10:08:03²Ä 2558 ½g¦^À³
|
³o¤SÅý¤p§Ì·Q¨ì Cliff ¤j®¦¼wªº¤j§@---Âù¹v¦V§ÜÅé °²¦p888¬O¥HGlobo H ©M PD-L1¬°Âù¹v,°µ¦¨ªºÂù¹v¦V§ÜÅé ®ÄªG¤£ª¾¦p¦ó? ©Î³\·|ÅåÆA¥þ²y§a? ¤Ñ°¨¦æªÅªº¤Û·Q ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/30 ¤W¤È 09:19:22²Ä 2557 ½g¦^À³
|
³Ìªñ«·s·Å²ß¤j¹Ù´¼¼zµ²´¹ªº¤j¤å ¬Ý¨ì¶Â½ü§B¤j¤j¦b½s¸¹¬°2017ªº½×z¡A½Í¤Î " 1.PD-1 ¸ò 822¨ä¹ê¦bªÍÀù³o¶ô¬O¦³¬Û»²¬Û¦¨ªº®ÄªG¡A°²³]822 ¥i¥H¿ëÃÑ¥XªÍÀù²ÓM¤WªºGLOBO H¡A ¦ý¦]¬°ªÍÀù²ÓMªí±¤WªºPD-1¡A·|Åý822©Ò²£¥Íªº§ÜÅéµLªk¤ÞµoT CELL¹ïªÍÀùªº§ðÀ»¡C ¬Û¦Pªº¡A§Y¨ÏPD-1 inhibitor¥i¥Hµo¥Í®ÄªG¡A¦ý§K¬Ì¨t²ÎµLªk²£¥Í GLOBO H§ÜÅé¡AÀù²ÓM¤]¬O¦s¬¡¤U¨Ó¡C 2.PD-1¬O³J¥Õ½è¡A³J¥Õ½èªº¦X¦¨¦b¥Í¤Æ¾Ç¬É¨Ó»¡¡A¬O¬Û¹ï¦X¦¨ÁÞ¤À¤l¨Ó»¡¬O²³æªº¨Æ¡A¥B¼t°Ó¤Jªù¬Û·í®e©ö¡A ©Ò¥H¤å³¹¤¤¦³´£¨ìPD-1 inhibitor me toÁͶաA¥i¬Ý¥X³o¶ôªº°Ó¾÷¤w¸g¬O¬õ®ü¤F¡A ¦Ó822¦³¯Î°|ªø¦bÁÞ¦X¦¨¬Éªº±M§Q°ªÀð¡A¨ä¥L¼t°Ó´Nºâª¾¹DGLOBO H µ²ºc¡A ¥H¥Ø«eÁÞ»â°ìªºªº¶iµ{¡A´N¬O¯E¹©´N¦n¹³¬OTSMC¦b°µ7©`¦Ì»sµ{¤F¡A¨ä¥L¼t°ÓÁÙ¦b·L¦Ìªº¶¥¬q±Ã¤ã¡C 3.822¥un²Ä¤T´Á¹êÅç³]pªº¦n¡A¤]¥i¥H¹³Keytruda²Ä¤T´Áµ²ªG«ÜÅãµÛ¡A¥i¥H´£«eµ²§ô¹êÅç¡A¥[³t¤W¥«´Áµ{¡C " «z! ³o¤]¤Óºëªö PD-L1§êºtµÛ§í¨î§K¬Ì¥\¯àªº¨¤¦â https://www.jci.org/articles/view/80011/figure/2 GLOBO H ¤]¦³Ãþ¦ü§@¥Î °²¦pÀù²ÓM¤W³£¦³³o¨âºØ¤À¤l¡A´N¦p¶Â½ü§B¤j¤j¦b1.ªº»¡©ú¡A ¤GªÌ¬Û¤¬¼vÅT´î§CÃÄ®Ä ¦ýY¨âªÌÁp¦X§ðÀ»¡A»¡¤£©w¤]¦³Åå¤Hªº®ÄªG? ¥t¥~ ¤p§Ì¤]¦b·Q¡A³oÓ¦]¯À¬O§_¤]´N¬O822¨S¦³§K¬Ì¤ÏÀ³¦¸±Ú¸sªí²{¸û®tªºì¦]? 822¨S¦³§K¬Ì¤ÏÀ³¦¸±Ú¸s,¬O§_¤]¬OPD-L1ªí²{¶q¦hªº±Ú¸s? PD-L1ªºªí²{©óMBC±wªÌ¨Ó»¡, TNBC³Ì¦h, HER2+¦¸¤§, HR+³Ì¤Ö ´N®³¤½¥q20160615ªk»¡·|P.31ªº¸ê®Æ, TNBC±wªÌ¤Ï®t³Ì¤j ¨S¦³§K¬Ì¤ÏÀ³¦¸±Ú¸s©Î³\¥Ñ©óPD-L1ªí²{¶q¦h,§í¨î¤F§K¬Ì¨t²Î,³y¦¨Globo H §ÜÅé¶q§C,¥[¥HPD-L1ªí²{¶q¦h,¶V¤£§Q¹w«á,§Î¦¨¤@ºØ´c©Ê´`Àô ¦Ó¦³§K¬Ì¤ÏÀ³¦¸±Ú¸s«h«ê¬Û¤Ï, ¬O¤@ºØ¨}©Ê´`Àô ¦ÛµM¨âªÌ¤§¶¡, ®t²§¶V©Ô¶V¤j ¨ä¥L¨È«¬¬O§_¦³Ãþ¦ü§@¥Î??? »P¹ï·Ó²Õ¶¡©Î³\¤]¦³¬Û¦ü±¡ªp??? «¢ ! ·¥¨äµL²á J«ä¶Ã·Qªº²£ª«, ½Ð«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/29 ¤U¤È 10:07:59²Ä 2556 ½g¦^À³
|
¥m¾´¤j 1 ¯E¹©¤w¸g»¡¹L¤F¥ô¦ó¨Æ±¡ªº¨Mµ¦¬O¥HªÑªF¬°³Ì¤j§Q¯q°µ¦Ò¶q,¦b»PFDA©P±Û¨ó°Ó¤¤§Ú¤£»{¬°¯E¹©·|¥u´£BTD¥Ó½Ð, ¤ñ¸û¥i¯àªº¬O¦h®×¦P®É©P±Û¨ó°Ó,¥t¥~¯E¹©¨S¦³¥²n§â¤T³±©Ê¨ÅÀù»Pª½¨úÃÄÃÒ±À¦V²Ä¤@ªi½Í§P 2 ¨Ì¾Ú¬ü°êÄY«¯e¯f¥ÎÃÄ«P¶ipµe ¬ð¯}©ÊªvÀø¥Ó½Ð®É¾÷: • With IND or after , Ideally, no later than the end-of-phase 2 meeting »P¥þ²y¤T´ÁÁ{§É¸ÕÅç¥Ó½Ð¦P¨B´£¥X ©Î ¥ý´£¥XIND¥Ó½Ð ,¦A´£BTD ¥Ó½Ð , ¦ý¤£¥i¦b¤G´ÁÁ{§É·|ijµ²§ô«á¦A´£¥X 3 Ó¤H»{¬°¦h®×¦P®É©P±Û¨ó°Óªºµ¦²¤¹ï¯E¹©¦³§Q,¬ü°ê¤T´ÁÁ{§É³]p¦³¥i¯à¶^¯}¤j®a²´Ãè! §Ú¥H«e±`±`´£¨ì³ÌÀ´ªk³W ¬O¯E¹©,¤£¬O§ÚÌ,§ó¤£¬O°]¸g´CÅéÂø»x¨º¨Ç¤H 4 ¯E¹©¦bµ¥¤zÂZªº§QªÅ¥XºÉ«á¤~·|ºÝ¥X¨ÎÀa®b½ÐªÑªF 5 ·í¶W¹L¤@¥bªº¤H¤w¸g¨S¦³@¤ßªº®ÉÔ,³oºØ§N²M¬O¤@ºØ¦ü´¿¬ÛÃÑ ¤£¥i«äijªº¥¿¦V«ü¼Ð ,¤]¶H¼x¾¤©ú§Y±N¨ÓÁ{ªº®É¨è |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/9/22 ¤W¤È 11:45:06²Ä 2555 ½g¦^À³
|
¥xÁÞ¤j, ¨º¯E¹©¹ï¤T³±©Ê»P«D¤T³±©Ê¦³©î¶}¤À§O¥Ó½ÐÃÄÃÒ¶Ü? ¥ý¨ú¤T³±©ÊÃÄÃÒ,Ä~Äò°µ¤j¤T´Á¡I ¦]¬°¤T³±©Ê±Ú¸s,ÄÝ©óÃøªvªº¨ÅÀù,Àò±oBTDªº¾÷·|¸û¤j,¥i¥ý¨úÃÒ,¬Æ¦Üª½±µ¨úÃÒ. ¦Ó«D¤T³±©Ê±Ú¸s©Î¨ä¥L±Ú¸s©Î±q¾ãÅé¨Ó¬Ý,¼Æ¾Ú¤£°÷º}«G,©Î³\ÁÙn¥ý°µ¤j¤T´Á¡C ®É¶¡¹L³o»ò¤[,¨S¦³¥ô¦ó¦n®ø®§,¤½¥q¬O¤£¬O²¨©¿¤F¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/22 ¤W¤È 10:04:02²Ä 2554 ½g¦^À³
|
¬Ý¬Ý IMMU-132 ·Q·QOBI822 쥻¤]¹wp¦bASCO¤½¥¬¼Æ¾Úªº¬ü°ê¥Í§Þ¤½¥q Immunomedics¡A¦]¥ý«e¤½¥¬¼Æ¾Ú¡A¦Ó³QASCO¨ú®ø¤fÀY½×¤å³ø§i¡C Immunomedics¥Ø«e¦b¤G´Á¤¤¶i¦æ¤T³±©ÊÂಾ©Ê¨ÅÀù·sÃÄÁ{§É¡A60¦ì¹êÅç²Õ¤¤¡A¦³18¦ì¨£¨ìÀø®Ä¡A¥ç§Y¦³30¢H¯f±w¦³®Ä¡A¸ÓÁ{§É¼Æ¾ÚÅýImmunomedics¨ú±o¬ð¯}©ÊªkÀøªk¡]BTD¡^¸ê®æ¡A²{¤w¿n·¥³W¹º¥Ó½ÐÃÄÃÒ IMMU-132: Summary Efficacy (Patients with at least one post-treatment response evaluation) Cancer Type1: TNBC ¤T³±©Ê¨ÅÀù (Âಾ©Ê) Numberof Patients: 60 ORR:33% «ÈÆ[¤ÏÀ³²v Median PFS: 5.6 months (81% ¼Æ¾Ú¤w¦¨¼ô) Median OS : 14.3 months ( 40% ¼Æ¾Ú¤w¦¨¼ô) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/21 ¤W¤È 10:39:05²Ä 2553 ½g¦^À³
|
¥t¥~n°µ¦óºØ³W¼Òªº¥þ²y¤T´ÁÁ{§É¸ÕÅç½Ö»¡¤Fºâ¼Æ? ·íµM¤£¬OªáºX ¬O¬ü°êFDA»¡¤F¤~ºâ¼Æ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/21 ¤W¤È 10:23:18²Ä 2552 ½g¦^À³
|
1 ªáºXÃÒªºµû¦ô³ø§i¤¤¹ï¬ü°êÂಾ©Ê¨ÅÀù¤H¼Æ¤ÎÂಾ©Ê¨ÅÀù¥«³õ¦³´£¨Ñ¤@¨Ç¥i°Ñ¦Òªº¼Æ¾Ú 2 p17 Type1 Hormone receptor positive (ER+/PR+) 80% ³oӼƾڦn¹³¿ù¤F (65% -70% ¤~¹ï) Type1 + Type2 + Type3 ¹F 110% 3 p26 Catalyst Timeline Second interim readout of Ph2 OS data End-2017 or 2018 ( ¬Ý°_¨Ó¬Û·í¬Ý¦n822ªºOS ) ¨ì2017¦~©³ OS ¬ù¹F58Ó¤ë ¨ì¨ì2018¦~©³ OS ¬ù¹F70Ó¤ë Final Ph2/3 OS data readout 2019 ³oÀ³¸Ó¬O³Ì«á¤@Ó¦¬®×¦b2014¦~8¤ë +5¦~ ¥H2019¦~¨Ó±À¦ô Ó¤H»{¬° ¨C¦ì¨ü¸ÕÆ[¹î¤¦~¬O¹ïªº ¦ý¬OFinal OS data ¤£¥²Æ[¹î¨º»ò¤[ ¬Ý¬Ý perjeta Final analysis** No. of patients with an event ¹ï·Ó²Õ 221 (54.4%) ¹êÅç²Õ 168 (41.8%) ( ¹ï·Ó²Õ¦´N¨ì50% ¹êÅç²ÕÆ[¹î¨ì 168Өƥó (41.8%) ±ß¹ï·Ó²Õ 15.7Ó¤ë ´N¹F¼Ð³Û°±¤F ) Median months mos ¹ï·Ó²Õ MOS 40.8 Ó¤ë ¹êÅç²Õ¹ï MOS 56.5 Ó¤ë The final OS analysis was performed when 221 patient deaths occurred in the placebo-treated group and 168 occurred in the PERJETA-treated group.1 www.perjeta.com/hcp/clinical/efficacy/overall |
|
|
·|û¡G§d¨ÎÀM10141531 µoªí®É¶¡:2016/9/20 ¤U¤È 01:41:36²Ä 2551 ½g¦^À³
|
·PÁ¾å¦à¤jªº¤À¨É¡C ¤p§Ì¼ç¤ô«Ü¤[¡C±z³o¤å¡C ¤p§Ì·Pı¤@©wn¥X¨Ó»¡Án·PÁ¡C ¤p§Ì¦b³oª©«Ü¤[¡C¥Ø«e¥un°¾¿Eªº¤å³¹¡C¤p§Ì§¹¥þ¨S¦³·Pı¡C ¤p§Ì¥u¬Û«H¦Û¤v¬Ý¨ìªº¡C»P¼Æ¾Ú»P¤å³¹¡C ±zªº¤À¨É¡A´¿¸g¬O§Úªº¤ß¤¤·Q¹Lªº¡C ·PÁ¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/20 ¤U¤È 12:18:04²Ä 2550 ½g¦^À³
|
·PÁÂCliff¤j ±a¨ÓGH»P¨xÀùªº¬ã¨s°T®§ ¨S¨Æ¦h¾Ç²ß ¾Ç²ß¦h¨S¨Æ |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2016/9/20 ¤W¤È 10:16:39²Ä 2549 ½g¦^À³
|
¦U¦ì¤j¤j¦w¦n¡G «e°}¤lµL¤j¤jµû½×¤F´X¤ä·sÃĪѡARussell ¤j°Ý¤FÃĵØÃÄ¡A§Ú²{¦b³¥¤HÄmÃn¤@¤U¡A§â§ÚÓ¤H¨Ï¥Îªºµû¦ôªk´£¥X¨Ó¡AÁÙ±æ¤j®a¦h¦h«ü¥¿¡C ¥Ø«e°£´¼Àº¦³¯ØŦÃijq¹LFDA®Öã¤W¥«¤§¥~¡A¨ä¥L·sÃĪѳ£©|¦b¬ãµo¤¤±ø¥ó¬Û¦ü¡Aµû¦ô¸û¤£¨ã½ÆÂø©Ê¡CÓ¤H³£¬O¥H¡uÁ`¥«Èªk¡v¨Ó¤ñ¸ûµû¦ô¥Í§Þ¤¤ªº·sÃĪѡG ¥ýºâ¥X¦U®a·sÃĪѪº¥«È¡G ¤ñ¤è ¯E¹©¤µ¤Ñ¦¬389.5¤¸ ªÑ¥»¬ù17.15»õ «h¨ä¥«È¬ù¬°668»õ¡F ¤S¦p ¤¤¸Î¤µ¤Ñ¦¬215.5¤¸ ªÑ¥»¬ù24.89»õ «h¨ä¥«È¬ù¬°536»õ¡F ¤S¦p ÃĵØÃĤµ¤Ñ¦¬178.5¤¸ ªÑ¥»¬ù21.84»õ «h¨ä¥«È¬ù¬°390»õ¡F ¤S¦p ´¼Àº¤µ¤Ñ¦¬244.5¤¸ ªÑ¥»¬ù12.25»õ «h¨ä¥«È¬ù¬°300»õ¡F ¤S¦p ¤ß®®¤µ¤Ñ¦¬120.5¤¸ ªÑ¥»¬ù10.24»õ «h¨ä¥«È¬ù¬°123»õ¡F ¨ä¦¸¤ñ¸û¦U®aÃĪ«µo®iªº²{ªp(PhaseI/II/III)¡A¥«³õ¼ç¤O(¥«³õ¦ôÈ¡B±wªÌ¼Æ¡B¨C¦~¼W¥[¤H¼Æ¡Bµ¥)¡A¦³¨S¦³Ävª§ªÌ¡ABTD/±M§Q¥[¤À¡C³oÓµû¦ô©Î¦]±µ¨üªº¸ê°T¤£¦P¡A©Î¦]Ó¤Hªº»{ª¾®t²§¡Aµ²ªG¥i¯à«nÁÕ¥_Âá¤j¤£¦P¡A§Úªº¬Ýªk¦U¦ì¥¼¥²¦P·N¡C ¦pªG¤£¦Ò¼{µu½uÃD§÷»P¥D¤O/ªk¤H©Ô©ï¡A¥HÓ¤H¥Î¦¹¥«È¤è¦¡ªºªì²L¤ñ¸û¡A¯E¹©¥H¥Ø«eªÑ»ù¨Ó¬Ý¡A»·»·¦n¹L¤¤¸Î¡BÃĵØÃÄ»P´¼Àº¡C§Y¨Ï¯E¹©ªº¥«È¨ì¹F¤¤¸Îªº¨â¿(¤ñ¤è»¡¹F1072»õ)¡A¤GªÌ©ñ¤@°_¡A§Ú¤@¼Ë·|¿ï¯E¹©¤£¿ï¤¤¸Î¡A¦]¬°¥¼¨Ó¼ç¤O¬Û®t¤Ó¦h¡C Ó¤H»{¬°¤ß®®¥¼¨Óªº¼ç¤O¦³¥i¯à¤£¿é¯E¹©¡C¤GªÌ³£¦³«Ü¦nªºpipeline (»·³Ó¨ä¥L¤½¥q¦h¦h)¡Cªì¨B¤ñ¸û°_¨Ó¡A¯E¹©¦³¯Î°|ªø±M§Q¡A³oÓ§Þ³N»Ùêµ¹¯E¹©«Ü¦nªº«OÅ@¡A³oÂI©Î³\±j¹L¤ß®®¡A¦ý¤ß®®¦³¨âÓBTD¡A¥B¦hÓÃĪ«¬O¥½´ÁÁ{§É¡A©Î¥´¥¡C§ÚÓ¤H¶R¯E¹©¡A¯Î°|ªø¿W¨B¥þ²yªºÁÞ§Þ³N¬O³Ì¥Dnì¦]¡A¦ýY¥H³o´X¦~ªº¬ö¿ý¨Ó¬Ý¡A¤ß®®¥D¨ÆªÌ¦ü¥G¤S¤ñ¸û¥Î¤ß¡A§ó¦³´¼¼z¡C§Ú»{¬°¤ß®®ªÑ»ù³Q§C¦ôªº±¡ªp»¡¤£©w¤ñ¯E¹©ÁÙÄY«¡C³o¬OÓ¤H·N¨£¡A°Ñ¦Ò´N¦n¡AµL¶·¬Û«H¡C ¦³¦Û¤vªºµû¦ô¤èªk¤~¤£·|³Q¥D¤O¦ê³q°OªÌ²oµÛ»ó¤l¨«¡A©Î³Q§ëÅU¦Ñ®vªºªá¨¥¥©»y©ÒÄF¡C¨ä¹êÓ¤H»{¬°§ëÅU¸`¥Ø¤Ö¬Ý¡A³o¨Ç¦Ñ®v¦pªG«Ü¦æ¡A¦Û¤vÁÈ´NÁȤ£ª±¤F¡A¦ó¶·¨C¤Ñ¤W¸`¥Ø¡H ¥t¥~ªk¤H¶R/½æ¤]¥u»Ý°Ñ¦Ò¡A¤£¥²ºÉ«H¡C ¥t¥~¤Ó´º¤µ¤Ñ¦¬26.85¤¸¡AªÑ¥»¬ù71.7»õ¡A¨ä¥«È¬ù¬°192»õ¡CÓ¤H¤]»{¬°³QÄY«§C¦ô¡C¤Ó´º¦³¤TÁûÃÄ¡A¨ä¤¤§Ü²Óµß·P¬Vªº©`¿Õ¨F¬P¤w¸g®³¨ì¤¤°ê»P¥xÆWÃÄÃÒ; §ÜC¨xªºÃĪ«2aÁ{§É³ø§i¬Û·í¤£¿ù¡A¤S±o¨ì¤¤°ê§Ö³t¼f®Ö¸ê®æ(¤¤°êC¨x¤H¤f¹O¥|¤d¸U¡A¥«³õ·¥¤j¡An°µ¤T´ÁÁ{§É¡A¯f¤H®e©ö§ä¡A¤@¦~´N¥i¯à¦³µ²ªG¡A¦]¬°ªvÀø¥u»Ý8¨ì12©P); ·F²ÓMÅX°Ê·sÃÄ«h»P¥¼¨Ó©Î±N¦¨¥D¬y§K¬ÌÀøªk¤§¤@ªºCAR-T(±qÀù¯g¯f±w¨¤W¤ÀÂ÷¥X§K¬ÌT²ÓM¡A¦bÅé¥~¤j¶q°ö¨|¡A¨ä¼Æ¥Ø¹F¨ìÀø®Ä«á¦Aª`®g¦^¯f±wÅ餺)¤½¥q¦pKITE¡BJUNO µ¥©ÎÄvª§©Î¦X§@¡C¤]À³ÄÝ©ó¬Û·í¦³»ùȨ㥼¨Ó©Êªº·sÃÄ¡A²{¦b¥¿¦b¤¤°ê¶i¦æ¤G´ÁÁ{§É¡C¥u¬O¤Ó´º¥Ø«e±Mª`¤¤°ê¥«³õ¡A¤£¤Ó¦³¥ß§Y©ÊÃD§÷¡C ¥H¤W³£¥u¥Hªø½u¦Ò¶q¤£¦Ò¼{µu½uÃD§÷»P¥D¤O/ªk¤H©Ô©ï¡A±N°ÝÃD³æ¯Â¤Æ¡A´£¥X¨Óµ¹¤j®a°Ñ¦Ò¡AÁٽФj®a¤£§[«ü¥¿¡CÁÂÁ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/20 ¤W¤È 08:40:13²Ä 2548 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼wªº°T®§¤Îµû½× ¬°HCC ±wªÌ±a¨Ó§Æ±æ ¤]¬°¯E¹©³Ð·sÃĪ«´£¨Ñ¤@Ó¾÷Â઺²z½×¬[ºc,¼W²KÃĪ«¦¨¥\ªº¾÷·| ¤]¦³³ø¾É«ü¥X ¡§X³J¥Õ·|¯}ÃaSmc5/6¡K Åý·sªºHBV¯f¬rÁû²ÉÀH«á²£¥Í¨Ã·P¬Vªþªñªº²ÓM¡¨ ¨º888 ¬O§_¤]¥iªvÀøHBV©O? «¢! J«ä¶Ã·Qªº ÁÂÁÂCliff ¤j®¦¼w¤À¨É³o¤Ñ¤jªº¦n°T®§ Åý¯E¹©ªº¤º¦b»ùȧó¤W¤@¼h¼Ó ÁÂÁ±z! ¤p©_¤j¤j ¥xÁÞ¤j¤j ÁÂÁ¨â¦ì§ó¶i¤@¨Bªº½×z §ÚÌ°µ¼ÒÀÀ,À³¸Ó¥u¦b´£¨Ñ¯E¤Í̤@Ó¥i¸ê¥H§PÂ_ªº¼Æ¾Ú ¨Ã¤£¬O¤½¥q¤½§iªº¼Æ¾Ú,¥²¦b§Ú̹w´úªºÂI¦ì¤W, §Ų́S¦³¯«¹w´úªº¯à¤O §ÚÌ´£¨Ñªº¥u¬O¤@Ó½d³òµ¹¯E¤Ḭ́ѦÒ,·í¦Û¤v©Ò¹w´úªº O1¡B O2 ¸¨¦b¦ó°Ï¶¡ ´N®e©ö¤F¸Ñ¸Ó²Õ¦X¬O§_¥i¯à¹F¼Ð,¶È¦¹¦Ó¤w ¤p§Ì©È¦³¨Ç¯E¤Í¥i¯à·|»~·|,©Ò¥H°µ¦¹»¡©ú ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/9/19 ¤U¤È 11:29:36²Ä 2547 ½g¦^À³
|
·PÁ²q·Q¤j¤j´£¨Ñªº¤½¦¡»P½Ñ¦ì´£¨Ñªº±À´ú¡C Globo H»P¨xÀù¡]HCC¡FHaptocellular carcinoma¡^Ãö«Yªº¬ã¨s¡C¡]ì¤åºKn¨£µù1¡^ 2014¦~¦¨¥\¤j¾Ç§d©Óס]¡H¡^/¤¤¬ã°|§d©v¯q³Õ¤hªº¬ã¨s¡A¥HÁÞ´¹¤ù¤ÀªR¤F134¥ó¤HÃþªº¦å²M¼Ð¥»¡Aµo²{±a¦³B«¬¨xª¢¯f¬rªº¨xÀù²ÓM¤¤¡]µù3¡^¡AGlobo H¦³¤W½Õªº²{¶H¡C¥BFUT2¡]Fucosyltransferase 2¡F©¥Ä¦ÁÞÂಾ酶 2¡F¦X¦¨ Globo Hªº¨ºÓ酶¡^¦b±a¦³B¨x¯f¬rX³J¥Õ¡]HBV X protein¡^ªº¨xÀù²ÓM¤¤¤]¦³¤W¤Éªº²{¶H¡C¦ÓB¨x¯f¬rX³J¥Õ¡]HBV X protein¡^¤w³Q»{¬°¦b±Ò°Ê»Pºû«ùB¨x¯f¬r½Æ»s¤W¦û¤F«n¨¤¦â¡]µù2¡^¡C¦¹¥~¡A¹B¥ÎmicroRNAªº§Þ³N¡Aµo²{microRNA-15b (miR-15b)¦b³o¨Ç¼Ð¥»¤¤¬O¤U°ªº¡A¦Ó¥B½T©w»PFUT2¤ÎGlobo Hªºªí²{§e²{¬ÛÃö©Ê¡C ¥L̪º¬ã¨s·t¥Ü¡AB¨x¯f¬rX³J¥Õ§í¨î¤FmicroRNA-15b¡A¦A§@¥Î©óFUT2¡A³y¦¨Globo H¼W¥[¡A«P¨Ï¨xÀù²ÓM¼W¥Í¡C§ó¶i¤@¨Bµo²{¡A³o¨ÇB¨x¯f¬rX³J¥Õ¹L«×ªí²{ªº¨xÀù²ÓM¡A¥i¦b¤HÅé¥~¡]in vitro¡^¥HGH§ÜÅé¥[¥H§í¨î¡A®ÄªGÅãµÛ¡C ©Ò¥H¥LÌ»{¬°³o±ø·sµo²{ªº¶b½uÃö«Y¡GHBX/miR-15b/FUT2/Globo H axis¡AÅã¥Ü¥X¤@±ø¥i³y¦¨¨xÀù¼W¥Íªº¾÷Âà¡A¤]¬°¨xÀùªvÀø´£¨Ñ¤@±ø¥¼¨Óªº·s¸ô¡C µ²½×¡GB¨x¯f¬rX³J¥Õ¤U½Õ¤FmicroRNA-15b¡A¦A¼W±jFUT2¤ÎGlobo Hªºªí²{¨Ó«P¨Ï¨xÀù¼W¥Í¡C Ó¤H¬Ýªk¡G¨xÀù¡]HCC¡^¤@ª½ÄÝ©óÃø·d©wªºÀù¯g¡A¥Ñ2008¦~³¯¹a¬z°|¤h¹Î¶¤¬ã¨s±oª¾¡A¬ù¦³90¢H¨xÀù¼Ð¥»·|ªí²{Globo H¡A¦Ò¶q¨xÀù±wªÌ´G®zªºÅé½è¡AÁÙ¬O¥ý°µ¿zÀË¡AY¬OHBV X ³J¥Õ§e¶§©ÊªÌ¡A¦A¬I¥´OBI-888¤ñ¸û§Ö/áC µù¡G 1¡B2014¡G¡uDownregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression¡v B¨x¯f¬rX³J¥Õ¤U½Õ¤FmicroRNA-15b¡A¦A¸g¥ÑFUT2¤ÎGlobo Hªºªí²{¨Ó«P¨Ï¨xÀù¼W¥Í¡C¡]ir.lib.ncku.edu.tw/handle/987654321/157905 ¡^ 2¡B2011¡G¡uHepatitis B virus X protein is essential to initiate and maintain virus replication after infection.¡vB¨x¯f¬rX³J¥Õ¡]HBV X protein¡^¬O±Ò°Ê»Pºû«ùB¨x¯f¬r½Æ»sªº¥²n¨¤¦â¡C¡]www.ncbi.nlm.nih.gov/pubmed/21376091 ¡^ 3¡B¨xÀù§Î¦¨ì¦]«Ü¦h¡AC«¬¡BB«¬¨xª¢¬O¨â¤jº×º¡A³o½g¬ã¨s¬O¥H±a¦³B«¬¨xª¢¯f¬rªº¨xÀù¬°¥D¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/9/19 ¤U¤È 11:20:49²Ä 2546 ½g¦^À³
|
²q·Q¤j¡A ¤p§Ì·Q¤F·Q ¤T²Õ¦b40Ó¤ë«áªº¨Æ¥óµo¥Í¼Æ¥Î6¡B6¡B10¤ñ¸û¤£·|¤Ó¼ÖÆ[ ¦]¦¹(87,65)¤ñ¸û¦n ÁÂÁ±z¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/19 ¤U¤È 10:36:00²Ä 2545 ½g¦^À³
|
ÁÂÁ¤p©_¤j¸Ñ´b ±À¦ô³o²Õ 86/67 ( 2017 02) ¤]¬O ¤T¼Ë³£¹F¼Ð HR 0.71 P<0.05 Power 80.5 ²q·Q¤j±À¦ô³o¤T²Õ O1--O2-----X^2-----HR-----_HR 95%«H¿à°Ï¶¡----power------¨Æ¥ó²v®tÈ ¹w¦ô¹F¼Ð®É¶¡ 75---61----5.679-- 0.665----0.458~0.926-----81.9 %-----15.71 % 2016 10 ²q·Q¤j±À¦ô®É¶¡ 86---67--- 5.167 --0.692----0.487 ~ 0.947---80.5 %-----15.64 % 2017 02 ¤p©_¤j±À¦ô®É¶¡ 90---70----4.792--0.707----0.502~0.961------83.2 %-----16.27 % 2017 05 ²q·Q¤j±À¦ô®É¶¡ ¤U±³o²Õ²q·Q¤j¨S¦³¹w¦ô®É¶¡ Ó¤H¼ÒÀÀ±À¦ô¹F¼Ð®É¶¡²q²q²q¬ù¦b 2016 12 81---64----5.602--0.675----0.469~0.931------80 %-------15.45 % 2016 12 ¥t²q·Q¤j¤]¼ÒÀÀ±À¦ô ·|¹F¼Ðªº¤T²Õ²Õ¦X ²q·Q¤j¨S¦³¹w¦ô¹F¼Ð®É¶¡ ( Ó¤H²q²q²q À³¸Ó¦b2016 10¤ë«e¤w¸g¹F¼Ð) O1--O2-----X^2-------HR---------HR 95%«H¿à°Ï¶¡----------power 70---58----5.967-----0.650------0.442~0.914----------- 81.8 % 70---59----6.496-----0.640------0.434~0.896----------- 85.4% 70---60----7.002-----0.630------0.428~0.881----------- 88.4 % (X^2 > 6.635 , P< 0.01) ²q·Q¤j¥mÀ{: ¥un¦w¼¢²ÕOS¦º¤`¤H¼Æ¾¨§Ö¥X²{ 822´N¥i¯à¦]¬°¤£¿ùªºHR ¦Ópower ¹F0.8 ¦Ó´£«eµ²§ô´Á¥½¤ÀªR §Ú³oºØ±À¦ô¡A¥u¦b´£¿ô¦Û¤v¡AÀH®É³£¦³¼Æ¾Ú¦¨¼ôªº¥i¯à ¥H¤W¾ã²z¨â¦ì«e½ú¼ÒÀÀ±À¦ô ¦]¬°¬O¼ÒÀÀ »P¹ê»Ú±¡ªp·|¦³¥X¤J ¦Û¤v¤ß¤¤n¦³¤@§â¿Å¶qªº¤Ø |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/9/19 ¤U¤È 10:21:35²Ä 2544 ½g¦^À³
|
¯u¤£¿ù °Ï¶¡¨S¦³¥]§t1 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/19 ¤U¤È 08:13:39²Ä 2543 ½g¦^À³
|
¤p©_¤j¤j ÁÂÁ±zªºÅ޿诫ºâ ¤p§Ì¨Ì±zªº±Æ¦C,¥Î¸Õºâªí¤jP¶]¤F¤@¤U ±o¥Xªºµ²ªG ( 86 , 67 ) X^2 = 5.167 HR = 0.692 HR 95%«H¿à°Ï¶¡ = 0.487 ~ 0.947 power = 80.5 % ¦³°÷·Ç ÁÂÁ±z! ¤]ÁÂÁ¤j®a! »¡©ú : ¥H¤Wªº¼ÒÀÀ¤D®Ú¾Ú¤p©_¤j¤j´£¨Ñªº¼Æ¾Ú,¤jP±Æ¦C¨Ì¦Û¤v¸Õºâªí¸Õºâ©Ò±o,¶È¬°¤@ºØ°Ñ¦Ò·§¦ô ¹ê»Ú¥B°ß¤@ªº±Æ§Ç,¤´«Ý¤½¥q¤½§i½T»{ ÁÂÁ¤j®a |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/9/19 ¤U¤È 07:27:09²Ä 2542 ½g¦^À³
|
¥xÁÞ¤j¡A ¡y¦b32Ó¤ë³o®É¶¡¡A¤T²Õ¥Ø«e©Ò§e²{ªº¦s¬¡²v(78%¡B60.5%¡B60.5%) (p17¬O 78% 52.99% 60.5% )¡z ±z¥J²Ó¬Ýp17¹Ï¤ñ¹ï¡A§C¤ÏÀ³²Õªº¤@Өƥó¨ä¹êµo¥Í¦b¤j¬ù33Ó¤ë®É¡A¨Ï±o¦s¬¡²v¥Ñ32Ó¤ë®Éªº60.55%¦]¤@Өƥó¤U°¤F¤j¬ù7.56%¡A¦ÓÅܦ¨¤F52.99%¡A³o¤@Ó¦b33Ó¤ë®Éªº¨Æ¥ó¦]2015/10ºI¤î®Éªºnumber at risk¤H¼Æ¤Ó¤Ö¦Ó¥¢¯u¡A¤U¤@±iOS¹Ï´N¤£·|¥¢¯u¤F¡C ¡y32Ó¤ë¥H«eªº°ª¤ÏÀ³²Õ¡B§C¤ÏÀ³²Õ¡B¹ï·Ó²Õªº¨Æ¥óµo¥Í¼Æ¤À§O¬O25¡B36¡B43¡C (p17 ¬O21 29 35 )¡z P17¬O2015/10ºI¤îªº¼Æ¾Ú¡A25¡B36¡B43¬O2015/10¥H«áªº16Ó¤ë¡A¤]´N¬O2017/2ºI¤îªº¹w¦ô¼Æ¾Ú¡AP17¥Ø«e¤´¦b16~28Ӥ몺°é°é¡A¨ì¤F2017/2¦³µ´¤j³¡¤À·|³q¹L32Ӥ몺¦ÒÅç¡A25¡B36¡B43»P21 ¡B29¡B 35ªº®t²§´N¬O³o16Ó¤ë´Á¶¡¨S¦³³q¹L¦ÒÅ窺¨Æ¥óµo¥Í¼Æ¥Ø¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/19 ¤U¤È 06:26:43²Ä 2541 ½g¦^À³
|
¤p©_¤j ÁÂÁ´£¨Ñ¼ÒÀÀ±À¦ô ¥t¥~·Q½Ð±Ð: ¹w¦ô¼Æ¾Ú»Pp17 ¦³®t²§ ¦³¦ó¦Ò¶q¦]¯À? ¦b32Ó¤ë³o®É¶¡¡A¤T²Õ¥Ø«e©Ò§e²{ªº¦s¬¡²v(78%¡B60.5%¡B60.5%) (p17¬O 78% 52.99% 60.5% ) 32Ó¤ë¥H«eªº°ª¤ÏÀ³²Õ¡B§C¤ÏÀ³²Õ¡B¹ï·Ó²Õªº¨Æ¥óµo¥Í¼Æ¤À§O¬O25¡B36¡B43¡C (p17 ¬O21 29 35 ) ÁÂÁ¸Ѵb |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/9/19 ¤U¤È 04:04:02²Ä 2540 ½g¦^À³
|
²q·Q¤j¡A ¤¤¬î¸`¡B»ä·©]¡AŪµÛ±zªº¶K¤å¤À¨É»Ppºâ¡AµÛ¹ê¥O¤H·P°Ê¡I ±z§â¦s¬¡¤ÀªR©Ò¦³ªºpºâ¤½¦¡³£«õ¥X¨Ó¤F¡A¤S«Ø¥ß¤FÃe¤jªº¼ÒÀÀ¨t²Î¡AO1¡BO2¡BHRªº¥i¯à²Õ¦X¥i¯à³£³Q±zµ¹Ån¬A¦b¤º¤F¡A»¡¤£©w¦A¤@¦¸OS´Á¤¤¤ÀªRªºO1¡BO2¡BHRªº²Õ¦X¤w¸g³Q±zµ¹´¦ÅS¦bªO¤W¤F¡I ±z¤w¸g°µ¤F¨º»ò¦hºØªº¥i¯à¼ÒÀÀ¡A¨º¤p§Ì¤]¨Ó½M²q¤@Ó¡A¯Âºé¬O½M²q¡I ¨âÓ¤½¦¡¡G X^2=(O1-E1)^2/E1+(O2-E2)^2/E2 HR=(O1/E1)/(O2/E2) ¤@Ó2015/10ºI¤îªº¼Æ¦r¡A(O1¡AO2)=(50¡A35) ¥H¤ÎP13»PP17¨â±i¹Ï O1ªº¼Æ¦r¦b2015/10¥H«á·|ÀHµÛ®É¶¡¦Ó¼W¥[¡A·|±q50ºCºC¼W¥[¬°60¡B70¡B80¡B90¡B100¡A¨º¹ê»Ú¬Û¹ïÀ³ªºO2À³¸Ó¬O¦h¤Ö¡H ¦ÓHR=(O1/E1)/(O2/E2)=O1*E2/O2*E1=(O1/O2)*(E2/E1) HR¬O§_ÀHµÛ¨Æ¥óµo¥Í¼Æ¼W¥[¦ÓÅܤp»PO1¡BO2ªº¼Æ¦r³vº¥©Ô¶}¦³·¥¤jªºÃö«Y¡AO1¡BO2ªº¼Æ¦r©Ô±o·U¶}¡AHR·U¤p¡F¥t¥~O1¡BO2ªº¼Æ¦r©Ô±o·U¶}¡AE1»PE2ªº®t¶Z¤]·|©Ô±o§ó¤j(E1¡BE2¤]»P¹êÅç²Õ»P¹ï·Ó²Õªº¨Æ¥ó¦p¦ó±Æ¦C¦³Ãö )¡A¦]¦¹HR»PO1¡BO2ªº¼Æ¦r©Ô±o¦h¶}¤ÎO1¡BO2ªº±Æ¦C²Õ¦X¦³Ãö¡A¨ä¤¤¤S»PO1¡BO2ªº¼Æ¦r©Ô±o¦h¶}ªºÃö«Y«×³Ì°ª¡C µù¡G É«Ó¥v¤j¸ê®Æ¤@¥Î Perjeta NR/37.6 NR 0.66 0.0008 113/154 402/406 Perjeta 56.5/40.8 38.5% 0.68 0.0002 168/221 402/406´Á¥½¤ÀªR ¤Wz¤D¦P¤@Ó¹êÅ窺¤£¦P®É¶¡©ÒÆ[¹î¨ìªº²Îp¼Æ¦r¡AÀHµÛ¨Æ¥ó¼Æ¼W¥[¡AO1/O2¤ñȬO·L´T¼W¥[ªº¡A´Á¥½¤ÀªR®ÉªºHR=0.68¤Ï¦Ó¤ñ´Á¤¤¤ÀªR®ÉªºHR=0.66°ª¤F¤@ÂI¡A¦]¦¹¨Æ¥ó¼Æ¼W¥[¤£¥²µMHR´N¤@©w¤U°¡AHR»PO1/O2¤ñȤU°Ãö³s«×·¥°ª¡C¦ýPÈ´N¨S¦³³o°ÝÃD¡A¥unHR¤£nÀHµÛ®É¶¡¼W¥[¤Ó¦h¡APÈ«ùÄòÀHµÛ¨Æ¥óµo¥Í¦Ó«ùÄò¤U°¨S¦³°ÝÃD¡C ¬Ý°_¨Ó«Ü²³æ¡A¥un²q¨ì2015/10¤§«áªº¹j12Ó¤ë©Î16Ó¤ë©Î20Ӥ몺O1¤Î¬Û¹ïÀ³ªºO2¡AµM«á¦A²q³oÓ(O1¡AO2)²Õ¦X¥i¯àªºHR¡A¥N¤J¨âÓ¤½¦¡¡A´N¥i¥Hºâ±oX^2¡A¤]´N±o¨ìPȤF¡C ¤p§Ì²q¤@Ó»P2015/10¹j16Ӥ뤧«áªº¼Æ¦r¡C ÁÙ¬On¥Î¤§«eªº¦¦¬®×»P±ß¦¬®×ªº¤èªk¡C¦¦¬®×ªº¦b2015/10¤w¸g³£¹L¤F28Ӥ몺¦ÒÅç¤F¡A±ß¦¬®×ªº«h¤w¸g¹L¤F16Ӥ몺¦ÒÅç¡A¦]¦¹2015/10ªº16Ӥ뤧«á¡A¦¦¬®×ªº±wªÌ¤£¬O¨Æ¥óµo¥Í¡A´N¬O¤w¸g¥þ³¡¶i¤J44Ó¤ë¥H«áªº¦ÒÅç¡F±ß¦¬®×ªº±wªÌY¤£¬O¨Æ¥óµo¥Í¡A´N¬O¤w¸g¹L¤F32Ӥ몺¦ÒÅç¡C¤]´N¬O»¡¡A32Ó¤ë¥H«eªº¦s¬¡¸ê®Æ§¹¥þ½T©w¤F¡C ¥Ø«eªºP13»PP17¥u§e²{¨ì32Ӥ몺¦s¬¡¼Æ¾Ú¡A32Ó¤ë¥H«áªº§¹¥þn¥Î²qªº¡A32Ó¤ë¥H«eªº¼Æ¾Ú¡AÁöµM16~28Ӥ몺¼Æ¾Ú¤´¦³±ß¦¬®×ªº¨S¦³§¹¥þ¨«§¹¡A¦ý¦b32Ó¤ë³o®É¶¡¡A¤T²Õ¥Ø«e©Ò§e²{ªº¦s¬¡²v(78%¡B60.5%¡B60.5%)¡A»P16Ó¤ë¥H«á(2017/2)¤T²Õ©Ò§e²{ªº¦s¬¡²v®t²§«Ü¤p¡A¦]¦¹¥i¥H¥Î¥Ø«eªº¦s¬¡²v¨Ó±À¦ô16Ó¤ë«á(2017/2)¤T²Õ¦b32Ó¤ë¥H«eªº¨Æ¥óµo¥Í¼Æ¡C 32Ó¤ë¥H«eªº°ª¤ÏÀ³²Õ¡B§C¤ÏÀ³²Õ¡B¹ï·Ó²Õªº¨Æ¥óµo¥Í¼Æ¤À§O¬O25¡B36¡B43¡C ±µ¤U¨Ón²q32Ó¤ë¥H«áªº¨Æ¥óµo¥Í¼Æ¡A¥Ø«eªºP13»PP17¨S¦³¼Æ¾Ú¥i§PÂ_¡A¥u¯à¥Î²qªº¡C¦]¬°°ª¤ÏÀ³²Õ¦b16~28Ó¤ë¨CӰϬq(4Ó¤ë)¦s¬¡²v¤U°¤j¬ù3%¡A§C¤ÏÀ³²Õ¤j¬ù5%¡A¹ï·Ó²Õ¤j¬ù¤U°6%¡F¥B¦b2017/2ªº32Ӥ몺number at risk¤T²Õ¤À§O¬O82¡B51¡B66¡A¦]¦¹²Ê§ì¤T²Õ¦b32~40Ó¤ë°Ï¬qªº¨Æ¥ó¼Æ¤À§O¬O6¡B8¡B12¡C 40Ó¤ë«áªº§ó¬O½M²q¡A¦ý¤jP¥Î°ª¤ÏÀ³²Õ¡B§C¤ÏÀ³²Õ¡B¹ï·Ó²Õªº°Ï¬q¦s¬¡²v¤U°¤À§O¬O3%¡B4%¡B5%¨Ó²q¡A¡A¥B¦]¬°¶i¤J40Ӥ뤧«áªºnumber at risk¤H¼Æ¤w¸g¤j´T´î¤Ö¡A¦]¦¹´NÀH«K¶Ã²q¡A¤T²Õ¦b40Ó¤ë«áªº¨Æ¥óµo¥Í¼Æ¤À§O¬O6¡B5¡B12¡C 32Ó¤ë¥H«eªº°ª¤ÏÀ³²Õ¡B§C¤ÏÀ³²Õ¡B¹ï·Ó²Õªº¨Æ¥óµo¥Í¼Æ¤À§O¬O25¡B36¡B43¡C¡K¤£·|®t¤Ó¦h ¤T²Õ¦b32~40Ó¤ë°Ï¬qªº¨Æ¥ó¼Æ¤À§O¬O6¡B8¡B12¡C¡K²qªº ¤T²Õ¦b40Ó¤ë«áªº¨Æ¥óµo¥Í¼Æ¤À§O¬O6¡B5¡B12¡C¡K¶Ã²qªº ©Ò¥H¦b2017/2®É¡A¤T²Õªº¨Æ¥ó¼Æ¤À§O¬O37¡B49¡B67¡A¦]¦¹¹êÅç²Õ»P¹ï·Ó²Õªº¨Æ¥ó¨Æ=87»P65¡C (O1¡AO2)=(86¡A67)©Ò¹ïÀ³ªºHR¨ì©³À³¸Ó¬O¦h¤Ö¡H¤p§Ì¤£´±¤Ó¼ÖÆ[·|¹F¨ì0.6X¡A´N¥ÎHR=0.72¨Ó¦ôp§a(87»P65ªº¨âӨƥó¼Æ¤]·|¦³«Ü¦h±Æ¦C²Õ¦X¡A¤p§Ì¨ú¤@ӱƦC²Õ¦X¨Ï±oHR=0.72¡A¤£ª¾¼Æ¦r¦^¤£·|¤ÓÂ÷ÃСH) ¥Î(O1¡AO2)=(86¡A67)¡BHR=0.72ªº±Æ¦C²Õ¦X¡A±o¨ìX^2=4.101¡C ¦ó®ÉO1=86¡H¡A¤ñ2017/2¦©Î±ß¡H O1=86®É¡A¬Û¹ïÀ³ªºO2·|¬O67¶Ü¡H (O1¡AO2)=(86¡A67)®É¡A¨Æ¥óªº±Æ¦C²Õ¦X·|¨Ï±oHR=0.72¶Ü¡H·|°ª¤@ÂI©Î§C¤@ÂI¡H ¥H¤W°²³]¼Æ¦r³£¥i¥H½Õ¾ã¡A¦pªGPÈ¥¼¹F¤p©ó0.05¡A¨º»ò´N§âÆ[¹î®É¶¡©¹«á©µªø¡A¥un¨â±ø¦s¬¡¦±½u¤À¶}¡A®É¶¡©Ôªø¡APȳ£¥i¥H¹F¼Ð¡C ¥H¤W¥Î¤F«Ü¦hªº½M²q¡A¦ý¤p§Ì§Þ½a¤F¡Aºâ¤£¥X¨Ó¤F¡C ÁÂÁ±z¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/19 ¤U¤È 01:13:34²Ä 2539 ½g¦^À³
|
«ù¤[ªº¯E§J¤j¤j ¥Î±zªº¼Æ¾Ú power = 41.7% OS¥i¯à¥²¶·´«ºâ¬° % ½Ð±z¦A´ú¸Õ¬Ý¬Ý¦n¤F ÁÂÁ±z! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/19 ¤U¤È 01:00:04²Ä 2538 ½g¦^À³
|
²q·Q¤j ¤p§Ì¨Ï¥Î±z´£¨Ñªººô¶pºâ¢Þ¢Ý¢å¢Ó¢à µo²{¹êÅç²Õ224¡@¢Ý¢á78¡@¦w¼¢²Õ112¡@¢Ý¢á50 alpha .05 2¡@±o¨ìPOWER¡@95.4% ¤£ª¾þ¸Ì¦³¿ù¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/19 ¤W¤È 07:48:21²Ä 2537 ½g¦^À³
|
¤j¹ÙÌ¡A¦¦w ¹ï¤£°_ ! ¤p§Ì¬Q©]¶K¤å¬O¦b«¢¤í³s³s¤¤§¹¦¨¡A»~º|¤£¤Ö ¬°§K¤Þ°_»~·|¡A¤p§Ì¦A»¡©ú¦p¤U ¤p§Ì¬Q©]©Ò±À´úªº¼Æ¾Ú¦¨¼ô¤é´Á ÅܼƤӦh¡A©M¹ê»Ú®t¶Z¥i¯à»·¬Æ ´N¥H¬Q©]ªº( 90,72 ) ±À¦ô¬ù¦b2017¦~5¤ë ¦A¥H( 75,61 ) ±À¦ô¬ù¦b¤UÓ¤ëªì¡A¥ú¬O¨âӼƾڶ¡´N®t¬ù¤C¡B¤KÓ¤ë¡A®t¶Z¥i¨£¤@¯ë §Ú³oºØ±À¦ô¡A¥u¦b´£¿ô¦Û¤v¡AÀH®É³£¦³¼Æ¾Ú¦¨¼ôªº¥i¯à ´N¦p«ù¤[ªº¯E«È¤j©Ò¨¥ ´Nµ¥§a ¨ä¦¸´N¡¨checkpoint inhibitors ¹ïBC ©ÎTNBCªº®ÄªG¦n¶Ü?±M®a³£»¡¦n³á!¡¨ ¤p§Ì¬Q©]©Ò»¡ªº¡¨±M®a³£»¡¦n³á!¡¨ ¡A¬O¤@ºØ¡¨Ë¡¨±Ôªk »¡¯u®æªºcheckpoint inhibitors ¹ïBCªºÀø®Ä ´N¥Ø«e¬°¤îªº¸ê®Æ¨Ó¬Ý¡A¤p§Ì¹ê¦bı±o¤£«ç»ò¼Ë Heather L. McArthur Âå®v¥Î¡¨ moderate ¡§¨Ó§Î®e¡A©Î»PT¤jªº¡¨©e°û»¡ªk¡¨²§¦±¦P¤u ¬Ý¤j¼t¦h©¹TNBCÀ½¡A´N¥iª¾¤@¡B¤G °Ú«¢ ! ¬Q¤Ñ¬Ý¨ìHeather L. McArthur Âå®v¶¤f¥O¦¡ªº»¡ªk ¡§¡Kbut some patients with PD-L1 overexpression do not respond and other patients without PD-L1 expression do respond.¡¨ ¤£¸TÅý¤H²ðº¸¤@¯º «¢ ! ¤]½Ð¤j®a¹ï¤p§Ì¤£¦¨¤å¤§¤å¤]¤@¯º¸m¤§ ²¦³º¥¿¸gª¾ÃÑÂö¦p¡A¥u¨£¤£Û¤£Ãþ¡A·q½Ð®ü²[ ¶È¨Ñ¯º½Í ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/18 ¤U¤È 10:13:57²Ä 2536 ½g¦^À³
|
«ù¤[ªº¯E«È¤j¤j ¥Íª«²Îp¤p§Ì¬Oªù¥~º~,¥u·|ʼ˵e¸¬Äª,±i«a§õÀ¹¦b©ÒÃø§K ¤p§Ì«D±`¦P·N±zªº¬Ýªk ¡§¥un¦w¼¢²ÕOS¦º¤`¤H¼Æ¾¨§Ö¥X²{ 822´N¥i¯à¦]¬°¤£¿ùªºHR¦Ópower ¹F0.8 ¦Ó´£«eµ²§ô´Á¥½¤ÀªR¡¨ ¾Ú²Îp MBC±wªÌ5¦~¦s¬¡²v¬ù¬°25 % ´«Ó»¡ªk 75 %ªºMBC±wªÌµLªk¬¡¨ì5 ¦~ 75 % * 124 = 93¤H ¤S°²¦p822¯àµo´§«pªø§À®ÄÀ³ ¤p§Ì¬O§ì ( 75,61 ) ( 81,64 ) ( 90,72 )¤¤ªº¤@²Õ¹F¼Ð ¨ºÁÙnµ¥¦h¤[©O ? ¥H( 90,72 ) ¬°¨Ò,¦A¥H½u©Ê¤º´¡ªk 72/93*5¦~ = 3¦~¤S10.5Ó¤ë Y±N¾ãÓ¹êÅç¬Ý¦¨¬O 2013¦~6¤ë¦P®É¤@°_¶i¤J¸ÕÅç ¤j·§¦b2017¦~ 5¤ë ¦ôºâ³oºØ¤é´Á ¤p©_¤j¤j³Ì¦³ÅÞ¿è ÅܼƤӦh,¤p§Ì¥u¬O«Ü²Ê²¤ªº¦ôp ¦Ü©ópower ªººâªk,¤p§Ì¬O¥Ñ¤U¦Cºô¯¸ http://clincalc.com/stats/power.aspx ª½±µ¶ñ¤J°Ñ¼Æ¹Bºâ,©Î³\°Ñ¼Æ·|»~¶ñ,½Ð±z«ü¥¿ ÁÂÁ±z! Heather L. McArthur Âå®vªº³X½Í,¤£ª¾¤j®a¬Ýªk¦p¦ó? ¤p§Ì¥H¬° 822ªºÀø®Ä·|¤£·|¤]©Mtumor-infiltrating lymphocytes (TILs)ªºªí²{¦³Ãö?(½M²qªº) ¤S¤j®a·|ı±o checkpoint inhibitors ¹ïBC ©ÎTNBCªº®ÄªG¦n¶Ü? ±M®a³£»¡¦n³á! Heather L. McArthur Âå®v¤]»¡ ¡§We have some evidence that PD-L1 expression is associated with enriched responses to immunotherapy in melanoma, but some patients with PD-L1 overexpression do not respond and other patients without PD-L1 expression do respond. ¡K¡K Thus, the presence of PD-L1 expression may enrich for response, but it does not appear to tell the complete story.¡¨ ³o¦n¹³©M822¦ü´¿¬ÛÃÑ,¦ý822«o¹ð³Q°ê¤º§åµû ¥H¤p§Ìªºª¾ÃѤô·Ç,¹ê¤£¸Ó»¡¸Ü ¯u¬O¨£¯º¤F,½Ð¤j®a¤@¯º¸m¤§ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/18 ¤U¤È 08:50:15²Ä 2535 ½g¦^À³
|
¤p§Ì¨ØªA²q·Q¤j¦p¦¹»{¯u¤£¾Óªºpºâ¼ÒÀÀ¼ÆÈ °ò¥»¤W §Ú»{¦P¤@¯ë²Îp¦³Ãö®ÄªGÈ¡Cpower»P¼Ë¥»¼Æªºì«h §Ypower¸ò¼Ë¥»¼Æ ´X¥G¦¨¥¿¤ñÃö«Y ·í¨ä¥L±ø¥ó©T©w®É ¼Ë¥»¶V¤j power´N¶V¤j ¥t¥~®ÄªGȶV¤j ¼Ë¥»¥i¥H¤Ö ´N¹F¨ì¹w©wpower °²Y 822¦b¦P¼Ëpower¤U¡Cn¸ò¨ä¥L§K¬ÌÃĪ«±µªñ©Î¦³§ó¦nHR ´NÀ³¸Ó¥i¥H´Á«Ý¸û¤Öªº¼Ë¥»¼Æ ©Ò¥H822¤@¶}©l´N³]p¼Ë¥»¼Æ¸û¤Öªº¹êÅç ¦pªG³]p¤H¼Æ¤W¤dªº¹êÅç ©Î³\¤§«e¸Ñª¼´N¦³¤£¦Pªº´º¶H ¦ý¬O¥Ñ©ó¦³©µ¿ð®ÄÀ³ ¤]¾ÉPnÄ~Äòµ¥«Ý¯f¤H¹L¥@ ©Ò¥H¹wpOSnÆ[¹î¤¦~ ¥un¦w¼¢²ÕOS¦º¤`¤H¼Æ¾¨§Ö¥X²{ 822´N¥i¯à¦]¬°¤£¿ùªºHR¦Ópower ¹F0.8 ¦Ó´£«eµ²§ô´Á¥½¤ÀªR ¦Ü©óHR¨ì©³¦h¦n¡C¥Ø«e±q¨ä¥L§K¬ÌªvÀøÃĪ«ªºHR ©Î³\¥i¥H§ìÓ¤j·§ GH§ÜìY¬O³o»ò¶È¨£©óÀù²ÓM ¦Ó822¤S¥i¥H¥´¨ì¤@¥b¹êÅç¤H¼Æ ¦³°ª§ÜÅé¤ÏÀ³ªº¸Ü ¤j®a¬O§_ı±o822HR¤ñ¨ä¥L§K¬ÌÃĪ«À³¸Ó¥i¥H§ó¦n¡H ¦A½Ð±Ð²q·Q¤j ¬O¥Î¤°»ò¤½¦¡pºâpower? |
|
|
·|û¡GRussell10140734 µoªí®É¶¡:2016/9/18 ¤U¤È 04:04:01²Ä 2534 ½g¦^À³
|
ÁöµMª¾¹D³o¬O¯E¤Íª©,¦Û¤v¥»¨¤]¬O¯E¤Í ¦ý¤´·Qª¾¹D¦U¦ì¹ï¥Í§Þ¦³¬ã¨sªº¤j¤jÌ.... ¹ïÃĵØÃĪº¬Ýªk... ¤UÓ¤ë§Y±N¤½§GPV¤T´Áªì¨B¼Æ¾Ú....¦~©³¥Ó½Ð¼Ú·ùÃÄÃÒ,©ú¦~¥Ó½Ð¬ü°êÃÄÃÒ ¤½¥q¹wp106¦~©³«e¶}©l¤W¥«¾P°â ÁöµM¬O©t¨àÃÄ ¦ý¹w¦ô¥«³õ¤´¦³10»õÁâ ¥¼¨ÓÁÙ¦³ET¤ÎB¨xC¨x¤T´Á¦¨ªG§e²{ Ó¤Hµû¦ô³o®a¤½¥qÁÙ¤£¿ù.... ·Qťť¦U¦ì¯E¤Íªº·N¨£ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/18 ¤U¤È 03:00:17²Ä 2533 ½g¦^À³
|
¤F¸Ñ¤@¤UCheckpoint Inhibitors©óBCªvÀøªºµo®i Heather L. McArthurÂå®vªº³X°Ý¤º®e ¥DÃD : " Checkpoint Inhibitors in Breast Cancer: Hype or Promise? " http://www.hematologyandoncology.net/index.php/archives/june-2016/checkpoint-inhibitors-in-breast-cancer-hype-or-promise/ ¥Zµn¦b Clinical Advances in Hematology & Oncology Volume 14, Issue 6, June 2016 ½Ð§O»¡ ¬°¦ó¨S´£822,¥u´£¨ä¥L ¤p§Ì²q´ú ¥i¯à¬O³X°Ý·í®É,Heather L. McArthurÂå®vÁÙ¨Sª`·N¨ì822,¦oÀ³¬O¦bASCO«á¤~ª¾ªº ¶i¦ÓÄ@·NµªÀ³¯E¹©·íESMO°Q½×·|ªºÁ¿ªÌ Y¦o¤£»{¦P822,À³¤£·|±µ¨üÁܽÐ,§K±o¯{¤F¦Û¤vªº©ÛµP ¥t¥~ ¤p§Ì±N¬Q¤éªºªí®æ×q,¦C¦p¤U: O1--O2-----X^2------HR-----HR 95%«H¿à°Ï¶¡------power------¨Æ¥ó²v®tÈ 50---35----1.262-----0.781----0.496~1.209------------ 23.6 %----- 5.9 % 50---46----6.765-----0.591----0.377~0.871------------ 83.4 %-----14.78 % 55---49----6.511-----0.609----0.395~0.885------------ 82.6 %-----14.96 % 60---52----6.299-----0.624----0.412~0.896------------ 82.1 %-----15.15 % 60---60----11.81-----0.539----0.355~0.753------------ 98.1 %-----21.6 % (X^2 > 10.828 , P< 0.001) 65---55----6.100-----0.638----0.428~0.906------------ 81.8 %-----15.34 % 70---58----5.967-----0.650----0.442~0.914------------ 81.8 %-----15.52 % 75---61----5.679-----0.665----0.458~0.926------------ 81.9 %-----15.71 % 81---64----5.602-----0.675----0.469~0.931------------ 80 %-------15.45 % 90---70----4.792-----0.707----0.502~0.961------------ 83.2 %-----16.27 % »¡©ú : 1.¸ÕÅç²Õªº¨Æ¥ó¸m«e¡A¹ï·Ó²Õ¥ç¥Ñ«e±±Æ¨ì«á±(°²¦p¨Æ¥ó¼Æ¦hªº¸Ü) 2.n¤T¶µ«ü¼Ð§¡¹F¼Ð( P < 0.05 ; HR 95%«H¿à°Ï¶¡¤£²[»\1.0 ; power > 80 %), ¡¨¨Æ¥ó²v®tÈ¡¨¬Òéw¦b14 % ~ 17%(¨ú¨â²Õ®tÈ,³o©Î¬Opower ºë¯«©Ò¦b) ; HR «h¥i¥H¶V¨Ó¶V°ª,Åã¥Ü¥X¨Æ¥ó¼Æ¼W¥[ªº®ÄÀ³ O1©T©w , O2¨C¼W¥[¤@¨Æ¥óªº³sÄòÅܤÆ,³o²Õ¤]«O¯d,¤è«K¤j®a°Ñ¦Ò O1--O2----X^2-------HR-----HR 95%«H¿à°Ï¶¡-----power 70---54----3.973-----0.698------0.474~0.993----------- 63 % 70---55----4.426-----0.686------0.466~0.973----------- 68.2 % 70---56----4.908-----0.674------0.458~0.953----------- 73.2 % 70---57----5.429-----0.662------0.450~0.933----------- 77.7 % 70---58----5.967-----0.650------0.442~0.914----------- 81.8 % 70---59----6.496-----0.640------0.434~0.896----------- 85.4% 70---60----7.002-----0.630------0.428~0.881----------- 88.4 % (X^2 > 6.635 , P< 0.01) ¶È¨Ñ°Ñ¦Ò,¨Ã½Ð°Q½×«ü¥¿ ÁÂÁ¤j®a! |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/9/17 ¤U¤È 09:11:09²Ä 2532 ½g¦^À³
|
¥H¥x¿n¹q¬°¨Ò, ±q Apple ¶}©l±µÄ²¥x¿n¹q, A9, A10, ¤@ª½¨ì A11 ¥x¿n¹q¿W®³q³æ ³oªá¦h¤Ö®É¶¡ cooking? ªá¦h¤Ö®É¶¡¸ò¤T¬PÄñ°«? ¦pªGªÑªFn¨D±i©¾¿Ñ»¡²M·¡©M Apple ªºÃö«Y, ±i©¾¿Ñ«ç»ò¥i¯à·|»¡ù? ³o³£Ã±¤F«O±K ¨ó©w§r! ¦pªG¯E¹©Ä@·N»¡, ¨º¤~¯u¬OÁV¿|, ¨ºªí¥Ü¨Ó½Íªº³£¬O¤£»Ýnñ«O±K¨ó©w, µLÃöµhÄoªº¨Æ |
|
|
·|û¡G¶³²H·»´10142966 µoªí®É¶¡:2016/9/17 ¤U¤È 08:26:17²Ä 2531 ½g¦^À³
|
¦U¦ì¯E¤ÍÌ¡A¼Æ¾Ú¤è±ªº¸ê°T¡A¦³¬¢½Í¦X§@ªºÃļtÀ³¸Ó³£ª¾¹D¤F§a¡A¦ý¬°¦ó¿ð¿ð¨S¤U¤å¡A²{¦b¤£¬O°ò¥»±©MÃĪº°ÝÃD¡AÀ³¸Ó¬O¦X§@¤è±¨S¦³¦@ÃÑ¡A§Æ±æ¤½¥q¤è±¯àÅý§ë¸ê¤Hª¾¹Dµu¤¤»·ªº©ú½T³W¹º¡A³Ì«nªº¬O¬ð¯}©ÊÀøªk¥Ó½Ð¶i«×¦p¦ó¡A¦]¬°¯à¤j´TÁYµu¥Ó½ÐÃÄÃҮɶ¡¡A§Æ±æ¦b10¤ë¼Ú¬w¬ã°Q·|«á¥l¶}¤j«¬§ë¸ê¤H»¡©ú·|¡A§â³Ì·s¶i®i¤@¦¸©M¤µ ³W¹ºÅý§ë¸ê¤H©ú¾é¡C¥H¤W°Ñ¦Ò¬Ý¬Ý¡CÁÂÁ¡C |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/9/17 ¤U¤È 08:09:16²Ä 2530 ½g¦^À³
|
You did a great job! Thank you! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/17 ¤U¤È 05:54:56²Ä 2529 ½g¦^À³
|
²q·Q¤j »{¯u¥[¤W«ä¦Ò²Ó¿°ªº²q·Q¤j«e½ú²×©ó«õ¨ìÂÃÄ_¹Ï¡A¤j®a¥i§Q¥Î°²¤é¦n¦n¼ÒÀÀ¤@½¡AÁÂÁ«e½ú §V¤Oªº¥I¥X¡C ¯E¹©¨ÅÀùÃÄOBI822 ¦]¬°§K¬ÌÀøªk¯S©Êªº¦]¯À³y¦¨¥DnÀø®Ä«ü¼Ð¥¼¹F¼Ð¡A¦b°ª¦w¥þ©Ê»P¥Í¬¡«~½èªº±¡ªp¤U¡A¥i¥HÃÒ©ú¨äÀø®Äªº°£¤F2016 ASCO§ë¼v¤ù P14 ,P16,P17¥~ ¦p¯à¦A¥[¤W P13ªº¹F¼Ð¡A§ó¯à¨ã¦³»¡ªA¤O¡A¤£½×¥xÆWÃÄÃÒªº¥Ó½Ð©Î¼Ú¬üÃÄÃÒ»P¥þ²y¤T´Á³W¼Ò¡A³£»P³o¥|±i¹Ïªí¡A®§®§¬ÛÃö |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/17 ¤U¤È 03:34:43²Ä 2528 ½g¦^À³
|
¤j¹ÙÌ ¦n! ¤p§Ì¤é¥HÄ~©]¦a´M§ä post-hoc power ªººâªk ¤µ¤é§ä¨ì¤@ÓÀ°¤Hpºâªººô¯¸ http://clincalc.com/stats/power.aspx ¦ý¤p§Ì®£©È±N°Ñ¼Æ»~¶ñ ¦b¦¹´£¥X»P¤j®a°Q½×¨Ã½Ð«ü¥¿ ºô¯¸¦³¤Ó°Ñ¼Æn¶ñ ¤À§O¬° Study Incidence Group 1---------% ; Group 2---------% Number of Subjects Group 1--------- subjects ; Group 2--------- subjects Type I/II Error Rate Alpha ---------------0.05 ¥H ( 50 , 35 ) ³o²Õ¤½¥qµ¹ªº¼Æ¾Ú¬°¨Ò ¤p§Ì¤À§O¶ñ¤J 22.3 ; 28.2 ; 224 ; 124 ; 0.05 ºâ±opower = 23.6 %(ºô¯¸ÁÙµ¹pºâ¹Lµ{) ¤p§Ì¨Ì¦¹¤è¦¡,±N¬Q¤éªºªí®æ¼W¥[power ¤A¶µ,¦C¦p¤U: (³Ì«á¤@¶µ¬Opower) O1--O2-----X^2------HR-----HR 95%«H¿à°Ï¶¡---¨â²Õ³Ì«á¥¥x¦s¬¡¾÷²v 50---35----1.262-----0.781----0.496~1.209-------0.693--0.605-------- 23.6 % 50---42----4.279-----0.651----0.415~0.976------------------------------- 64.8 % 55---46----4.778-----0.648----0.421~0.953-------0.670--0.480-------- 69.1 % 60---48----4.167-----0.675----0.446~0.983-------0.660--0.450-------- 63.1 % 60---49----4.661-----0.662----0.437~0.960-------0.660--0.440-------- 68.5 % 65---51----4.019-----0.689----0.462~0.991-------0.630--0.420-------- 63 % 70---54----3.973-----0.698----0.474~0.993-------0.600--0.370-------- 63 % 75---57----3.903-----0.708----0.487~0.997-------0.580--0.330-------- 63.2 % 81---61----4.206-----0.708----0.492~0.983-------0.550--0.370-------- 65.8 % 90---68----4.235-----0.720----0.511~0.983-------0.480--0.210 -------- 75.0 % ªþµù: ( 60, 60 ) ªº power ¬O 98.1 % ¥t¥~¤p§Ì¤]¼W¥[¤@²ÕO1©T©w , O2¦U¼W¥[¤@¨Æ¥óªº³sÄòÅܤÆ,¨Ñ¤j®a°Ñ¦Ò O1--O2----X^2-------HR-----HR 95%«H¿à°Ï¶¡-----power 70---54----3.973-----0.698------0.474~0.993----------- 63 % 70---55----4.426-----0.686------0.466~0.973----------- 68.2 % 70---56----4.908-----0.674------0.458~0.953----------- 73.2 % 70---57----5.429-----0.662------0.450~0.933----------- 77.7 % 70---58----5.967-----0.650------0.442~0.914----------- 81.8 % 70---59----6.496-----0.640------0.434~0.896----------- 85.4% 70---60----7.002-----0.630------0.428~0.881----------- 88.4 % (X^2 > 6.635 , P< 0.01) ¶È¨Ñ°Ñ¦Ò,¨Ã½Ð«ü¥¿ ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/17 ¤W¤È 08:44:59²Ä 2527 ½g¦^À³
|
ÁÂÁ«ù¤[ªº¯E«È¤j¤jªº«ü¾É ¤]ÁÂÁ±z´£¨Ñ¸ê®Æ¨Ñ¤p§Ì¬ãŪ Y¦³©Ò¤£À´³B ¦A½Ð±z«ü¾É ÁÂÁ±z! ¥xÁÞ¤j¤j HR ©M 95%«H¿à°Ï¶¡ªº¤½¦¡ ¤w¦p«ez https://books.google.com.tw/books?id=HmnIBAAAQBAJ&pg=PT129&lpg=PT129&dq=HR%3D(O1/E1)/(O2/E2)&source=bl&ots=_2y_TneZ4E&sig=ccKOdk2NVzNFaCS_FZOIr_o6Cdk&hl=zh-TW&sa=X&ved=0ahUKEwjkv4KBrpDPAhWKmZQKHT1tBMkQ6AEIHTAA#v=onepage&q=HR%3D(O1%2FE1)%2F(O2%2FE2)&f=false ¦]¬°¦³¥[Á`ºtºâ,©Ò¥H¥²¶·¨Ï¥Î¸Õºâªí pºâ¥i¥H«Ü§Ö,¦ý¿é¤JP.13ªº¸ê®Æ«ÜÁcº¾ ¥B·|¦³»~®t ¤p§Ì¨º¨Ç¼ÒÀÀ¸ê®Æ,»P¤½¥qµo¥¬ªÌ ¦s¦b¤p»~®t ¦ý¥Î¦b¦ôp,À³¨¬°÷¤F ¥Ñªí¤¤(¹ï·Ó²Õªº¨Æ¥ó¼Æ§¡°²³]¦b¤¤«e°Ï¶¡µo¥Í) §ÚÌ¥i¥H¬Ý¨ì ¨â²ÕMOSªº¥i¯à»Ýn¨Æ¥ó¤H¼Æ ; ¦ü¥GP < 0.05, HR 95%«H¿à°Ï¶¡´N¤£P¶W¹L1.0 ; ´N¦p«ù¤[ªº¯E«È¤j©Ò¨¥,¶V¨ì«á´Á,¤@Өƥó¼Æªº®t²§,´N¥i¥H±NX^2©Ôªº«Ü¤j, PÈ´N¤U°±o«Ü§Ö ; (¨Æ¥ó²v¤ñ)(¹ï·Ó/¹êÅç)¤ñ©Ò¦CªºÁ{¬ÉÈ(ªñ¦ü)ÁÙ¤j ´N¶V®e©ö¹F¼Ð ; §ÚÌ´Nµ¥§a! ©Î³\þ¤Ñ¤½¥q¦Aµo¥¬¼Æ¾Ú,´N¬O¹F¼Ðªº®É¨è (¥un¹ï·Ó²Õ¨S¦³¶W¤Zªºªí²{) ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/16 ¤U¤È 11:30:33²Ä 2526 ½g¦^À³
|
¯E§J¤j²Îp¾Ç°ò¥»Æ[©À«Ü±j¡AÁÂÁ´£¨Ñ¤À¨É¡C ÁÂÁ²q·Q¤j´£¨Ñ¦h²Õ¼ÒÀÀ¡A¥t¥~½Ð°Ý81,61¨º¤@²Õªº·ÀI¤ñ HR 0.70 pºâ¦¡¤l ? ¥un¹êÅç²Õ¨Æ¥ó¼Æºòºò«r¦í¹ï·Ó²Õ¡A·í¨â²Õ¨Æ¥ó¼ÆÀHµÛ®É¶¡³v¨BÂX¤j¡A¥un®t¶Z¦b23¤H¥H¤º ¡A¬Æ¦Ü§ó¤Ö¡AP value´N¦³¾÷·|¤p©ó0.05¡A ¬Æ¦Ü§ó¤p¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/16 ¤U¤È 11:08:33²Ä 2525 ½g¦^À³
|
Power¤å³¹³sµ²¦p¤U dasanlin888.pixnet.net/blog/post/34469720 |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/16 ¤U¤È 11:03:15²Ä 2524 ½g¦^À³
|
²q·Q¤j §Ú¥u¯à»¡ OS ¬Otime to event ªºÅܶµ ©Ò¥H¦³¤H¦º¤` ¹êÅç¹ï¶H¤~¦³¸ê®Æµn¿ý ¤£µM´N¬O³]¸ê®Æ ³]¸ê®Æ¶V¤Ö ¶V¦nÀËÅç¹êÅç®ÄªG ¦ÓOS¬OÀH®É¶¡¶i®i¤~·|¥X²{ ©Ò¥Hnµ¥¼Æ¾Ú¦¨¼ô ¦Ü©ó¦º¤`¨Æ¥ó¤H¼Æn¦h¤Ö ©Î®É¶¡¦h¤[ ¯uªº§Ú¤£´±»¡¤°»ò ²¦³º¸ê®Æ¦³ ¥t¥~²Îp¦ÒÅç¤Oªºpºâ ¥i¥H¥ý¬Ý¥H¤U³sµ²¤å³¹ ¦A¦Ò¼{¤U¸ü³nÅé ¾Þ§@¬Ý¬Ý §Ú¤£½T©w¦³´£¨Ñcox proportional model ªº²Îp¦ÒÅç¤O¤ÀªR |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/9/16 ¤U¤È 09:02:28²Ä 2523 ½g¦^À³
|
«ù¤[ªº¯E«È¤j¤j «D±`¦P·N±zªºÆ[ÂI "¤@¤Á»Ýn®É¶¡µ¥«Ý" ¥u¬Onµ¥«Ý¦h¤[©O? ¤p§Ì¤µ¤Ñ¤@ª½¦b´M§äÀË©w¤Oªººâªk,©`²@µL©ÒÀò(½Ð°Ý±z¦³¨S¦³¸Óµ¥¤½¦¡?) ·íµM´NµLªkºâ¥XÀË©w¤O ¤p§Ìª¾¹D±z¦³²Îp³nÅé ¥i§_½Ð±Ð±z n¹FÀË©w¤O0.8 ,¤@©wn¨Æ¥ó¼Æ¤j¶Ü? n¤j¨ì¦óºØµ{«×? ¦pªG¨â²Õ¼Æ¾Ú¦b¤¤´Á´N©Ô¤j®t¶Z, ¨Ò¦p(60,60)(¨â²Õ¨Æ¥ó¼Æ) ³o¼ËÁÙn«Ü¦hªº¨Æ¥ó¼Æ,¤~¯à¹FÀË©w¤O¼Ð·Ç¶Ü? ÁÙ¬O¤£¥Î¨º»ò¤jªº¨Æ¥ó¼Æ´N¯à¹F¦¨? ¤p§Ì¦³¼ÒÀÀ¤@¨ÇÁ{¬Éª¬ªpªº¼Æ¾Ú O1---O2-----X^2-------HR-------HR 95% «H¿à°Ï¶¡---¨â²Õ³Ì«á¥¥x¦s¬¡¾÷²v 50---35----1.262-----0.781----0.496~1.209-------0.693--0.605 50---42----4.279-----0.651----0.415~0.976------- 55---46----4.778-----0.648----0.421~0.953-------0.670--0.480 60---48----4.167-----0.675----0.446~0.983-------0.660--0.450 60---49----4.661-----0.662----0.437~0.960-------0.660--0.440 65---51----4.019-----0.689----0.462~0.991-------0.630--0.420 70---54----3.973-----0.698----0.474~0.993-------0.600--0.370 75---57----3.903-----0.708----0.487~0.997-------0.580--0.330 81---61----4.206-----0.708----0.492~0.983-------0.550--0.370 90---68----4.235-----0.720----0.511~0.983-------0.480--0.210 ¤p§Ì¤£ª¾þ²Õ¤~¯à¹FÀË©w¤O0.8? ¥xÁÞ¤j¤j¤Î ¤j¹Ṳ̀]½Ð°Ñ¦Ò ¤]¬O¶È¨Ñ°Ñ¦Ò³á ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/9/16 ¤U¤È 01:39:43²Ä 2522 ½g¦^À³
|
²q·Q¤j¡A¯E§J¤j (50/224)/(35/125)=0.790 ³o«Ü¹³¬O¤½¥q¤½§iªº·ÀI¤ñpºâ¦¡¤l (81/224)/(61/124)=0.736 ¦pªG0.790¬O·ÀI¤ñªº¸Ü¡A¥H¤U¨âÓÓ¼ÒÀÀ¦³µo²{¤°»ò¶Ü? (75/224)/(61/124)=0.681 (70/224)/(61/124)=0.636 ¨â²Õµo¥Í¨Æ¥ó®t¶Z¶V¤p¡A·ÀI¤ñ´N·|¶V¤p¡AÀø®Ä´N·|¶VÁͦV¥¿± |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/9/16 ¤W¤È 10:08:50²Ä 2521 ½g¦^À³
|
²q·Q¤j ¨ä¹ê±qASCO§ë¼v¤ù OS´Á¤¤¤ÀªRªº¨â±ø¦±½u ´N¥i¥H¹w´Á¹êÅç²Õ¤§«á·|¥X²{«p§À®ÄÀ³ ³oÓ³¡¤À ¤]¬O¥i¥H±q¤@´Á¹êÅçµ²ªG¬Ý¥X ¥u¬On¹F¨ìHR=0.7 ¬O»Ýn®É¶¡ PȤ~·|¹FÅãµÛ.05 ¦Ó¥B¨Æ¥ó¤H¼Æn¨¬°÷ ¤~®e©ö¹F¨ì²Îp¦ÒÅç¤O0.8 ²¨¥¤§ 822¥D°Ê§K¬Ìªº©µ¿ð®ÄÀ³ ¤ñ³Q°Ê§K¬Ì§ó©µ¿ðµo¥Í ¦ý¬O«p§À®ÄÀ³µ²ªG¥O¤H¿E½à ¬°¤F¦³®ÄÅçÃÒ822Àø®Ä µ¥«Ý®É¶¡ Åý¨Æ¥ó¤H¨Æ¦¨¼ô ´N¬O¹êÅç²Õ¦º¤`Áͽw ¦w¼¢²Õ¦º¤`¦p¦P¥À¸sÅé«ùÄò¼W¥[ «h¹êÅç®ÄªG¹FÅãµÛ©Ê(¿ù»~©Úµ´µêµL°²³]ªº¾÷²v.05)¡A ²Îp¦ÒÅç¤O(¥¿½T±µ¨ü¹ï¥ß°²³]ªº¾÷²v¡A§Y822¦³®Äªº¾÷²v>.8)¤]¦X®æ ´N¥i¥H¨ÏFDAªº²Îp±M®a¬Û«H822Á{§É¦³®Ä ¤£¬O¦]¬°²Îp°¾»~¤§¬G «hÃÄÃÒÀH¤â¥i±o ¤@¤Á»Ýn®É¶¡µ¥«Ý |
|
|
|